var title_f1_9_1168="Contents: Leukemia myeloproliferative disorders";
var content_f1_9_1168=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?39/57/40861\">",
"       Hematology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Leukemia myeloproliferative disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Leukemia myeloproliferative disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute lymphoblastic leukemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/56/31625\">",
"           Clinical use of minimal residual disease detection in acute lymphoblastic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/25/22938\">",
"           Cytogenetics in acute lymphoblastic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/32/15880\">",
"           Detection of minimal residual disease in acute lymphoblastic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/11/9400\">",
"           General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/5/23642\">",
"           Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/28/44489\">",
"           Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/44/40649\">",
"           Overview of the outcome of acute lymphoblastic leukemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/58/4009\">",
"           Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/6/31850\">",
"           Overview of the treatment of acute lymphoblastic leukemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/15/39161\">",
"           Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/26/3497\">",
"           Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/55/37753\">",
"           Risk group stratification and prognosis for acute lymphoblastic leukemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33658\">",
"           Therapeutic use and toxicity of high-dose methotrexate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21753\">",
"           Treatment of relapsed or refractory acute lymphoblastic leukemia in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Acute myeloid leukemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/50/39720\">",
"           Classification of acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/58/20393\">",
"           Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/42/39594\">",
"           Cytogenetics in acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/7/19576\">",
"           Hyperleukocytosis and leukostasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/41/30362\">",
"           Induction therapy for acute myeloid leukemia in younger adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/0/25607\">",
"           Involvement of the central nervous system with acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/17/25882\">",
"           Molecular genetics of acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/53/14168\">",
"           Overview of the complications of acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/33/35354\">",
"           Pathogenesis of acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/55/17274\">",
"           Post-remission therapy for acute myeloid leukemia in younger adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43768\">",
"           Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/55/36730\">",
"           Prognosis of acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/50/12073\">",
"           Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/35/39480\">",
"           Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/29/29146\">",
"           Treatment of acute myeloid leukemia in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/51/29498\">",
"           Treatment of relapsed or refractory acute myeloid leukemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Acute promyelocytic leukemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/12/200\">",
"           Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/11/28858\">",
"           Initial treatment of acute promyelocytic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/35/17976\">",
"           Molecular biology of acute promyelocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/37/12888\">",
"           Treatment of relapsed or refractory acute promyelocytic leukemia in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Agnogenic myeloid metaplasia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/63/1018\">",
"           Clinical manifestations and diagnosis of primary myelofibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/30/25064\">",
"           Pathogenetic mechanisms in primary myelofibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/3/36922\">",
"           Prognosis and treatment of primary myelofibrosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic lymphoproliferative disorders (including CLL)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/22/20841\">",
"           Clinical features and diagnosis of hairy cell leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/6/24680\">",
"           Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/16/17671\">",
"           Evaluating response to treatment of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/61/35800\">",
"           Hematopoietic cell transplantation in chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/36/20040\">",
"           Natural killer (NK) cell large granular lymphocyte leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/12/35017\">",
"           Overview of the complications of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/42/29352\">",
"           Overview of the treatment of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/38/35431\">",
"           Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/23/42361\">",
"           Pathophysiology and genetic features of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/13/6362\">",
"           Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/6/15466\">",
"           Staging and prognosis of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/15/18680\">",
"           Treatment of T cell prolymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/17/4378\">",
"           Treatment of hairy cell leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/46/2793\">",
"           Treatment of large granular lymphocyte leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/46/30442\">",
"           Treatment of relapsed or refractory chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cytogenetics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/47/18167\">",
"           Chromosomal translocations, deletions, and inversions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/55/28536\">",
"           Cytogenetic and molecular genetic diagnostic tools",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/35/14905\">",
"           Cytogenetics and molecular genetics of myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/42/39594\">",
"           Cytogenetics in acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/21/6489\">",
"           General aspects of cytogenetic analysis in hematologic malignancies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/5/41049\">",
"           Genetic abnormalities in hematologic and lymphoid malignancies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/23/42361\">",
"           Pathophysiology and genetic features of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Essential thrombocythemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/28/18890\">",
"           Diagnosis and clinical manifestations of essential thrombocythemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/28/32202\">",
"           Prognosis and treatment of essential thrombocythemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myelodysplastic syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/57/41882\">",
"           Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/35/14905\">",
"           Cytogenetics and molecular genetics of myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/39/8826\">",
"           Hematopoietic cell transplantation in myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/54/25450\">",
"           Management of the complications of the myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/26/19880\">",
"           Overview of the treatment of myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/39/34425\">",
"           Prognosis of the myelodysplastic syndromes in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/53/9049\">",
"           Treatment of high or very high risk myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/30/31210\">",
"           Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myeloproliferative disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/33/40474\">",
"           Cellular and molecular biology of chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/9/19609\">",
"           Clinical manifestations and diagnosis of chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/63/1018\">",
"           Clinical manifestations and diagnosis of primary myelofibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27290\">",
"           Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/28/18890\">",
"           Diagnosis and clinical manifestations of essential thrombocythemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/32/9738\">",
"           Diagnostic approach to the patient with suspected polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/18/33066\">",
"           Hematopoietic cell transplantation in chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/55/7034\">",
"           Initial treatment of chronic myeloid leukemia in chronic phase",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/30/27111\">",
"           Interferon alpha for the treatment of chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/49/31512\">",
"           Molecular genetics of chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/17/29978\">",
"           Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/52/21322\">",
"           Overview of the myeloproliferative neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/16/41225\">",
"           Overview of the treatment of chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/30/25064\">",
"           Pathogenetic mechanisms in primary myelofibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28554\">",
"           Prognosis and treatment of polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/3/36922\">",
"           Prognosis and treatment of primary myelofibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/20/27976\">",
"           Treatment of chronic myeloid leukemia in accelerated phase",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/40/7816\">",
"           Treatment of chronic myeloid leukemia in blast crisis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/17/20762\">",
"           Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polycythemia vera",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/32/9738\">",
"           Diagnostic approach to the patient with suspected polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/17/29978\">",
"           Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28554\">",
"           Prognosis and treatment of polycythemia vera",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-98F1B8B30F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f1_9_1168=[""].join("\n");
var outline_f1_9_1168=null;
var title_f1_9_1169="Blood in the urine (hematuria) in children";
var content_f1_9_1169=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/9/1169/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/9/1169/contributors\" id=\"au6305\">",
"       Tej K Mattoo, MD, DCH, FRCP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/9/1169/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/9/1169/contributors\" id=\"se839\">",
"       F Bruder Stapleton, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/9/1169/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/9/1169/contributors\" id=\"de7255\">",
"       Melanie S Kim, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?1/9/1169?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BLOOD IN THE URINE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Hematuria is the medical term for blood in the urine. Blood in the urine can come from the kidney (where urine is made) or anywhere in the urinary tract (",
"     <a class=\"graphic graphic_figure graphicRef65630 \" href=\"UTD.htm?14/27/14769\">",
"      figure 1",
"     </a>",
"     ). The urinary tract includes the ureters (the tubes from the kidneys to the bladder), the bladder (where urine is stored), and the urethra (the tube from the bladder to the outside of the body).",
"    </p>",
"    <p>",
"     Although seeing blood in the urine can be very frightening, most of the time hematuria is not life threatening.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      TYPES OF HEMATURIA",
"     </span>",
"    </p>",
"    <p>",
"     There are two main types of hematuria:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Gross hematuria &mdash; Gross hematuria means that blood can be seen in the urine with the naked eye because it turns the urine pink, red, or tea-colored. If you see blood in your child's urine, you should call your child's healthcare provider.",
"      </li>",
"      <li>",
"       Microscopic &mdash; Microscopic hematuria means that the urine is normal in color, but it has an increased number of red blood cells (blood) as seen with a microscope. If your child's urine dipstick shows blood in the urine, the urine should be examined with a microscope to confirm that blood is present. (See",
"       <a class=\"local\" href=\"#H5\">",
"        'What tests will be done?'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HEMATURIA CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Some common causes of blood in the urine include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bladder (also called urinary tract) or kidney infections",
"      </li>",
"      <li>",
"       Kidney stones",
"      </li>",
"      <li>",
"       Irritation of the urethra (the area where the urine exits the body)",
"      </li>",
"      <li>",
"       Trauma (for example, after falling off a bike and bruising a kidney)",
"      </li>",
"      <li>",
"       Vigorous exercise",
"      </li>",
"      <li>",
"       Kidney diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Less common causes of blood in the urine include certain medications, inherited kidney diseases, and other underlying medical problems. Cancers of kidney or urinary tract that cause hematuria in adults are very rare in children.",
"    </p>",
"    <p>",
"     Sometimes, the urine appears to have blood in it because other red substances are contained in the urine. This can be seen when children eat an excessive amount of beets (called beeturia), food dyes, or with certain medications (such as",
"     <span class=\"nowrap\">",
"      phenazopyridine/Pyridium&reg;).",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      HEMATURIA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Hematuria may not cause any symptoms. This section will describe the symptoms of some of the most common reasons for hematuria.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bladder or kidney infections &mdash; Infants with bladder infections may have fever, be irritable, and feed poorly. Older children may have fever, pain and burning while urinating, urgency, and lower belly pain. &nbsp;(See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=see_link\">",
"        \"Patient information: Urinary tract infections in children (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Children with kidney infections may have fever, chills, and flank pain (pain in one side of the back).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Kidney stones &mdash; Children with kidney stones may have belly or flank pain. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?15/26/15779?source=see_link\">",
"        \"Patient information: Kidney stones in children (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Kidney diseases &mdash; Children with kidney diseases can have a variety of symptoms, such as weakness, high blood pressure, puffiness around the eyes, joint swelling, abdominal pain, pale skin, skin rashes, or seizures.",
"      </li>",
"      <li>",
"       Depending upon the amount of bleeding, a clot may form in the bladder, which may cause obstruction to the flow of urine.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      WHAT TESTS WILL BE DONE?",
"     </span>",
"    </p>",
"    <p>",
"     The evaluation of a child with hematuria depends upon the type of hematuria (microscopic or gross) and the child's recent history, symptoms, and physical examination.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If the child has microscopic hematuria but has no symptoms (pain, fever, recent trauma) and no protein in the urine, a urine test will be repeated several times over a few months to determine if the blood persists. No further testing is needed.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If the microscopic hematuria does not resolve but the child has no symptoms and no protein in the urine, the child will be monitored over time. The child may be referred to a pediatric nephrologist (kidney specialist) if hematuria persists.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If the child has hematuria and has symptoms of a bladder or kidney infection, testing will be done to confirm the diagnosis. This usually includes a urine culture.",
"      </li>",
"      <li>",
"       If the child has hematuria and symptoms suggestive of a kidney stone, testing with an ultrasound or CT scan of the kidney is performed to confirm the presence of a kidney stone. A urine sample will be collected over 24 hours to measure substances that cause kidney stones.",
"      </li>",
"      <li>",
"       If the child has had a recent injury, an imaging test may be recommended to examine the kidneys, ureters, and bladder.",
"      </li>",
"      <li>",
"       If the child has hematuria and protein in the urine, further testing will be done. This includes blood and urine tests to evaluate the child's kidney function. The child's blood pressure will also be measured because high blood pressure is a common finding in children with kidney problems. The child may be referred to a pediatric nephrologist if the tests are abnormal.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Family members of children with persistent hematuria may also be tested. Familial hematuria, which has no serious long-term effects, is the most common cause of persistent microscopic hematuria in children.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      HEMATURIA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There is no specific treatment for hematuria. Rather, treatment is aimed at the underlying cause, if a cause can be determined. Treatment of specific causes of hematuria is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=see_link\">",
"      \"Patient information: Urinary tract infections in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/26/15779?source=see_link\">",
"      \"Patient information: Kidney stones in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413520811\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13063333\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/51/17202?source=see_link\">",
"      Patient information: Blood in the urine (hematuria) in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=see_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/31/37363?source=see_link\">",
"      Patient information: Glomerular disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13063348\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=see_link\">",
"      Patient information: Urinary tract infections in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/26/15779?source=see_link\">",
"      Patient information: Kidney stones in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42937?source=see_link\">",
"      Acute cystitis in children older than two years and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13623?source=see_link\">",
"      Clinical features and diagnosis of nephrolithiasis in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1127?source=see_link\">",
"      Evaluation of gross hematuria in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30584?source=see_link\">",
"      Evaluation of microscopic hematuria in children",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Centers for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Academy of Pediatrics",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aap.org\">",
"      www.aap.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?1/9/1169/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?1/9/1169?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1169/abstract/1\">",
"      Diven SC, Travis LB. A practical primary care approach to hematuria in children. Pediatr Nephrol 2000; 14:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1169/abstract/2\">",
"      Bergstein J, Leiser J, Andreoli S. The clinical significance of asymptomatic gross and microscopic hematuria in children. Arch Pediatr Adolesc Med 2005; 159:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1169/abstract/3\">",
"      Patel HP, Bissler JJ. Hematuria in children. Pediatr Clin North Am 2001; 48:1519.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f1_9_1169=[""].join("\n");
var outline_f1_9_1169=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BLOOD IN THE URINE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           TYPES OF HEMATURIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HEMATURIA CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           HEMATURIA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           WHAT TESTS WILL BE DONE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           HEMATURIA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14769\" title=\"figure 1\">",
"           Urinary anatomy pedi PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f1_9_1170="Stockinette folded";
var content_f1_9_1170=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stockinette folded for final application of casting tape",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Titus, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1170=[""].join("\n");
var outline_f1_9_1170=null;
var title_f1_9_1171="10 year old boy with mucopolysaccharidosis type VI - MPS VI";
var content_f1_9_1171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    10-year-old boy with mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1171=[""].join("\n");
var outline_f1_9_1171=null;
var title_f1_9_1172="Metaproterenol: Pediatric drug information";
var content_f1_9_1172=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metaproterenol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19812?source=see_link\">",
"    see \"Metaproterenol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/29/34260?source=see_link\">",
"    see \"Metaproterenol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3149994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Orciprenaline&reg;;",
"     </li>",
"     <li>",
"      ratio-Orciprenaline&reg;;",
"     </li>",
"     <li>",
"      Tanta-Orciprenaline&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta",
"       <sub>",
"        2",
"       </sub>",
"       -Adrenergic Agonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Bronchodilator",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19812?source=see_link\">",
"      see \"Metaproterenol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;2 years: 0.4 mg/kg/dose 3-4 times daily; in infants, the dose can be given every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-5 years: 1.3-2.6 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6-8 hours; maximum: 10 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;6 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;27 kg: 10 mg 3-4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;27 kg: 20 mg 3-4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 20 mg 3-4 times daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as sulfate: 10 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Administer with food to decrease GI distress",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light and moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Syrup: Store below 30&deg;C (86&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bronchodilator in reversible airway obstruction due to asthma or COPD (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F193756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Metaproterenol may be confused with metipranolol, metoprolol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Alupent may be confused with Atrovent&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F193754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache, insomnia, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Chest pain, diaphoresis, edema, facial/finger edema, hives, hypertension, laryngeal changes, spasms, syncope, vomiting, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metaproterenol or any component; pre-existing cardiac arrhythmias associated with tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with ischemic heart disease, hypertension, hyperthyroidism, seizure disorders, CHF, cardiac arrhythmias, glaucoma, hypokalemia, and diabetes mellitus. Metaproterenol (a less selective beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist) is not recommended in the management of asthma due to potential for excessive cardiac stimulation (NAEPP, 2007). Oral systemic agents (eg, tablets, syrup) should be avoided due to increased risk of adverse effects (eg, excessive cardiac stimulation). Inhaled bronchodilators are preferred therapy for COPD exacerbations; oral systemic agents (eg, tablets, syrup) should be avoided due to increased risk of adverse effects (eg, excessive cardiac stimulation).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Beta-agonists may cause elevation in blood pressure, heart rate, and result in CNS stimulation/excitation. Beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may increase risk of arrhythmia, increase serum glucose, or decrease serum potassium. Excessive use may result in cardiac arrest and death; do not use concurrently with other sympathomimetic bronchodilators. Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported. Syrup contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid use of sodium benzoate containing products in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Blockers: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F193722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic and embryotoxic effects have been observed in some animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1060218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, respiratory rate, blood pressure, arterial or capillary blood gases if applicable, pulmonary function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relaxes bronchial smooth muscle and peripheral vasculature by action on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of bronchodilation: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: (~1-5 hours) regardless of route administered",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive first-pass in the liver (&sim;40% of oral dose is available)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Mainly as glucuronic acid conjugates",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/29/34260?source=see_link\">",
"      see \"Metaproterenol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12586 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1172=[""].join("\n");
var outline_f1_9_1172=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3149994\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060219\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060212\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193711\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193695\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060223\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060215\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060222\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193756\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193754\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060227\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060211\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060210\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299679\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193704\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193707\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193722\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060218\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060209\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060225\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060226\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060217\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12586\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12586|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19812?source=related_link\">",
"      Metaproterenol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/29/34260?source=related_link\">",
"      Metaproterenol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_9_1173="Lymph node compartments of the neck";
var content_f1_9_1173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F87027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F87027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Lymph node compartments of the neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 497px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHxAgIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiijNABRSbhTS1K4WH0VHv96QyUXHYlzSZqHzKTzKXMPlJ80bqr+ZSGSlzBylndRuqt5vvTTL70c4cpa3UheqZmphn96n2g+Qv76N4rP8/wB6PtHvR7RD5DR3CjcKzxP70on96PaIXIaG4UbhVDz/AHpRP70/aIOQv5oqkLj3pwnp86Fyst0VXEw9akjkDHGapSTFZklFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRQSBQAUUwuBUbSe9JyQ7ExIFIXqs0tRtNUOaKUC0ZPeo2mHrVN5qhaas3VLVMvGf3phmqiZaaZaz9qWqZdMtJ5tUvMpRJS9oPkLnme9L5lUw9OD0c4cpZ8ykL1BvpN1HMHKTF6YXqMtTSaTkPlHmSo2kphNMNQ5FJDzJTfM5qM00k1PMyrE/m+9KJfeq2aN1HMxcpZ833oE3PWqxak3U+cOUuCb3pRP71R3Um80e0YchpCf3pUvPLcEnoazhIajnYlMjtT9q0L2aZ2EUiyxh0OVPIp1cppOrG2fZJkxHqPT3rqY3WRFeNgynkEV2UqqqI5qlNwY6iiitTMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopC2KAFpCwFRs9RvJipcrFKJK0lQtJ71BJLVaSb3rGVQ0jAtPN71A89U3m96qyXaA43Z+gzWEqptGmX3m96Z5vvWY16gPKSY9cVJHcxy/cYZ9DwaydS5pyWLjSGoy9RFqM1PMPlJN1JuptFFwsODU5TTBThTTCxIDTgajFOFUmS0SZozTBS5p3FYUmkNJmkJouAGm4paKQxpFMIqU01qLBcipKcaSpGNNNpxpppMBppCacaaaQwzR1BoUZOKjv5hbQEA/O3ShK40ruyKE86JKQBk1a0zWpLK5Xqbcn50/qKyRkncTzTJ5404ZgO3NXH3XdG/s4yVmeqqwZQynKkZBparaaGXTrVZPviJc/XAqzXprY8dqzsFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUjMBUTPSbsNIezVEz4pjviq8ktZSnYtRJJJarSTVFLL71Vkk965p1TeMCWSaqd1ciNMkZJ4A9TQzZqtFiW5d25WPgVg5NmyjYkCM677lwB2UdBUMt7bx8KAcVma5fiPLOx2A4Cr1Y+lYccl1dOMP5YPQKP6msZVLaI2jTvqzqhexPxtxShYpuV4IrlZ47+1+YSufqAatabqbGVYrgBJD90jo3/16nn7lOHY6iMsFwTnHepVbNVoJN6Z71KDWiZk0TZpRUYanA1Qh9KDTc0oNMRIDSg1GDTgaaYrEgNLmmZpaq4hxptBptFxC0opKUUwFNMan5pjUARt1pDStTTUjA9aY1OJpppANNJ1oqrfzTRRH7Om5qRSV3YsT3MdrHuYgv2Fc1qWpoJN875Y/dUck/QVC8N9dPm4m8seiDn8zU9tYRQNuWIlz1ZuT+dUdMYRhvuUFW/1A9TawHpgZcj+lW7fQrWJhI2+SQfxOxJrSQHP3CBUh3nouKNBub6F/T/EVzYOsd0WuICep+8o+veu2hkSaJJY2DI4DKR3FebGGRyBtyTwBXoGjwNbaZbQyDDqgyPQ+ldeHm5aM4MVCCtJblyiiiuo4gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmO+OlI78cVXkkxUSlYpRuPZ6geXHeoZJqqSTVzzqG0YFiSb3qrJLULyZqJmzXNKpc3jCw93zURNGaSsm7mqQE8Zqnbv/AKI7Z681cPIrPtctatGeoyDUjRz9/F9o1GFD0C5/En/61TxxGOZR/dNF3+71eAnoyY/I/wD161ntQ7BhWSWptfQhvlzFmua1lf8AR968PG4INdbeoBDj0Fctqw/0YqeruAKJIIm9oV0bm2jkP3iMMPetcVzPhnK70/hBzXSgj1q4PQzmtR4NOBqPPanA1ZFiUGlzTAadmmIfmlBpgNKDTuKxIDTgajBpwNUmIcaTNJmkzTEOopM0ZoAdmmk0UhpgNNNNONNNIBhpppxppqRiGkNKaSkMaUX0FIVHpT6KAIWUDtTGwBUzjNV5B8pqWUjY8LwLLdSTMM+UOPqf8muorn/CGPs9x67h/Kugr08MrU0cNd3mwooorcxCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikJwOaAFJxTHbims1QyyYFRKRSQksmBVCabrzS3EvvVCSTJrkqVDphAdJKT3qBmJppNJXK5XOhRsLmkooqRhRRRQMKoJ+6vZU7N84/Gr9VNQUqqzAcoefpSYIydetzsE0YJaI7vw71o6ZOLi1RgcnHNP4mjBHNZEedLvcHIt3Py+g9qz2ZotVY17wZjIrktbbZLbr/DkmuwciSPKnIIrlvE1q72+5B80Z3ClIcS3opCBz/eNaF3qNvZgGeQAnoK5bSr8eWpB5HUVFcqbm5kllyR/D7UKVloNxu9TubaZJkV42DIwyCKsA1yvhy58hWtmbnO5M9x6V08ThxxVp3M5KxMppwNMFOFWQOpQaQUUwHg0ZpoozTuKw/NGaZmjNO4rEmaM0zNLmi4rC0E0maQmncLCmmmgmkNFwsIaQ0ppppMBKKKKBiUjU6kpAMzxULDJqximstJoaZb8PXS2l20chxHKMZ9D2rrQc1wLrkVq6ZrMluFiuVLxDgMPvAf1rpw9dQXLLYwrUnL3onU0VHbzxXEYeFw6+1SV6Cd9UcewUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAE4HNQSPk+1E7849KqSS4qJSLjEleTFU55ajmn96qSS5PWuWpUOiEBJZMmoCc0rHJptcbdzoSsFFFFIoKKKKACiiigApCMjB5BpcUUCMwj7DMFbPkMflP90+lS3dul1AVYZBq68KzIUkUMp6g1Se3uLLLIGlgHYfeWpcSlIy4JptNcRXGWgPR/T61fkjjuY8oQQamDQXcWDhgetUjp8ts+6zf5f7h6VNi0zDvNBZZS9s+xjzgjiqzafqSL8kcch7gNXVLcEcTxEH6VZQQuMjANJRQ+Zo8+uWurfH2y2lhAPDYyB+IrW8N65JJfraSuJgykrIOox2NdW9sr+hHoajh021hk82OGNHPUquKFFp3QnNNalxTkA+tSw7S2CeagztFYusX8lnGlxHyFkCsPVTXTRpyqzVOO7MKklCLk9kdRLDhdy9KhqLSdRS6hQ7gysM5q+8Q6jpScRKRUop7oQaZUlC03NLSGgBc0ZpuaKAHE0maSkouA7NFJRTACabTjTaYhRRigUtAhtIaWikMSijFLtNADGXNNEdThCalSLNFgvYitpZLWQPE21h+tdRp94l5DuXhxwy+lc9Lb/J71XtLp7K5WReg4YeoralVdN67GU4KotNzs6KbG4kRXU5VhkGnV6RxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAU78FAHHToax55/euikQSIUboRiuT1WJ7Wco3I6g+ormr3jqdFGz0GyTZ71GGyaqGXnFSRSbXBPSuByudijYuqhIpChHap4ZlPpVhQrjIp8tyOexnlTRir7Qg0wwClyj50U8UYqyYab5VLlY+YgxShasCGpBDT5RcxAqU/wAselTiPFOCVXKS5EAjxUqrTwlKBiqSJbKV1p1vO29k2yf304P/ANeqb2U8X+qkEg9G4NbJNROKlxTGptGQxkX/AFsDj3AyP0qMT278Aqa0pHKnioZBHKf3sSOfUjn86jlNFPuVhLGBgEUjToB1qU2MD/cLofTORXLeJfEfh/w+HW+1aJrhf+XeIb5M+hAzj8cVtQweIxMuShByfkrkzr0qavN2Nqa43nC1zHiq6xHFAnzAPvkx24/+vXE6v8TL6RIxo+kPBFO/lw3N1nDn27frVePTPFWp25ln1iC2VjykK5bPfJwP517+GyHEYKrCti5xpdUm7vTyjc5ZYyliIShTi5rrZWX3ux6RBfDT7PQySPLljkRn91YAfzNdrpl4syAE18/3+j+J9Ps7Yw64buEBxHHMDhTkZAznGcD0rrPCfxCXUNRWz1O0OnakVB2k4SUkZyuemeuOc9jXnf2LUpYf2uFmq0U5uTi3ePvNq8ZWlZJ2bSaVjOGJ5Z+yrJxva1+vzWh7FJEGHFVHiIpdMvluIwCeavlAa8+ylqdd3HRmWUIppBrQeEVGYalxLUygaKzLzxNolpd6zbXF7sn0e2F5fL5TnyYipYNkLhuAeFyfatHSrm21XTLTUNPl86zu4lnhk2ld6MAVOCARkEdRScGh86FNJVkwGk8g0WYXRBS1meMtdtPCPhq81zUo7iW0tdm9YFDOdzqgwCQOrDvW55Bo5XuHMtitSYq2Lc0ot6dieZFQKaUIapQa7Zy+Mrjw0sdwL+CyW+aQqPLMbOUABzndkemPet4QCq5WhcyKAjNOERNXxCK5C2+IXh9tJfVbh7q10r7edPhvJYC0c8m7buUpuITcCu5goyKag2JzsdIsBqQQYrnNS+IvhfTIr6W7vrgQ2V39huJY7G4lSOf/AJ57kjIJ6Dg9SB1NW08aaI/iK30ISXw1a4gW5jt3065UmNgCGLGMKoGcEkja2VOCCKrkfYnnNtYamSMCsjwl4js/E1pdzWkVxby2l1JZ3NtcqFlhlQ8qwBI6EEEEggitzpRy2FzXK90vycdqw5WLvID1U1t3cmFIrAVs3U30FZTNaZ1vh+bzdMjGeUJQ/wCfpitKsDwoxKXS9gVP8/8ACt+vSoS5qaZx1VabQUUUVqZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVU1KyS9tzGeHHKt6GrdFJpSVmNNp3R53eQy207RTKVcfrTY5M8Gu11nTI9Rgx92VfuP/T6VxFzBLaXDRTrtdf1ryq9F035Ho0aqqLzLIdl+ZSeKt2d8CcE1nxPxzTZ4S3zRHDfzrNSsXKNzp4pVcdak4PeuQj1J4G2Sgqw9a0rfV0bgmtFNGLptG4QKNorLGoxno1PF8h6NT5kLlZpAUuBVBbrPenfah607oVmXuKMiqJuhTGuqOZBysvlhTGcetZ7XWe9IJielLmHyl5pBUEkp9arzTJBA81xIkUKDczuwVVHqSeled6t8RJdRvDpngSwfVr48NcFSIY/fnGfqSB9a78HluIxrfso6LdvRL1b0RhVxFOj8T17dWd3qF5b2UD3F7cRW8CjLSSuFA/E1wOofE2O5uTY+DtLudZvTwHCMIx7+pH1wPek0j4ZXWs3i6j491Oa/uT8wtInxGn+zkfyXH1NemaRY2mlxC00+2htYF6JEgUfpXqKhl2Bfvfv5/dBfPeX4I5XUxFbb3F97/wAl+J5hD4W8b+JwW8S63/Zdo3JtLPG7HoSpx+Zauo8N/DjwzpDqU05Lm4T/AJbXR8xifXB+UfgK7OQBZ1I6NxUY+W4B9aVbN8TUj7ODUIfywXKvw1fzbCGFpxfNL3n3epwfxPGlW3h6a91jT2vIrSeMRKjbShPGeo9cVx1nct9jhu4slHCs6jv7/WvU/FMNpLot6NQsxe2wjkuHtz/y0CfMB+grzDSNStNTtFu9PtVtbWddqW2QQm07cD8Ap/GuGEXUwaq2fu1Gr30SaVklfTVN7HfgqnLWlTdveje3XT/hzccR3ekwtwyl2Bx7gnNcV8SoY5vC2l/ulS9srjyFlA5eJskc+xx+fvXUwlrWCXy/+PdZFkZT1jJ4z7jrmk1S2S80a9hIBQMkgB7HOD/SvHjKph5KvSlyzp1Lpr+9p9zvqnuepGlRqTjGvHmg90Ynw68dz210mleIJds2QIbhzw/oGPr6H8+a9v0/UBKgDGvmW50WO/8AFGmafds0UVy/kiRRypIwD+eOK6Xwr41m8MajNoPiVyVtJGhjugCRhTjDdyPQ9a+hnQhmsHiMHHlqr4oLr/egvzj06aHFjsI8tqKE5c1OSvGXb+7Lz7Pr6n0OCGHFBWsGw1NJY1ZHBDDIIOQRWlFdg9wa8NSRi4tHmXiv4X3uu+I/GupG7WNNX0tLSxWO9nh2yrGy5mVMKyZI4O8YzxXJXHwz1KLxj4T0cJI2l3GlWkfiF4o3NtK1nt2DzCACWKhcHnaM4FfQIuVPWniVD3FaqoyHA8A0D4f61qvjrVdQNjBpcVn4tk1FdSmR0upoAP8AVRAphonzy2/HXg9y2+FOtwQTmLWbC1nsbO/trvUdPaWa71GSYFk+0IEyGQMpADO3Tb1Fe6azqtppGk3uo3j7ba0heeQjrtUEnHvx0rI8B2Uum+G4W1EBdTvXe+vRnOJpTuZfouQg9lFP2j3Fyngmh/DnWfEFh4p0/T9GttFjm0qwsY5pYJ7aCeaKVHdwJIUkJIQkkp944yetd5ffC7WpvGc2qR3OnEvraaqmqNI4vY4FXH2MLsI8vtnfjHVTXrz3Ma9SKqy6nEn8QzSdUapni+n/AAf1m3s9cs2j0wWOoWvk7FvgbtnaZZGLXos1kKYGNjrJnoTjot38KfE03he10mT/AIRMwi7uZZY1s4I2SN0VY9kgtSpcbfmYRIWAABGAR63JqzNny8D3NQfbAWzNMT7Co9uV7E474Z+BtY8M69aX+sXtnciLQotLcxSu7GRJWfPzKPl2kAHr7Vj6/wDCvUtR1/XdWtpdMS7utZs9Rs52dxJDFEuJF3BMqT6AkHAyRivTP7RTGIkZvesXU/GmladuF3qdnEw6p5oLD/gI5rSkqtaVqUXJ+SuKUYwV5Oy8zoNFfWTb3o8QNp4lNzILY2BfAt/4N+//AJadc449K8t8P6Hq978H4/BL20VlNbztp9/LexsFa38ws0sHykSMykYOQASeQRVu++K2gICIrq4uG7LDA3P/AH1is5vHmpX4/wCJP4a1a6U9HZSg/QEfrXpQyTMmrui4r+9aP/pTRzvF4bbnv6a/kM1TwL4h/wCEBuvCWnyaNJZJqgu7O4nuZEkEAl83bIBEdz543ZOc57c9K2m67L8V7HxVNFpKWUWlf2dLEt7I0gLMJGZR5IBw2VAyMjB4+6ObN18QbwZt9BtbZD3nlBI/8eH8qQaV8SJfmN1pkH+z8p/9lP8AOrWUVP8Al5XpR/7fT/8ASbi+sQ+zCT+X+djqvhgLn+1PF2uXVtNZRavqW+3gmjMb+VGgjEjKeRuIJwR0we9d+btSOteFy6h490y58ie30+9cDJCMMge+CMVas/iVc6bIkfiTR7yzB48xRuU+4zj9CamWSYqbvQlCp/gkm/u0f4FLE04r94nH1TX47HrWo3BC5BrLsGMj3Dn2FZ+n65Ya3ZfatOuknh6Hb1U+hB5B+taVghjswSMFyW/wrw6sJ05uFRNNbp7ndBxcbxd0zpPCY/4+j2+X+tdDWR4Yi2aeXI5kcn8Bx/jWvXo4dWpo4qzvNhRRRWxkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVS1TTodQh2yjDj7rjqKu0UpRUlZjTcXdHnl7aTWFwY51I/ut2Ye1JHJXfXVtFdRGOdA6Hsa5XVdCltSZbQNJF3Xqy/wCNebVwzhrHVHfTxCnpLczpYo51xIoP8xVN9OKZMTbvY1OkhHB61OkgPWuY3ZnBNpw+5T71MgGOGq/ww5AI96jNtETkDB9qZJXzKo+U0ollJ5qbySjAqA49Gbb/AEqVJoE/10MkfuRkfmP61pCHN1M5T5egyJnxzUyxu9WovJdQ0e1x7GpOf4MAD0Fbqh3MnV7FdLbuc1YZVijcqu5lUkD1pzHcm6lm6SY/u5raNOMehm5NnhEI1r4qR3s9/fCw0yBmjgs4QSrShcruPfqOT+AFdp8B7qG48DvbJBHDd2Vw0c5VQrOTyGb1POP+A1jfBNFVvFNhIAUivB8v/fQ/9lqfwdu8LfF3VtIdj9l1WL7VDn+Jhk//ABz8hX2uYVlV+s5bBJRpqM4JaaJLm9XaV9ex49GnyKniW7uV0/0/I9XY5USDqOf8adL8skbjoaYcLIy9jyKB81uUzypxXxp6pNccx57qc1HcHapf+7z+FVL6/S2VfMzhx27UyTUbcwIDIqmXCAE+uBUuaim2Wqcmr2JXUSYSRQypEEcHoc9R+QrxyDVbO7+2R2Okw6XHpl09u0MLA7i2Ru6DnK16ldassIuDCFkYsAOe+AMfzryu9voLjxPqukJYQW8sUZuWmjwGuHODubjtvPrVYJurg6lCMbysp3vZJKSu7X13stG1v3LpwdOvTnJ2TbXrdfgdHp4W4TaxBWaMx7v5Z/WqMObRpYJv9RNEyjP8J7D86r6bLLBEsgJKcEOOx7A/41ugRT3sXygwz5O089Qcj8/51xZhReHqVIzVuZX+cdfxX5HoUasZxUoO6ONuIUd7G8xve2mSZD0J2sDj9PyrI8aWttfa/rgUbllVLuJscqSoz+oINbJBtXlt5CTGGIDemP60zxBY/wCkQ3kSjdLb7XI70UqtSjONei7SWqaPoIKlUfs6yvGSas9uj/Q5Hwxr3iPw7LZ28ET3VtdJ5kFu2SHHP3D1ByCMDv2r0PSfihYSN5OorNp9ypwyTKSAfqB/MCuOu5z/AMK80e+TH2rRNVaEHuFY+Z/PFexX2l6Nr0MU2oWVtcsVHLoCcex6ivsMXicDj8NRxeLo2lO6lKDs+aL1dndO6aeuvmfGPAVsLiq2GoT0g9FLVWe2u/QisvGGn3KAw31rIP8AZlU/1q9/wkVsFz58X/fYrm7v4b+EZ+V09oT38udx/Mmq9t8LPC082Ehuig6nzz1ryPqeVvVVpr1gn/7cacmMW8I/+BP/ACE8Z+JrPUL3SdGe8t1t5Zhd3ZaUAeTCQwUnP8UnljHdQ3vWhdePtIjB36taf8AkDfyrA8JfDXw1qKanqzWTPbTXLQ2IaZ/9TEdm7g87nEjD/ZK1tp4J8NW7hP7Dtcj+Jmd/0JprD5VHSpOo/RRX5tihTxdTWCivVv8AyMu7+Jmgx5/02WY+iRN/UCs4/E21nfbpul6jdv2CoP6Emu5h0rQ7RQLPR9PVx0K26Z/PFbNl9ptofkhVVPZcAVallFP4aM5/4p2/9Jj+pf1TGNe9UjH0X+bPMR4p8V3K7rXwjcIp6NcMVH6hf51YS1+IV+m9pdJ0qM+gDsPz3V311K7kGdxgn7oqG42B1RJCw74o/tKhT/gYaC9U5P8A8mbX4GscslL+JVk/Sy/JHn8ngfU9Tbbrviq+uI/4o4gVX8ATj9K2tD+G3huBw7WL3Kr/ABXEhbcfoMD9K6uxtlmZ3Zf3YOBnvWmqhQAowB0FY18/x8o+zVRxXaNor/yWxM8BhKb92F33ev53KVjpOnaeALGwtLbH/PKFV/kKvUVS1PUrfTowZiWkb7ka8s30H9a8aVSVR803dlRgvhii27qiMzsFUDJJOABXOX+sSXhMWmlkiPBnxy3+6P6//rqjcyXWqtuuzsgByIQflX6n+I1YRAkefuR+vdvpTjHudcKSjrLcitoEh4QBpDye/PqT3qPUWt1tZWvDG0YUlzJjYB757fWs3xJ4ksNCtt90+1m5jgTmST/Ae549K53SfDeveO50u9caTTtD3b47YcM47cd/94/gK9nB5Y50/rWIl7OkuvV+UV1f4LqzlxONUJeyprmn26L1fT8zL8GXlg/xRig0ASRaZeKySRnhSVQsdo9Mrxn1Ne77DI6RxjliFArybQLOzl+LawaNAsWnaHbNH8nILkENk9zlyP8AgNe3eG7Xzbhrlx8sfC/71dXEnJWxNHkTTdON7u8utuZ9+W1zy8vbp05t/wAztbbpt5XudBbQrb28cS9EUD61LRRXAlbQHqFFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzdS0i3vgWK7Jezr/X1rl77SruxBZ13xD+Nf613VIQCMGuerh41NdmbU68oadDzpZKkWWuo1HQLe4JeH9zIf7o4P4VzN7Y3Nk5E0Z254cdDXBUozp77HbCrGew8PnoaXcapq5FSrJ61jc0sDJtcyRHZIe46N9RV6xvBKxDDbKB8y+o9R61SzmkZW3LJGQJE5U/0PtXRSrOLs9jGpSUtVubigbivZhxSvyv1SqMWowOiAvtkGDtPUe1X+G6dOf1rtTucri1ueRfCk+V428bw9vtW7H/A5P8ak+MscumXvh7xNbAlrC5CSY7qTuA+nDD/gVRfD3918UvGcP95y3/j/AP8AXrt/HGkf254T1OwAzJJEWj/31+Zf1AFfQYvFRwueQrT+FqCfpKCT/A46NJ1cDKC3TdvVNtGp/acNxbW8tu3mCUAx7f4g3T+dbFlpscka/ab0GaQkhYXGMjqPfHevJfgzqqXenaSLhubaQQNuPTb939Ctc1puhav9k8Lp/Zd/vRPFIZfs75UyD92Dxxu/h9e2a8nEYd0MRUoz+y2vuOvmXs4Tj9pXPafEugyW0H2iCV5oV+8r9Vyev0rmXO8Wns2W/wCA5P8AhXn3wa0TUND1iwuJ9EubaBvDjWl+39kzaakMobcvmmTi5lYnbvXGB2rvYzlbkd0QqPq/T+VeTmC5Kb5eun36HoYSo5w97oIpdZI3RciRSyjnlmOR+Wf1rmdR1FbHxfZaV9jhP26Es10R+8yA3H6D86wdB8SXdzpGoXV/4khtdVt4p2l02aCMJYeXLtQngN0wPmYht2R0pujeM3k0jwbd3JtL641BFjubr5d0b5UMPl4B+bpxivSyvCKVaUIw5m4yW9tk2n8t7dSMTXUYKXNazXS/VK3z2Oy8OIDvhPZypFPe2lt79ba124LbooycYcc4BPqO3/1qi0dvK1yZCCNx3gH6/wD1xS+Mi0YkaIlZFJZWBwQcZBHvmvRrYZZlheT7XLo+zW339fI8qdWWCxEnHZv8GZN60dxd3cbqUcuTtYYIPv6EUQTboLWCZcMm5QT0YelaOv2Y1HVp0spkbW7eFHkg4H2yMrkOv+2OhA6/lXM2t8t1EIDuSeGVgyMMNGeOCO3SvictzCnjKSa0kkrr9fR9H+p9rSftIJrp/kU/E8Udn4T1y3CuFnmhmU9gwbBB9Dg/pXpPh4eboekzGQqJrSJ/xKDP615/4jk8/wAK62rgeYscZPvhxzXVfD/Uw3hjTbPU/ljEK+VN/cGOM+3v/wDrr66Vv7Gg+1WX4xj/AJHi1JOOZzfeCv8AJtHcRQwBPnYP9a57xndSWeiPHo8xiv7+RbG2x2kkON4/3F3P9ENa32SSFzlWkj7FT2rmxLDqfjlmQkWuiw7QPW6mHP4rFj/v8a8uLT1OqWq913udLp8EGladaabb/u7e3iWGJR2VRgD8hV8TW8ceNmT3JrNklhI5XcfXPNNWJ5X4ikK9gQaOYr2atroSJPicuqfux3A71Jc6llNoY/SnJBdMNqoET3NTJpyk5mbd7DiodRLqKU6a1ZlR7rl87WYDsB1rQttPJbdMAq/3R1NaSIsahUUKo6AUtYuo3sYTxLekdBqqFACgADoBS0ksiQxtJKyoijJZjgAVzN7qs+okx2e6G0PHmY+eT6DsP1+lQlcxhBzLmp64sbPBYBZpwcMx+5H9T3PsKx4Lc+Y0ty7yzyclj95/8BU0MMcMYCKqqvfsv+JrP1zXLLRrJp76fykboOskp9AK6aNCdWap01eT2SOhuFGLk3ZdWzRkdYwS20lBnH8KD3ritT8V3OqXx0vwjC1/qL53T4/dxDuQTwfqePrUNjp+v/EIhjv0jw4T16vOP6/Xp9a9S8O+H9N8O2ItdLt1iT+Nzy8h9WPevbdHC5VribVK38i+GP8Aja3f91fNnlTxNXFaUPdh/N1fp29Wct4L+H0Glz/2nr0g1LWXO8u/zJEfbPU+5/DFaPxE8Ux+G9GYQnfqd0DHaxLySx43fQZ/PArQ8XeJbHwzpT3l8+W6RRA/NK3oP6ntXF+CfD954g1pfFfiNC1xKQbK06iJf4Tj+X51VGU8W3meZu9OOiW3M1tCK6LvbZeZzTSpL6thvie77Lu/PsdF8LPCUuj6SkEozqV23nXTk52+i59h+pNevW8CW8CRRjCqMVV0iwFlB82DM/LH09qv1xVKtTEVZYmt8cnd/wCXyG1GEVSp/CgooooJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmyIsilXUMp4II606igDl9a0EIpnsVOBy0XX8q5wNivS65jxPpOM3lsuP+eqj+dcGIw6S54HbQr392RgK1SKearI1TA1wnWYut/ub5XHG9ea0NO1SZTGGbIIHX8qp+JVylu/uV/r/Sqtk3+r9h/WuinJ2OnkU6auc14GlJ+MXibjHmRs2P8AgSH+tetivIPC4MPxx1ZRwJLYn6/LGf6V6+tezxE716U+9Om//JUeLgFywnHtKX5niuhIND+I3iDRcbIJXNxCvYA84H4N/wCO16xp3iy9trSOOZUuNvy7nyG/E9683+LtudK8XeHfEEYxGzfZpiPrx+as35V04HyuPcGts3k6qo42P/LyKv8A4o+6/wAk/mbZfGMozw818D09Hqv1NjVNcutVLxTbUhXkRp0znqfWsq3GCwIz5su4/RRj+YFIp2SFsZ+U8fhT41KXUak52JsJ9zyf5Cvm67dSpCL73+7/AINj01BQXLEtQoMSqRxmuJ+IOryaNZ2TQ20EwFx5bmRc7QeRjHrg/lXbs6x5ZuhXH1PauV8fapdaBoTT2ccU07upm3gkYPHY/h9K9LASvjKVJQ53J2s3ZO/n0OXFytRm+blsr33tYfPKBrtvdKCI5Gx9Qf8A6+Kf4qYSox7Gq1xIbrT4rjHzbUkwO2QGrR1W402x0e41vWo7qbSLMwmVLUAyOZZFjQDJAxlgTz0BxzXtZZKOGTjPaK/4H6HlZpT9pyyh1/4f9TifGUskfi61uY3aOU6dbyK6kgg7eoNVtE8aQazqclr4i0xZ7mP5U1G1xHPj/aHRvxr13X/Fvg3S/DXiDUtV0PzLXQr4aM0Yto5JZnCxlRHk8jEo6kHgmvLtT8PaRFcaR4u8KvJ/wj+uQmZIpfvW8gHzIeT7jGTgqwyRivh/7FVOhCM9XHS6umvR7/1sfY5fj8NjYxw1SLUktH6X6lPxVPp7aRqiWGoC4cRjgoUbG4cEH/8AV710PhfFx4R0toZIPOihC4Zzk+qkY71w1iN2neMphyFtI0/OZf8ACvSfCukTw+E9Gv7DMu61QzQE8sMfw+/tX0lNT/sKKcn/ABXrp/IvI8vH01h82dO97QX5mhYarNFAiLdTNajjEUahozxgFnBG0c9sitPQPDz2AuJI5/La5mkuJJA/nyOztn77AKABhRhOijk9axpVjDreQsfKflyB/wCPY/nWvp15Jp5UKDJatyUHJX3X/D/J8GeBhUd6jcvJvT7lZfeOpTv70dzobezht5DIgZpWGC7sWOPx6fQVbHkxwXFzdyiG0tommnlIJ2IoyT+QNV7a4iuYVlgcPG3QipdQtZdR8LeIdOtVDXd5YTQwqSBuZo2UDJ9yK6aFOPMoWsjhqycYt9TPv/HvgHTfsqX2sxRG5tYr2J2SXBgl+5ISFwoOR1x71t6haC2ZWjbfC4yrV4b4h+EPivUY9OjisYn/AOKWsdIfOpGFIbmLBJkRQwmRSM7SCCQD2r3i7Wa30jTrW+mSe9jiQTSou0OwUBmA7AnJxXbXpQULpWOWjOTla5nVV1G+hsLczXDEDoqjlmPoB60zU9ShsQqtmSd/9XEvVv8AAe9c8wkmnN3eOGn6DH3Yx/dUf1rijG56VOnzavYjuJLnVZRJegJCpyluD8o92Pc/5FSMyRLjvjp04/oKz9a1qy0m0869nWCL+EdWY+w6k1yMEPiLx9Js01G0zQC2GuZOGlHfHc/Qcepr1sFlk8RF1ZNQpreT29F3fkiMTjIYf3Ery6RW/wA+y82W/EHjAi6Gm6BEdS1VztVY13JGfw6/5zWt4W+HbzXA1XxpL/aGoNgrbk5ji9j2J9un1rrvCnhTS/DFp5OmQYkYfvJ35kk+p9PYcVvYxW1bNaeGg6GWpxT3m/jl/wDIryWvdnF7GdeXPiXftFbL/N+YxVVECqAqgYAAwAK5zxr4rsfC+nGa6PmXD8Q26n5pD/Qepqn478bWvh1Ba26/atXmGILVOTk8AtjoPbqf1rB8GeDrt9U/t3xS5u9alOY4j8yw+ntn0A4H1rPCZfTp0ljcfpD7MftTfl2j3l92pNWvKUvY0Pi6vpH/AIPZFfwt4a1DxRqkev8AjCMyOT/odgRhUGcglf6Hr3r3TRtLWzQSSgGcj/vn2FN0LS/saebOAZ2/8dFa9ViMRUxk1UqqyWkYraK7Jfn3MlGNJckNb7vq2FFFFQSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUjAMCCMg8YNLRQBweuWP2G/ZVGIn+ZPp6VTB4rsfE9qLjS3cD54jvH071xiHivIr0/Zzstj06M+eFyj4gGbCM+kg/kao6eMqtXtf8A+PBf+ug/kaqacpJH5UUzvh/DOY0cbfjpcY72fP8A3ytetrXkfh/998cr8jnyrM5/75T/ABr11a9vP/jw6/6dQ/I8XB/8vP8AHI474v6X/afgLUNozLa4uk9tvX/x0tWR4Uvv7S0GwuictJAA3+8OD+oNeiX1sl5ZXFtJ9yaNo2+hGD/OvGPhVNJFp97plxxNY3TIV9AeMfmGqqH+0ZTOPWlNP5TVn+KRpTl7PGr+/Fr5rX8mzugN01uo6MwJ+g5/wp6/Mvmj+J9/4dv0xUW7bDM4PzqPLX6sf/1Vd2jaQBxjivnqb560pdrL9X+h6r3Odt/FcN9dXAsNM1G6t7SSVBdRxI0UskedyLlsk5BUEgAnoao3XijzfC2r6lplnLBeadctbzW12g+SQFcr8jEEAMMYY1cg8IR2rXjadquqWUF0ZJRbwunlxSSZ3OuUJzkkgEkA9BRZaEfB/g2/g0y7uLwxxSXERukjLBsEnOxV3Enkk5Jz1r1MLy+3hdX1Wj667P1OOrz8j1to9Svpl3LqWl291cKFluLdXdQMANjniro0v/hK/BWpeGFuorO4vXtxFNKCVzDOsm3juVXA96oaBf3GqaPY316ALiUHzBt2/wARHT8KivMxNcRAkHcHH16f0FexGhfFyw8ly3bWmqVn+Oxw4id8Kqq1tZ/p+p2Op/CP+19babU9akOkNrsuuSWVujxPJIYY44x5quCpQxlsgZO7t1rhfEOlWngqybwfp+qC+tY76bUYoShDWEcn3YCxZt/JY5ODzz1qPx34x17Tb3S7W01a8ggl0mCRlSTBLHOTnrnj1rzjw7JLL9suJGZ3kdmZmOSxJPJNfKxzKOLoqUFa59Xk2RyhKGKqS0tdL8NTd0xCPBPjaVVLKxtkJ9P3n/1xXsvw+mT/AIQ/RYjlXFpHw3GflHIrx3ToGHwq8UXIkI3XkUbL/eAKH+Zr2Xwk0N74S0SBlCvHZwrnvkIK9prlyOHnVl/6TE8bOJ82dVfKMUN1iyNpOZ4xm1mb94uPuMe/0P8AOs23U2lx9lcnym+aIt0x6exFdRcQ3NvG0dxEbi2YYPrj+tc/dRLMr2pk3BCHjkP3gOxPfI6H/wCuK8iDvozSlUurMlgaezmaW1wN3Lxt91/r6H3rodM1JLnmItFcR/fjPDIf8Peuct2mgAMwZ4lO1mHJjPofb0PQir2n20d7rEG4KY40LkjuOmPpz09qvkUnoKqlZtnXLrFxjaHQt645rB1fVJRcGG3UTXjDczMfljHq39BWw1lZFDi3i+m0V55rvibSfC8Vx9rlUXBlcrCnzO3zHBI+nrxXTTwlbETVOneTfRHDTqUoJznZJGg0CwFpZ3aW4k5dz95//iV9q4vXPGJe/XTfD9u2qapIdixwgsin8OuPbj1NR21l4p8fSGSQvouhSdSf9bMv8zn8F+td9NYad8LvhprmveH9Pgkv7S3L77jLNJgjhmGDj2GBXswweEwErYt+0qfyRei/xSX5R+bMKuOrVo/uFyx/me/yX6v7jm/D/wALL66uV1fxwXu7n7y2i8xxj0bHX6Dj616PDEkUSRxIqRoAqqowAPQCuS8dfF2bw14w0XTYrO1l0zy7aXWbl2INos77E289sFjnPBFd/rMSw3WUAAcbsD1rzs0xNfFNTqS0WiitEl5Lb9RYSMIXSWr3fV+rKBOK4L4geODpE8ek6JD9t1yf5VjXkRZ6Fh6+34n3g8feNJ4rsaB4WH2nW5jtZkwRAO+e2fr071L4F8HLoxMkhN7rVySZrhuTk8kAnt6nv+lb4bB0cDSji8crt/BDrLzl2j+MvQKlWdeTpUHa28u3kvP8iv4H8GNY3Z1LVHN/4guTuaRvmEZPUL7+/wCWBXr+i6OtliWY77gj8F+lSaNpUdhGGYBrgj5m9PYVqVjVq1sXV+sYl3l07JdEl0SJ9ylH2VLRfmFFFFMzCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBk6B4ZFPRlI/SvNl4OK9MPSvNX/ANa+P7xrgxq+E7cJ1RmeIn/dW8f95y35D/69GmjAT61BrZ338KD+FM/mf/rVPCywwGRjgKjOfYVjSWx6u1NHJ/DUfbPif4pveqxJ5OffcB/7Ia9cWvK/gPC0um61qkg+a8u8f98jP83NeqivY4kdsfKktoKMfuik/wAbni5frQ5/5m397YteKPF/Y3xd1u3xthvYvtK+54Yn899e2V458breez8TeHtUsHjS5lDWuX+71GM+3zmq4f8A3tWrhL/xISWu117y/IWMl7JQr/yyT+Wz/M6pFbESMOWzO348KPy/lWghyqf7orzmLVPG8f76TSrK7VwPmjfBIHH97+lSjxrr1ooF54Tu9q9WjZiP/QTWeF4fxXJ7koTb1dpx6+rTOqWY0l8alH1i/wDI9GjGYh/snFMu5GTTpnjIEiK23Izzjj9a4GD4padEWW/03ULYn/YBx+ZFaFl8R/DUzyNLdyRBcMiPC3zN+AIq6+S5lh48/wBXlK3Zc35XIWY4WeiqL8vzK/hO+1DVdF+0atGyXe9gQ0ezjtgVJra/v45egkXB/wA/hWV4P8XrqbXra1qFqs3nER7mWMFMDGAfxrW1WSG4sibeWOQo3GxgfcdK9DGUa2ExXPUp8lneyvZdbJ2WnyMcNKGJocile6td7/M4P4tsW1fRliPI0i3X+Z/rVDRLJrPw8ZZOpFaPxJG/xXp8Z426dbAf98Vc12FbXwxbhepXJr89ytf7LF+R+lYOSjhaEe42JfL+COpyEf8AHxqQP4AoP/ZTXu2h6bFP4b0gEmOZLKEB16/cA59a8PvIzD8BbQn/AJb3pYf99sP/AGWvofSITFY2cY422yD9BX3VNJ5NRjLrOf5RPznNpv8AtevJP+rsoQ301hILfUFBQnCv1B/z6Ven0+xv0DbFz6irGomxhgmbUpYIrYjLNM4VR+Jry7VfiXoPh2cx6fqB1UZIEdupbb/wI/KR9DXnUssxOIly4eDmvJbfMxeKpwV5y5Wd4fD7QzCW1nYEKVKtyCOvP+e5rG1W6s/Ccct9qU1pao4xgvguR/dXkk+wFcePGvjjxSmzQNMt9FtW4N1dHc2PUZH8lP1q7oXw20t78aj4r1K412/JBImYiPP0zkj8ce1d0csw2ElzY6sotfZi1KXpf4V838jN4utVVqMbp9Xov82Zs/izxT41D2/gvT3srHO2TUpuP++TjA/DJ+laXhT4fWeiT/bNQibVdVY72uJzkK3qoPf3OT9K9Qhe2S3SGBY44UG1ERQqqPQAdKenlE/KBUYnOJum8Pg17Km97fE/8Ut36Ky8hUsKlL2lX3pfgvRGJunP/Ls2PqKXUrKz8QeG9Q8P62txFYXyGN3jIDAHHQ846elbxKAcgVFcSxgYKjFePD92+ZM7JPnVmjldY+GvgO9i1iXWLO1vJ9S2+bdzlZJ4wqBFET4ygAUfdrlPiH4umgltfC3hXzbnVmiS3WRm3NDGF4Zm/vEc57dfSuk8WahDZ2FzOxwkUbSOfRQMn/CuJ+E9g72l74kvlzfanI2wkfcjB6D6kfkor2cBKnGlUx2IjeMLKK6Sm9k/JK7a9DkrQfNGjTdnLd9l/m9jb8C+DoPD9uIoR9p1Sf8A10+OWPXA9F/n1NeraLpaafDlgGnYfM3p7CofDumfZIfPmH7+QdD/AAj0rZrllOriarxOId5y/r+uxcnGnFUqStFBRRRVmQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGbrevaPoMMcuu6rp+mxSHaj3lykKsfQFiMmr1vNFcwpNbypLC4yrowZWHqCOteZfFvwxqWq61pmr6Da62ur6fBIlre6VdWylGc8pJFcFVKEAchs89CK8tu7bx9Jr114Zil1B/EEXh62lji0jUBZWtpcmc5lZA6IRtOGCq2T/AA4wQAfTNpqVjeXV3bWl7bT3FowS4iilVnhYjIDgHKkjnBq1Xh2seHPiRcajqAW61JoZdc0yVXt9SESm0SHbdFAHBRC/JTAJ6gGqlx4e+I8Gg3Olx2+qXaHXb37PdvrUhuLexKr5DDbdRGUZ3cSSZXrtPSgD2j+3tN/4Sf8A4R77T/xOPsf2/wCz+W3+o37N+7G373GM59sVqV4x8KfDHjKz8Z6NrPjG3laaPwu2nXVzLcxyubj7azqpKsSx8vad3I981B460n4jXnxCS88P2l5a6bBqFpIssGqOYrmAYEoeJ7lY04/gEBzgndn7wB7dRXh9poHxBXwr4gtpP7aHjSUT+RrD6sG091MgKrFB537pimVUmIbTzuFR+I/D3ja50vRY/Ddt4n022jkk/tO3vNY+1XUzGNQkkcgvV+RW3fKJYxnkqw4oA90orwPUPD/xHD+H3tpdf1Oa2to4LiO+uksoGPmktK7W18H8wJgcrKp/EgOu/D/xObXNffR5dSCXaXT215ql95Zt2YYjjiiiupIWXAIDNChXOc5FAHvVFfPd54Y+Jk2h61FpEniDT4pjYC2t7rWlmu1kUj7TIs3msFQjPy7+f7o6UeM9E8TaN4/8OeFfD3i3Xrq08QW3lXct3qDvc2qwzLJJOrDAQtGTGMAZ6daAPoSiuD+I2ja7quteEI9Gl1CPSorx/wC1Ta37WxMBjwNxV1ZufTJzzVL4Wf8ACbaRoPh7SfFOl3F5KxuvtupXGoxySWyq7GEMASZSykDIPGOaAO01HxBpmnaxp+lXd1s1C/Dm3gWNnZlQZZjtBCqP7zYHbNRJ4s8OvaW12mv6S1rdSGKCYXkZSZx1VGzhiO4FcdfSLpn7QFnc6h8sGpaAbKwkYYBnScyPED03FSre+32rlfCng3xHo3j+08UzeHc2N5dXztpEdzCTpHmbAsyZkCF5BH8+0nAbjHIoA9MuPiD4Si0m71SPxBp93YWjItzNZSi6EG84UyeVu2AkHk4HHWuoVgyhlIKkZBHIIrwXTIbvwj8GvH8HjHR57D7bcXsttFNLBJ9pNzkRxqI5HO/OARx1GM4OPT/D2j61B8PfDmmjUzYaraWVtFczGFZizLEFZcN/td/b3oA6qRtsbN6AmvNQdzEnuc1oa/p/iWz052bxbuL/ACBf7NiGc9e/pXEXGn69BbSSnxJ90cf6DHye3evPxjTko3O7CRdm7blmRvP1OdxyA20fhxVfxjeDTvCmqz5wwgMa/VvlH86ytO0nW9m4eIMd/wDjyQ/1rmviRaaw1vpWkya2Z31G5VQgtUXoQM8e7Cu7J8Oq2MpQeqvd+i1e/kjpzCs6VCbWmll67I9Q+FOn/wBneBNKjK4eWMzt77yWH6EV2Irk7XQtfghjhi8TbY41CKP7Pj4AGB3qcaP4i/6Gj/ynx/41w4uu8ViJ129ZNv73c56UPZU400tlY6avJvjREl94Vn1EjLQ3aR2xHUKpKu34scf8BWuq1HTfEsUKpF4n3TTMI0H2CMcnqc57DJ/CotR0Y6l4W1Szz5yQWLWNu+3G90X53x2y6qP+AVx4XGSo5thYU5fDJSl/hT2+b0+8jE0/a0Jx7plDw/dC80m1uFxiSNH47ZANbEP8Y/GuF+FV59p8LRRk5aBmjP4HI/RhXc25+fnuMV6+YYf6ri6lD+WTXyvp+B3Yer7ahCp3SYtwu8KmEIc7TvPAFZp0LR7+dHn0iz8rbsUNCuT7niuWu/EFxH47vbPUda/sq3tnt/sdn5CN9vRgC7ZILHnK/IRtxk0nw91+81PxHrNo+sf2xYQRxSwXKCJlBYsGBaNVCngHyyCR61zx56clUhJprs2tyJck3yyVzR1LwR4dM5H9mRqOM7HZf5GsPVfh9o0e5rcXMJ2kjZLnn8c16Df/ADXTY6cVT1IZtt+O1e7SzfHU4q1aW3dv8zieCw83rBfceGa/pZs9ehtIrqd2MSnfKcsvJGPpxV7X7DVrTT4/O1Pz4NuQjLggVreNrVU8bxOq4DRKPxAH+NUvHkV4Yd0d/shKDEXkqdvA79fevIocQ4ycL1XGX+KEX/7bc+uo5JhHToukpJv+Wcl/7dYZqsPiSL4eaPHdSWzaFPODbIoHmBzvODwD3b1rvNQtPjFeEqP9HUAKEtpYI8fQ5z+tchqtnrB8M+CtOl1gtDcTwNFGbZP3ZIHfPP3q99TRvEpMZ/4SzksT/wAg6L/Gvr1m8qOCoT9hTu+Z/Dputknp5n57isMp4ysueWj6u767vqeEyfDzx5PqHn6vo76rIOSLq+DZ/ESA/rXUaNa+NvD5Dab8PtDgkB/1q4Z/puMpP616gujeJfOkP/CWfxYz/Z0X+NZXiLT/ABJbaO7HxTuNw/lAf2fGPvdTnPpk/hWdfietWhy1aUWu3vJfcpWIpZbFSXJJ3fp/kebDWvGs7yXSeG7YCZt48p9qjPoN/T/GpBrvjlOB4cwR/dbP9a6aDR9eVFUeI9oHOPsMfHp3oXTNfVN3/CSdf+nGPt0715DzDDS+LC0//Jv/AJI9b6nU2VWX/kv+Rz0fi3xzD9/w07Dp3qxa+OPGcoYw+ErmUKdrFNxwfTp71o39j4hjVY4vERkmY+WiCxj+ZyenX1NdZpvhnxDYWYtovFIARcH/AIl8ZySck9fUmnHGYOT1wkPvn/8AJGNahVpxv7V3flH/ACOJHjrxmAC3grUCD6LJ/wDEVHN4+8U4Ik8F6kCPaTj/AMcrv5NF8RJ08Vf6tf8AoHR/41Sm0nxEFAPijk/Mf+JfH/jVTxOXpXeEj/4FP/MwjHEN2VV/cv8AI8i8V+KtX1uzj0OXRbnT7rUJ0XdMWG9c8KAVHG7BJ9q908FaLFBHa2sa/wCi2MaoM/xEDA/xrxq1sdX8RfFC8lOub00SPykuPsiY3nIxtzjqX5/2RXtOk+HPEtvYxqvivYWG9h/ZsR5P4081lT5KOEpU/ZxiueUbt+9Lbdt/DbfvsPD8y56s5czeifkt/wATo/Emv6X4a0w6hrd2lrah1jDFSzO7HCoiqCzMeyqCadoWtWWuWsk+ntPtjkMUiXFvJbyRuADho5FVl4IPI5BBrkvHXgzV9e0fw+9vqlvca5oepR6lDJdReXBcshb5HCZ2/K2NwBIx05rL8a+DvE3i2fRL7VLXw9crYS3Bk0Oe5lezmWSIIjtKYss6Nlh+7A5wMEbj5xZ6nRXz5cfA7WrnTbW11DUdN1SS38MT6Sk14XJW6aZpI2GUOEQEKG+8No4pdV+CmvXFrqFvaXWkRRXtppaTL5sgElxbkGaVsR8lsHDdTnnFAH0FRXha/BvUrbX47/Tn0i0WDxWmr25iLK0NjtIkhQCPCljg7B8pxyaraV8G/ENqyhr3SopYrDUrSe+hlkM+sPchhG10CgwE3A/ekPHGKAPfaK8k+F3wxv8Awb4ssNSZ9NjtV8Nw6ZeR2rOGnvEkBMpBUBhtGAxO72qzB4C1S18ea9rUtl4f1n+0JVls9Q1JmNzpoCECONPLYMgJyAHTOTmgD1KivmhvgZ4ultNeQ3Xhy1fVNIWyeK0IhgM63McofZFbRhVCKw5Dtk/eIPHSeKPgpI2IPDUOmSae2lS2UdtqVzMwsbqSTe15CxWQtJk99p4HzAcUAerv4r0hdW1XTFuJpdQ0uFLi6t4bWWV0RxlSoVTvJx0XJ9qg8Z+MNP8ACXhVvEGow3klkrRLsiixL+8ZVXKuVxywyDgj0zxXll98GtUGoeIJYG0W/l1XQU00ahdlo7iK5WAxvNgRtnzDjcdwOCfvY5oeKvgt4h1YXyq+hXb3FppkFtc3k8gk082yqJUiAib5ZCCcgqeeRQB9C0V558YfB+r+MbTS7XS10Z7WOSQ3a6hCjSbSuFMLvDMEYHOfkyR0I6074XeHvFvhTQ/D2h6pcaPc6bZWUkd1KjyvOZ/MYpsJAHlhCAcgHI44oA9BooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiqOr6gmnWhlbBc8IvqaUpKKuxpOTsjmvF13518tup+WEc/7xrkNbm+WO3Xq3zN9O3+fatSeYvJLPO3Jy7GueiZru7aVx945+g7V5F/aTcme5hqfKvQu26bIsewFcjZx/2/8AGW3jxuttHh8wjtuAyP8Ax51/75rrppEt7dpZSFRAXYnsB/8AWFY3wRtXurfWfEFwv77ULohCeyLzx7ZbH/Aa9/LH9Xw2IxXVR5F6z0/CKZw5i/aVKVHu7v0j/wAGx6eoxT8UgFUtWlfZHaW7Fbi5JRWXqi/xP+A6e5HrXzVarChTlVm7JK7NdylNNJM7TxFfNmc2tnj+Ff45P/HSfoq+tatpbR2lrFbwriKNQig88D1qjpUCPMblAot40+z2ir0WMYyf+BED8FX3rUrz8qozUZYmt8dTX0X2V8l+NxvseHeBYv7K8R+I9IPAt7slB6qSQP0C17Fo2madG9rHq17DHe3EbTQWjTKjtGuNzbc5IGRnHTPNeU+JI/7L+MrsPlTUrRX9iQMf+0/1r0TxNpl7qnxI8MatYWskunRaRfxPMv3UeRU2Kfc4P5V93m0VWxEcS/8Al5CEvnaz/FM8+hVlTw/so/ZlJfjdfgzauLHRb10g0jUbWS9lt/tUUCXCuZYcgeYozkrkgbhxkgVgsMRrxg9Dx3rF+FvhrWNJ8VeE7rUtPmt7e08FrYTyOABHcCeNjGffAJ/Cty8cXd9dLCdsRlZ2YH7qk5x9a8XFyhQjzy0R2YWpKd1LoZ0jB3LKcjpn6VXvButJF9M1OrRsZfKx5YPy49MVDcco49UNdlN80It9v0H1fqcJ45gzr6SY+aMqPwKj/AVznjVy1kpPXFb/AI2uNT/ty6UaRlFYBH+0r8wGMHHbI5xXE+KLzUZreOJ9M2FiAP8ASFPNfP0oP2MfRH22V4iPLBO+nk/8j0bxBbpHr/w4s1+VFniHPYKYhX0CQElLZ+WNcV81eJb7WLrx94XibRdlxDG0iR/a0O7qc5xx939K9Rbxj4k+zeWfCitIfvMdQTB/DFfa45pYXDU10i398mfmEG51qs31f6I722ZnjJ7k5/OuU8TX0c+spaBx5VkuG93IBP5DH/fRrmrzxL4sNtJJJoTRQoMkJexqP5ZrG0+510Jl/D+95CWY/boxnnJ7V41R9D08JFXc30Ove6Xywqhi0nfpj/IprXce4ZRlVMHHXnsKwP7S1sFnPhz2H+nR8evaq91qWvFVjTw5+9kbYg+2ocsfw7D+tZ2OxSR2XhK3+26u14fmt7YNHGf70h6n8Af19q7eFcrIT/eryPQ9X1/QLmJP+EcLQfddTfR8n16dc12qa14kWFseFM5br/aUX+Fbwjyo82vU9pO/Q3bgDDqOd74/Kua8W6qmj6NqGovjFvEzgHu3RR+JwPxqF9b8RnYf+EW9W/5CMf8AhXmXxd1vW72wsNCOh/Z7jUbhQoF4j7gpHHA45K8+xrfDUI4nE06Mvhb1/wAK1f4GMpunTlUW6Wnq9je+BmkSNpSXVzlptSuDcOT1KD1+uGP417vXlngebXrC0VbXwnvigjWCP/iYRjAAHt9K7K3N/r9jqGneIdC+w2VxA0L/AOlJN5iuCrLhRxwTSxGIeLxFTEv7bbXp0XyQ+RUoRpL7K/HqdDRXzZ8O9A8VQ6u7eItJ1RoPAWmXVlpDRxbWvpnZwssPmAq37pVUdRnb9KktvF3xXfSfETWun6y+LW2ns3u9O3XEBZwJlUfZoVlkUZO0Iw9Cw65iPo+ivnjTfHHjOe7v20y/1jVtN0zxTaWtyx0lDcjTzGxmDwpCrg525wgYe1Mm8VfE7+wo7lxrPnpqF5utItGkiubiAFRAEk+ySxIOT99VJ/vegB9FUV534/1HxVD4T8KyeHU1GHUbrULKK/220dxNFA4PmlwEKDHGWAAB6YFVfh94l8SW0VzYeLtP13ULhtfutOtL1dOEY+yoFMc820KoQ5IDquDQB6dRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFVr+9hsYDJO4H91e7H0FJtJXY0m3ZC313FZW7TTthR0Hcn0FcDqV9Lf3JllPsq9lHpUuqajNqU26T5Yx91B0Wuf1K+8pjBbnMp4Zv7v8A9evMr1nVfLHY9PDYZr1ItXut5FrEc5Pzn+lJaxYHHfgVWtovmyeSOPxrTUCPJ7IP1pQjY9F2iuVHJ/FDURYeGLmNDiW5It0A9Dy36Aj8a9D8EaU2jeE9LsHULJFAvmAdnPzN+pNeY6pbf8JD8TNB0j70FmPtdwO397B+uFH/AAKva69vMGsPl9DDLed6j+fux/BN/M8SL9riqlTpG0V+b/ERmCKzOQqqMkk4AFYBaa+lOzMb3qgKcYaG2HVvZmJ49Mj+6at6zLHIxtZWxbInn3TdhGOin/eIP4Bqs6XDLiS6uQRPcYYof+WSgfKn4ck+5NfEYn/bcSsKvghaU/N7xj+r8rdzr21LcaLHGqRqFRQFCgYAA7U7FFFewSeRfGtDZeI/C2qjhFkaFz6DKn+Rau20PXbzT4kSB1aJh9xxkA+3cVg/Hex+1eBHnUfNZ3Ec2fY5Q/8AoQqHw7d/bNHs7nOfMjVz+IGa+hxLdTLMNWW8XKD+/mX4NmODivb1aUlo7S/R/kdlqev397YOu6KLna20EDHqepxWRDiYG2UYiXPmENnzG9M9x3P5etcX4x1y50/xHYWUus/2FpU1rLM175SP5kylQsWXBA4JOMZOMCqdr4o1yT4oaVp9xDPbaROlxGkbWwX7R5ap++3HkAljgDoMZ5OB4tSgqzjKettTrvGD5Uju4ubiYeoP6VWuuFJ9BRcXKWXmXEqytHGcsIomlYj2VQWP0ANYl54o08hwLfWuQRzo14P/AGlXqSdl8jnur6i+L492r3HphR/46K80159+pWUXTMyD/wAeFdvr/iWwuNRnYW+sYIA+bSLsHoOxirzrV9VtZvElgUiv8faIyVNhOG+8Oi7Mn6AV8/Spy9jBW6I+vyvEU4RalJbdz0pm+0fGPTB1EFi34ZD/APxVemd68Y0jxFZN8Wbu7MOqmKO0ChV0u6ZwdqdUEe4Dk8kfzr0Q+MdMAJNtroA6k6He/wDxqvtM1a/cRT2px/V/qfm+GT99v+ZlzxDcNPJb2SHgsJZAPQdP15/4DSx5Ckjv8q/SuWg8WafcXUty1vrWZThMaNeHC9ukXpz+Jq23i3TQMi21vA4A/sW8/wDjVeC7t3Pfp8sIKNzddsYH8K1c8Lr51695KPlXMcOf/Hm/p+frXFXXiyylKW8NvrXmOeT/AGNeZUdzjysnFb1h4s0q2SOOO114IgCj/iRXx/8AaNVCN3dmWJqqMOVPVnVa9Z/L5ijg1b0C9aTSijHLwsFP07Vz9z4z0ua1KG18QZ/7AF//APGaxrXxtp+n3TkWmuNFINrqdFvRn35irY847jVrk2yoq4LO238M8/5968kt5v8AhIvjBeXS/PaaPEYUPbfyP5l/++a1fEXxB04W1xei31hFgiJTzNIu1G7HGWMeBk4HJrm/hLqVlYaP5l3b6093qE/myNHo15Llc4GCsRDdzxnrXbRccPhK+I+01yR/7e+J/KK/ElXqVYU+ifM/lt+P5H0ZocPkaXbrjBZdx+p5q/XKDx3o4AAs/EgA/wCpc1H/AOMVifE7xdrWiReD5vDjWEcWu6pb6a41KwmLxiYErJt8yNlKhTlGGeeq4weCMeVJFyfM2z0aq2pafZarYy2Wp2lve2coAkguI1kjcA5GVYEHkA/hXA3fxb0ey1mbTp9O1dvI1WPRZbtIovJFzIuUGPM37Tzzt4xz2zzvhr43InhWXVfGOmyWUj6rJptoIGhRJiGIxl5sKVA+dnKpyME1Qj1zR9J03RbMWmjafZ6faBiwhtIViQE9TtUAZq7XlUXxx8PXUGjPpul+INSl1QTeVBY2izyIYmCuGCv7g5Ulcc5q9pnxe0XUNWs7FdO1eFbu/uNNhuZY4hE1xCMsvEhYZ4wSoHPOMHAB6PRXinin40Wd54d8WWnhw3Nh4h0zTGv43eS0uUADhDhopZU3AkZVueeldZ418aXHhb4c6dr0gkd5RbLNOtqk4QybQWaPzouCTj5WOCQcEZoA7+ivPpPixoSagLM2mp+afEA8N5EcePtJGd/3/wDV+/X/AGapWXxn0G8vLCO307WGtNQa8WzvfLi8m4+yoXlK/vN4GBgEqMk/UgA9Oorxfxl8ZbSbwddt4aXULPV7jw+2u2c80MRWOPzfLwwLMN+QeMEY71uXXxa0nQ77Q9K12O5+2X4tYhPHNasC8yAhjEJfOVckgt5YGenGMgHplFcX4I+Idh4x1fUbHTNK1uFLF5YpLy5tQlszxuEKLIGILc5x1x1xVXSPilo2q+IYNCtrPUhq0l9c2Els6RhoDAoZ5Hw5Ajwy4YZyTgCgDvqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiql/qFtYR7riQKT0Uck/hXJaprlzfEpFmGA8YB5P1NYVa8Ke+5rToyqbbG9q2vQWe6ODEs/oDwv1Ncfd3MlzI091LnuSx4ArPvL6G0yCfMl/uDt9fSsS7uprxh5hwv8ACg6CuCpUnWeux6uHwltfxLl7qrS5jtAVTpv7n6elVbeLqx5P86SGLJAH0FaEMWCAO1EY2O33YKyHQRhQCf4efxqadlht8yEBcF3J7AcmnJHukC9l5P1rk/idqRs/DF0IziW7ItowOuD1/QGu3BYWWLxEKEd5NL+vQ5MRWVGnKq+iuT/BSE6nqHiDxJOh33M3kQk9kHJA/wDHB+FepXU6WttLPL9yNSxx1PsPesXwJo39geE9N09lAljiDS/9dG+Zv1OPwqXUrjzbgts329q4CJ/z3uP4VHsvXPr/ALprn4mzSn7epXgrpNRgu9vdil62PPwdJ06UVLd6v1erIrO2ee4W3uNrSbhdXpzkeZ1jjHsMD8FGfvVtXs/2WyubnyZpxBE8pihAMjhVJKqCQCxxxkjnvTNOtfslsEZt8zEvLJ/fc9T/AEA7AAVftZBDcI56A815eXYX6tTUajvJu8n3b3/yXkjebdtDC0D4j+H9VuvCtnpMF5NL4htZLyHEaf6PHGPmMx3cfMCvy7vmBFVvCPxC8O+Pb/W7TQBcpc6S+HaZFVbhNzL5keGO5cqeSAeRxzWV4U+DqeGrjxXd6PrzJNq9vJa6czW2RpcMju7Kg3/N8zAj7vK96Tw58JbHwRq2g6loWq3Eclpp76ffQy75VvlbnIDPiECTL7VBGT06k/QVIx5HfY4IOXMrGz44sf7S8H6za4yz2shUf7QGV/UCvNPhpdCfwtaLnmPdGfwY4/TFezsAylSMgjBFeC/DsGwvdb0luDaXbKB+JX/2WunCv2uV16f8koy++8X+h00/cxkH/Mmvus/8z0uF8NGx6ZxT52EaszcbOc1UibMRHcVZcC4kX/nmih39z2H9fyrxqtVUoObPTkrFNTuYn15qW9w20jo4FRQ/cU+1SE7hGvpIB+or1K2ik/JnBHoZWor5mp3ns9cDcWwbx9ooxnMp/wDHQTXfTt/xNbr0aRx+tYNpaCXxtp0hH+pkdz9DGw/nivHoRvTpr0/Q+ipVfZUpv+6//SWL4GHm/FHxPN18tPK/VR/7LXc67ORAlrGf3lxlT7L3/wAPxrznwBdlfE3iu7UEiS6wCB23uf8ACuztbh7+6ad/un5U9lHf+Z/KvreIHy4n2faMF/5Kj4vKafOud7Xb/Fl+3TyoRjqRtX+pqK6lEaHBwF6f41NJIACV/wB1apQRi+vVQ8wR4Z/f0H4/y+teD5I9u6ScpGl4dsnlInKfv7jCxg9VTt+fWu9tNBt4kHnM7ydyDgVgaFNGmq25dgBkj8SCBXlnxE8HeIJPiNqPhzRtPuW8K+Mrm0vNRu4o2Mdr5RJnUtjClwqnkjJOB6V0xVlY8ipN1JOTPa7+GGOKY2sqyCJtsihgTGcZwcdOo/OuL1KbMuB1NT+GrSTRrv4iSXFpJa2s2pR/ZN8ZRJE+ywoCmRggEEceh9KpWMbXNyXb7oobSV2Sld2RxHxRmeW10jw/bE/aNTuFMgHUICAM/ic/8Br1XwbZxxX1vDCm2C2iwo9ABtFeU6IP+Eg+KWraqcPaaYv2aA9t3K8f+Pn8RXuPg+2MdnJOw5lbA+g/+vmuzNPc+r4JbxXPL/FKzs/RcqDDfDUrd3Zei0/F3OgrnvFng7RfFj2D65DdTNYSi4tvJvp7fy5R0kHluvzDs3UZOMZNdDRXII5Sf4eeF55p5ZdMLyT6hFqsjG5ly11GMJJ97t6dD3BqE/DTwp5VxGumyxxzXg1DbHezoIbgEnzYcOPJb5jkx7c8Z6CuxooA52z8GaJaarp2prDdz6hp6Sx21xdX9xcOiyffGZHbIOO+cdsVSHw28JhIUOkKyQ3k1+itPKw86YYkYgtyGHG05HoK6+igDhLf4S+C7eCWFNJmaKWxbTCsl/cyAWxcOYl3SHau4Z4xjnHU1N8Q/A7eLvDVn4eg1CPTtJSSFp1+zmWR0iZWVEcuAn3cEkP/AI9rRQBx03w08Jza4dXfTH+2m/TVMrdzrH9qTpL5YfZu9fl575rm9H+D9rZ+MrPWbi8tjYWTXb2+l2tvNHCGuFKuWEk8ij5SchFQE8kdq9VooA4OH4R+CoYZIl0iVo3sm07a9/cOFtmfeY1zIdq7ueMY7VPP8LfB89812+lOJWlhnZUvJ0jeSEARu0YcKWUDqRnrnOTXa0UAZXh3w9pfhy1ubfRbX7NDcXMl3KvmM+6VzlmyxOMnsOKoJ4G8Np4k1PX00uIavqcBtru4DvmSMgAjGcLkKMkAE4610lFAGf4f0aw8PaNaaTo8H2fT7VPLhi3s+1c5xliSevc1oUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVa/vrexhMlw4X0XufoKTaSuxpNuyLBIAJJwB1JrndW8RpGWisAJH6GQ/dH09ax9U1m51Jii5jt/7g7/AFNYV9qMFkCq/vJv7o6D6mvPq4py92md9DCXfvasu3EhdnuLuXJ6lmNYN/qzy5jtAY0P8X8R/wAKo3NzNdvunfOOQo6D6U2NOMkVzqHVnrU6CjrIRUJPP1qaKPgt+AqRYzwo6mrBjClUA6VokaORJaxhVZz/AAjAq1CoRC7c/wBTQEwkaevJp7D5wvZeT9atHO3cD+7gPPzucVws8S+Jfirpelfes9LH2mYdQWGDg/jsH4muv1K8S0t7i5lOIraNnP4DNeY+A9b1zQpbzXx4cn1JNUfAnQkH7xyq4B7+38NfR5FhZunXxULc0Y8sbtL3pabtpaRuzxs1rxjyUZbN3el9F6edj3rUbqSMxW1qAbufO3IyI1HVz7DPTuSBVTRrYTPFcAsbS33JbbjkyE/emY9yecexJ/i48yj+J1q0kq61p2p2jzvi5ZUB2xjpEucEDnk9eT68dlp3xN8IXKIiamtvgYCSxMgA9M4x+tfMPhvNZ4j6xXoS5IfBb3vWXu3XkvLXqOOPw0tFNfl+Z21FZtlr2kX2PsWqWM+e0c6sfyBrRUhhlSCPUUTpTpu000/M6IyUtYu49JZEHyOyj2OKazFiSxJJ7k5ooqbvYLCV4RIDp/xh163PCz/vR75Ct/7Ma93rxH4nR/YPizpV0OEurZQx9SCy/wAgte5kfvrEUX9qnL742kvyObES5KlKp2kvx0/U61ZxECx5yAAM9T2FXWDQ2Qt0Y+a2Wdx2Hf8AwH/1qwJdX0+zuLKK8u7JJ5WAjguJVUzZ4wAeT+A61Z0jWtLvri9tbHU7O5uY1bfBFcLI8Sg4wQDngnHPevCnh3WnC/wp7fkexVaWhetuYvocVJAc3SL6up/IiobU8svrzU1r/wAhC3H+3/Q16uLdqNR/3X+RwR3RjynN5cv6Ssf1qgr+R4kgkH3TkH8Rj+tX4vmmmz3Y1m3y7Y57j+KCIvn6EH+lcFGPwr0Pbn/Ckn2/QwPhjm4s9UKnD3N0cn0UDJ/9Cx+NeiRwGOMeWcFhgew9a4b4RQKvh+SQ8NJO2T/sgAV3k0m1Cx4BHI9B2FfQ8QS5syreTt9ysfPZXDlwkPPX7zPvrh0XCrlmG1VH6fnU2lpPujt40CvI3Lu2AWP4Vc0S1Nw7Xs6gqTiFfbu39B7fWugFlDLGV27Se47V5lOPVjxdW79nHZFV9D1SMElIm29dsh/wq/H4h1fT4Ql1bb1HAkkGfzZT/OtDT9UaJBb6mSMNkT44b6+hqzeFZEQxFWjAwGU5FanEcpqV/e6w6i5ICDlUUYUVm+K9RXw14Tvr0ECZI8R/754X9TmulMUScRxqoHQDtXl/xVd9b8R6D4Ygb5JX+0XAHZeRn8AHP5VeWwhjcXCnPSC96X+GOr/KxpXToUnJfE9F6vQvfC7SzYeE7QkE3F4ftDkjklvu/oBXutlALa0hhHRFC1xHhmzSTU7eNEAhhG7aBwAOg/lXe1g68sXXqYqe822VUgqUIUV0QUUUVoYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUyaWOCJpJXCIoyST0rjtZ8QSXe6G0zHD0LfxN/gKyq1o0lqaU6Uqj0NfWfEEVoGitSJbjoT/Cv19a466uHmd7i7lyepZjVa5uIrSPzJzyfuqOprAvLqW9lBfheyA8AV5k6k6z12PXw+FS2+8uajqrSr5VplEPV+hP+FZqpkgdhzUkceWyfpU8Ue49Ov8qajbY74pQVkRiPgD15NTomWAp7KN59BxUtuvVj0HNXYlyJLdB5ju33VFSQJvk3n60FdsCr3c5NTKNsWB1bimZNio3DSkfQfypEISNnb6n3NE5AAQdv502fhY4/X5jTJOD+KeoMum2ukW5P2nUJQCACTtyPT3x+teg6NYSWdvaWFsPKnggWKJeD9kixgyN2MjYP/wCoMT534T83xH8ULzUYY/PTTh5VuSD5aNyN7H0HzEDqTjHcj2nTrNLKAorM8jnfJK33pGPVj/ngAAcCtuIaE5Ro5W9KcFz1P705aqPpGNr927dzyKEvbVZ4jvovRf5u4+1tYba1S3jX90oxhuSfUknqSeSazr/wvoOoZN5o9hKx6sYF3fnjNbNFc1KrOi70pOPo7G8oRnpJXODv/hR4Su8lLGW2Y94J2H6EkfpWO3whS0bdofiTVLA9uc/+gla9Uor1KfEGZU1yqs2vP3v/AEq5yywGGlryJemn5HlX/CMfEXTf+Qd4qgvEXot0Mk/99K386kj1X4nWAzdaJp1+g6mKRVY/k39K9QorR55Kp/GoU5f9u2f3xaF9RUfgnJfO/wCdzzL/AIWXqdj/AMhzwdqtsB1eIF1/VQP1rg/iV400nxHqmgXmnrcxSWcjees8e0hSykdCc9Gr6Jryn4/28X9jaPN5Sb/tyqW2jJBVuD+VerkWMwNXHQjHD8kpXV1J21i09Hf8zlxtKvCi5e0ulZ6pdGuqsee2t/anxJdX9reaTPDeRQwSC/Lo0IjZjlBtIYEHoSvIBzW54HsG0/Vb27iv7GOwljf/AEO1v3uEklZ9xl2uB5ZxkbVyDmrOoeGtH+0xtJp8IjfghAU5/DFQ3PgLQ5EcolxCeo2S5/nmuKCyio1GM6kX5qMvya/I9apDHRXM4xl6Nr80/wAzt4ThlYdM1btuL5D6ZP6GvOYPARjQNY63f2/sD/gRVmLw/wCKbdi1l4maQhGP+kR54A567q1xuAwdShOMMVFXT+KMl+SZyRxFeLXNSfyaf+R0Vodyb/Wql7gaRrbnolszfof8K5m0bxlbRsIhp92qnnPB/pVbUtb8QxaLqkd7ogWKaIxyTxvlYwcjPf1qMLkk5VoKnVpyV1tNX37OzPSxGZxjRnzQlHTrF/mro3vhmBF4TtTj77Ox/wC+iAP0rp1Q6jciAMREOZXz29B7npXn3w/1i5e1sdIXS7gBgwS4GdrE5IGMd846966nQNUuZPE8nh8aXcpc+bIhuHJWNimeQcdMLxXRmmXYmpjq8+XS7luvhu7dfLbc82hjaVHCU1F62S2e9lc9AhMahVTaFAwAOwq9AQehrzjTfEsV94vbw7DbzrfrNJDuY/u8pnJz1x8p7VZ0rxTFe+JZNEsWLaikkkZTkAlM7ucY/hNc8stxUL3pvRc3y7+hxrEU39rrb5npI+6QwHPY1z1+/wBjvENuSm48qp4P4VgWXjyyn1V9LE7G/R3jMRRshlzuGcY7HvSadr+nat4hFiL2M3iuyeTzuyucjp7GsqmDrwT56bVld6Pbv6eZUasJNcslvb5nZzyJFE8srBURSzMegAGSa8t+HOdd8Q694onU4lk+z22f4UGP6BB+daXxT8WWEfhe+sNMvrebUJn+yNFHIC6ZOHyB7Aj8a6DwToH9maFpmlIMShR5h/225Y/mT+VTCnLAZbOc01Os+VX0fKrOT+bsjoclXxMUneMFd+r0X3as7zwlaGKze4cYaY8f7o/+vmt6o4IlghSKMYVFCipK5qcOSKiTUlzycgoooqyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqlqmpQadFvmbLH7qDq1V9b1iLToyi4e5I+VPT3NcVO9zezNNMWd27n+lclfEqn7sdzpo0HP3pbEupalc6lLmViI8/LGOgrK1G7Sxi4w0xHyr6e5qTULkWcZVRmcjgf3fc1zzRu8mXJZjySe9cCTm+aR69GireQyR5bmXfMxZz69qkiTGWqWOEjefTipvKwijHBNapHU5LZDETCgfhU8S7Szegpsa5kx6VMB+7PucUyGyLb8mT1NWYkHlD1Y0xl+6PerKgAqD/COaaIkxrfPLjsvFTdHY/wAKDAqO34Bc+7U/HyqpP+01MhjEUtMoPJHJ+prmvH2t/wBk6FeXETbZn/cQ+u49/wABk/hXSo+yN5D1IJrgZbT/AIS34k6bpQG+x00faLr0zkHH4/KPxNerk+HhVxKnW/hwTlL0j0+bsvmcWPrSpUXyfFL3V6v/AC3PQ/hZoY0HwXYwvHsuZ1+0T567m5wfoMD8K64UgpRXl4vEzxVadepvJt/eZ0qapQUI7IWiimPdWNq8H9p31tZxzSrBGZ5Vj82Vvuxrk8scHAHJxWEYuTshtqKux9FS6j4g8L6Y11DqWs6PaPalFuFuLyONoS4ygfc2V3AEjPUdKr217pup2y3mh6haahYuxUTWsyzJuHUblJFbVMPKCuRCspOw+kpaSsDUK8u/aA/5FzSf+wgn/oD16lXlvx/58P6Ovc6gv/oDV7fDn/Izo+v6M48w/wB2l/XUW9txc2zp32gg+9UYrhmsTv4kjIRvzrcs13A/7n9awdZX7JceZ0jkIVv6GvMpr30z6Fu6cTTs5MoR+IqeBsG5Of8Alg5/HgVk2cm0rz04/CtBWK2t6392L+ZFb41/uJedvzRxRh76RUsztX/eGKzPGDeX4B1l+7NGn/j6/wCNX4j/AKPkdRyKyPiBJs+H1x/02ukA/n/SurJIc+YUI/3o/mjfN5cuDqvyZvfDW1jjtLd3G5orWEqp6AsuCfrx+telW2oPGoWOZlH9xxuH+NeeeGT9ivo4HGAbYL+I24/ma69TnBWnOfPOcu7b/E8XERcZJPsvyOiTU2dlZ7eF2BzuQ4P61D5enpcNcixSKchsSiAbgSMdRz61keXeACSIROh7EkH8+n54p12+ppHj7I+MdVdW/kaFJrZnPZDJNH0N9WN5badZLcqd/mrAqvuPU5xnNVoPDWjW2rf2lb6bbx325n85Vw2WyCfxyauaZDLGjyXKlZG7E5IFO1K8jsLC5u5ziKCNpWPsBmuOriq86jhCb193d6rt6eR10qMIwvJLueRX2jaXqHxlhtNPtEjis1+1XbKSfMl+9zk+rJ+te6+GLQGWS5cfd+Vfr3/z714/8HbSSSx1TxFf/wDHxqU7MGP9wEk4/wCBE/8AfIrsbfV7yK5Z7Wd0BP3c8flXpZ/iuXFww8pOSoxUb3veX2n9+nyMcDRcqMpxVud3+XT8D1KiuPtPEd8qDz4opPcZU1oweJYSQLiCSMeoO4V58cVSl1sU8PUXQ36KgtLuC7j328qyL3x1H1FT10Jpq6MWmtGFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZevaounW+Ew1w/CL6e5q1qV9FYWrTTH2Ve7H0rgpbqS9vzPcHJJ/ADsBXLia/s1yrc6KFHnfM9i/p2nvd3BkuWLO3JJ5rXntIY0wiZIqpp14kLDJrTN1FJ1xXJTUXHzN5uV/IwZ9Nsbpy1xxKTzzioJPDkIcSRSfIB09a3rizjuB0B9xWfNp01upeGVwB2JrTma3jcIzl9mVjn7nRJ4VChdxLdvSqtzbmF0jYcgc10lrqmJhFdc54Bq81pDc7nKqxPAPtVRUai91m31qcH76OFiT5ZG9jTiNoQH0Jro7zRQkRWDqzDj2FY+oWrwylCOigE1Lg4nTCvGpsysBkqPb+dPHKyN6nApYly59v6CnAYhjHqc/lSNGxyDOEHfr9KbIflZv7x2j6U4cI7Dr90VFKcMF7IP1oEjN8RalHpejXN3L92JS2PU9h+JwKj+B2kyw6Fd61ejN3qspkyRzsBOPzJY/TFcv44Euva7pPhi0Y77qUPOR/Ag7/AJBj+Ar22ytorO0htrZAkEKLGijsoGAK9ms/qWWKn9uu7v8AwR2++V38jyasvb4r+7T0/wC3nv8AcvzJhS0UtfPnQJXO/Efw3J4s8C6tpNp8uplFubB9wUrcRHfHgngZIxn0Jro6M1cJ8klImUeZWPGLz4deL7v4ePe3unO3jLVPEcOrahFbTwb4Yo2IRUZ28s7V5UEn72Dmux+GOiavoaeI11i1kt0v9Ukv4TdPC13JvUbmm8kmIEkcBMADtXe/a59m3zWx+v51UnnjiBeeVEHUs7Afzroq4hTjypGNOg4yux9FZE3iPTI8hLgzsO0KF/1Ax+tUZfFDFv8AR9Pcj1mkCfoM1y2Z2KlN9Dpa8p+PjZs/D0X9++z+Qx/WuqOuapKv7uG3i99rP+pIFeZ/FOe8udY8NQ3lwZi1ySFwoC/Mg7D/ABr3eG4P+0abfTmf3RbOPMqUo4aTfl+aO9s02kA/88z/ADrK8R24ltJFI7g/pXVaHpNxqUimEBYlQhpG6A56Vd1jwVdSWzm2uI5XxnYRtz9DXnUYNyT6Ho1MRCLab1PKdMnO0xSH95H8p9x2NbJl/wCJXeHuRGv/AI8f8Kw9Xt5dPulmZGRkOyVCMEc85q+kgbSLhgfvSIB78E1ONf7qz7x/M3px5pxZLb8WuPTisP4jc+DtMgHWW/A/Rq24WHkgf3hj8aw/H/zW/hSD/nrd5x/wIf8AxVerw4v+FKk+139ybMs9dsHNd7fizv4IreXXbSO8+WNyU3jII4OOnviukk8P3cIEmn3STxEZw56D6j/CuR1dzBPDOOGikVvyOa7K2kYtlSQ3qpwf0rjpPdHn41axl5EAl1KzYrLZSkjr5fzfyqBru4uZtkcMsbt1JQrj8cVuy308ALeZuJ67lBqnaX0l3cyIyrtUZyBj+tVUlyxbOOEeaSRO2QACcn19a85+NGpvB4dg0q2P+lapMsKjP8IIJ/XaPxr0eQV5HPnxL8Y23/NY6FHn28wf13H/AMcrTIacViXiqnw0k5v1Xwr5yaNcdJ+yVKO83b79/wALnX/Z49F0Gy0y3PyxRrHn1wOT+J5pLCIuw44pk7m8vCf4R0rd062CKOK8Gc5VZucndvVnoxioRUUTQxEIOKe0II6VcjjGKcUp8pPMZarJbSiW3do3Hda6PS9ejmCx3mIpum7+Fv8ACsiVKqSxA9qunVlSfukzpxqLU74HI45FFcNZ6jd2BAiffEP+Wb8j8PSui0/XrW6ISU+RL6P0P0NehSxUJ6PRnFUw84arVGvRSAgjIIIPcUtdJgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVDd3MVpA007BUUcmnXE0dvC8szBUUZJNcJrOqSapOAMpAv3U/qfesK9dUl5m1Gi6j8iPVtQl1S73sNqLwi+g/xpLaDgZFFtBgZq/GleS25O7PR0irIrS2ZcZjYg+lV2+0W5wWP41sotOaJXXa4BFPlJ5ippupOjgP0qzqesqLdgMZqrJpoJJikKexGazmsWW6AunJQHIwODVc04qxPJBu4/SbOS+uDK42qTxXSnSpIU3W0hP+yaNMa2WMBWANaqyAAYII9q3o0opXZjVqNvQxY7jEgW4Uqw4zSXFvHMhDqDvPX2rWubeK5U8YasxoZLViPvJW3M46S1RmrPWOjMe70gKJGh4yuAPesm8gkg8kSLt+UkV16kSlSp4HUUlxbxXDnzEBxwM1TgpK6NqeJlB2kcc6bfJQ9SN5qheTrDDNNI21FBYn0ArrLrTvPn84NtGMAY7V5P8V76Sw09NKhIFzfv5Q5xhMjJ/HIH4mt8FgpYvEwoR+09+y6v5K7Np4yFOlKq+i/HovvLXwZsJNW1vV/Fd2pAlY29sD2HGT+ACj869fBridC1HT/D+g2Wl6XHLd/Z4wpdV2KzdWYk+pJPGetSy63q10MQLDaj1UeY35nA/SpzbFrG4qVSmrQWkV2itF+GvqZYTB1KdJKe71fq9zssjGTWdd67ploSst5EXH8EZ3t+S5NclJYS3hzf3E1x3xI5K/8AfI4FWYLGGMBY14HZB/hXnqDOxUYrdmpL4pgI/wBFtLqb3ZRGP/Hjn9Koya9q1xkQQW1uD0zulI/kKmjtQP8AlkB7tUxhCj55Ao+lWqaHanHZGW41S5GLnULgg/wowjH/AI6M/rTI9Kh3biu+T1xub8zk1rq0Q+4hk9z0/wAKGuGAxlUHtzVKKRXO+isUvsAAGY/++2/pThHHGceYM/3UWnSSKeWLN9TgVVlvUjBCso9kFGg1zSLTBevl593P9K8y+IcguPHnhm3VgdhD4AwBl/8A7Guzm1AlxHGrPK3RQC7H6AVwGrpcSfFexS6jKSQRKSjEEgEEjOOn3hXtZE7VqtT+WnN/+S2/U4cxh7kIP7Uor8b/AKHr/i7VLvQvhJ9v0ic292Lq0TzFAJw95EjjkY5ViK4vWfHXi+18b3/gCDUXOv3etwvp979liPl6Y6GRzjZtYoEK5Iycnniu0025gexfT9UtIr3Tm2StBKoI3q4ZSM+hVT9QK0tU1zRhqS6nFo8EutRReTHeTQp5iIcnaH5bbyeAR1NcNKakkkYV6E1NvozmPilbxtrkwQDLou7HriuDgdodDELn5xdfoFrrtWllvZY57hi8sjbmPvXK+KITZw6fOo/dtK4f6GuTMPhh/i/RnsZf8UYMuglYOP8AeFZXjE+b4g8EwjoZRJj2Lp/hV+J91uOeV/lVHVv33xC8JQY/1cAf/wBCP9K9jh3TFuf8sJv/AMlZlny/2dR7yivxR6FrkMdzaOrjBxwR9K19M0rUH02zurG6hmSaNWCycEZGeoz/ACrOulJi56fdzWj4UuU/siFWIDRFo89+GIH6Yrz6W5xYtXgvJi3MOq7D5truA7o4NXtHtJLeBjNxI5yR6e1Vr2/ma4jhhlfLsF+8Txmto1GKnZKJzYeN3zGV4i1KLR9FvdQnxstomkx6kDgficCvNPhnaS23hefUrnm91edp3buVyQP13H8av/G+9luLXSfDll/x86pcKGH+yCMZ/wCBEH/gNbkFpFaR29nb/wCotY1hT6KMV21P9kylL7VeV/8At2H+cn+AU/32Lb6QX4v/AIH5k+m2xBziugtlwBVOyUKgrRhWvBijukywg4obpTlHy1FKcVb0IWpE55qFlBNPY0wVBaImSoXiDVcK5prJUtDTK9rc3di2baVgvdDyp/CugsPEcEmEvF8l/wC91U/4VhslQSRBq0p1p0tnoTOlCpud+jrIgZGDKehByDTq4KwvrnTXzC2Yz1RuhrrtK1OHUI8odso+9Geo/wARXo0cTGrpszhq0JU9d0X6KKK6TAKKKKACiiigAooooAKKKKACiiigApsjrHGzyMFRRkk9qcSAMngCuK8Sat9ul+zWzf6Op5I/jP8AhWVaqqUbs0pUnUlYr67qsmpXBSMkWyn5V9fc1Xt4O+KLaDgcVoRx46V5EpOb5pHppKC5UJFHirSJgURpipQKpIhsbilpaKpCMrVJESdjfLM1ksYKrGjMGbJzu2/8BwDxyfwk0622CQvGIo3xttgciMc8+gJ9uPr1OgVDKQwyDwax7yxuIr/7TavL5TRCJkhxvAXJGN3B6n3HbqaAXYnNvFMrPZTKcEqdrZAI7UyC8ubSTbKTgetZVjJDZSxFPtkNpvCrDgkbjxljjJ9NoLfkOOkkVJlKthscfQ1NuqG/M0bK+SZQc81bkO9ecGuTaOS1fcp+X1ra0678xPmPNbQqX0ZjOnbVBJEUk3R8Gnq4ZCOj4PFWnUOMjrVaSHPB6+tXFuD0IaUtxAuMD0FeEPKvin4r6hfOwew00+RBjoWGRkevO4/lXteqxXp0q8is3AuHhdYZD/A5UhSfocV866BqMngqZ9L12yms595Yykblf3BHUdORmvo8pjOeGrywy5qrSikt+V/E0t3oradzlnyKvTVZ2gne/S62X669j15LdVxsjyfVuBUyxt/G4UeiD+prK0rW7fULZZIbiNkP8SHNXPtUXYFz6tz/ADr52UXF8slZo9/WWqLY8rshc+5Lf/WqXzHxj5UHuf6CsuS+J4JCj86ha74zhm+pwKVx+zbNgyqvWQk+3FRPMF5Cge7f/XrGiu5bhilorSHoRAhf88dPxq5DoerXJBaGOBD/ABTyZP8A3yuf1IpOYOEY/Ex8l8vd8n0WqU+pbSACqsegJyT9BW/a+E4AB9uuZp/VU/dr+nP61uWNhaWKbbO3ihHfavJ+p6mocyHWpx2Vzh4rHV74gxWkiqf45z5Y/L736VsWnhNcq1/dPJ6xxDYv59f5V1NFQ5NmcsRN6LQrWNha2EZSzt44geu0cn6nqfxrxGYNe/GTW7g8rCwi+mEA/wDZTXu9eDeBCdQ13XdVHzJc3shB/HI/Rq9zKn7PCYur/dUf/ApL9EzgqfvMTRi+7f3J/wCZ6PbD/WH/AHVqld8yyH/a/pWjBGUtwWGC7E1n3alSSR1Jriw3xfI76zuipKPlhH0rK8UQifT7eIjjax/GtuWM/aIlxyAP5VQ1iJnEQA4VB+tZY5X5F5v8mbYF2q3OS0iZ2iCPkvEdjfStOC0+0fGrRraQELFZH/0CQg/qKq2MbW3iKJekdx8h+tbmlfv/AI+XJ6/ZrEY/74T/AOKr2Mgjb6xLtTn+Nl+pz8RVWvZQXWSZ6jDYQxGSMrvV15De1Z1joViRejzpYGE+RtbAClVP07mt+cbZVYDIz+hrnNQv0tLmddxDSANwfw/pXFBKx5c5ye7LWn6ZbQXBmjmedl4BYg7fyFadUdHDCxV3yGkJc5rM8c62NB8L6hqGcSRxkRe8h4X9SK4/ZzxOIVKGrk0l+R0xapU+aWyVzhdNk/4Sb4sarqZ+ey0WP7NB6eZyM/n5h/Ku0tYC0hJ7mud+EGjNp3gyGWYH7RfublyeuDwv6AH8a7mKAg5Irsz6pGeLdGk7wpJQX/bu7+bu/mRgIuNHnlvLV/P/AIA2GLGKvxL8vFJFASRu4FW1AAwK8qMTeUiIggVDIvGasuMDJqlLJuYqp4HWnLQUSI8mnKtAFSKKysbXALxSFKmApMc1ViblZkNQupFXyoqN46loaZnOmRyKhXzIJVlgYpIvIIrQeOq8iVFrFp3Oo0PVU1CLa+FuEHzL6+4rUrz2KWS0uEnhOHQ5+o9K7uyuUvLWOeI/K4z9D6V6uGr+0Vpbo8/EUuR3WxPRRRXUc4UUUUAFFFFABRRRQAUUVR1i6a2tGMX+ubhfb3pSkoq7HFczsjF8U6v96xtjz0kYf+g1gWsGTk0+K2YyFpMkk5571oQxYFeNUnKpLmkepCKpxsgijwKsolCLUoFCQmwApaKKZI00lOIpDTAQUtJS00BBeWwuEX948TodyumMqcEdwR0JrEi068sJ1EDmSLhiVwpZv9v2xjoCevGea6ImmtSaTGmYy38sUjreonljJ3KGBx05Xnqcgc84zirUWY1WW3JMbAMB7VJeWVvdhRcQpJtOVJHK/Q9RT8YAA6D1qStGWrO/V8Kxwa0wNwyOR7VzksIbJQ7W9RUSX97YvnJdPSrjUt8RlKnfY6oKCOlZmt6Bp2tWrW+o2sU8TfwuoP4j0PvTrDXbe5IWYbHrWADDdGQy10wlZqdN6rtuYSTWkkeI6z8HpLCd7rwtqc9lJ1ETksh9s9cfXNc3e6h4s8NArr2jm6hX/l5tzlcepx/XFfSJ2sMGopbKKVegNews3qVvdxkFWXnpL/wJWf33MIU/Y60JOHpqvuen3WPEPDniDw1rAQTa99jmbrDLEISPbe2VP4V6BZ6Bo4RZFhW6B5DyyGUH8CcfpRr3w68P6s7SXmlwGVusiAox/FcZ/GuLn+FM+mSNL4Y13UdObOdm/cp/LH65rKdDLK/wVJUn2kuZffHX/wAlNvreMXxWkvJ2f3PT8T02MJEgSNVRB0VRgCnbq8laH4naOx8u5sdWjHRZAqn9Qv8AM0o+IfibT+NZ8H3Jx96S3Lbf5MP1qf7BrVP92qQqek0n90rMn6/BfxIyj6r9Vc9Z3Uu6vLoPjDouQt7ZanaN33xAgfrn9K1Lb4o+FJwP+JmYz6SQyD+mKxqZDmVPehL5K/5XKjjsNLaa++x3u6jNcpD468MzAbNcsR/vyBf54q9F4o0KTGzWtNb6XSf41xywOJh8VKS+TNlWpPaS+8seLL8aZ4Y1W9zhobaR1/3tpx+uK4f4KaYsXhW3kkAJlzIRjuWP9NtR/GfxFZnwNNbWN9bTy3cyRFYpVYhQdxPB6fLj8a6Hwbd6Po/h+2tZNUsEaKNUbdcoOQoUnr6iveoYepSyq3K71J9ukV/nI8+rVjLFaP4Y/i3/AMA682UMkaF0BOM1nanoqTiNlO0AdKZd+MvDNvGQ+vaZwuAFuUY/oax9Q+KXg62IB1dZtvaGF3z+OMVzUsuxdR/u6Un6RZo8XCG8195snQ4/tW4Md+09fpWfN4fklicbhuBH4VzMvxi06Wdxo2i6rqMhGFAQKD+W4/pUC+J/iNqis2leE4LOFznN2xDD/vpl/lXW8gxbs6yUF/ekl+bv+BMM1jB/u25eibLWp+Gpo5oZVAPlP5m76GsvwE32v41eI5iOVsguPQ/ugf5Gi7X4ozQ/vjpVshI4Gw9T+NZXwNvJ7vx/rlzfTRy3UkREjoAFc7wCRjHHSvQwWWfU8NiqqqRl7lvdd7XkvLyMcXj5YupSjOLVn1VujPd93+jxt3U4/KsnVJoE1B/Pt4pC6Lt3AHGCenHvWqo/dSr6HNY2pR+bqlo56BGJ9zxXzKlyps6uXmaReLcV5f8AFmSTXNc0Dwlakl7uYXFxt6rGMgfoHP4CvS2dURnkIVFBJJ6ACvnhPEWojxlL47iVm0+G+FsV7mEgjGP93H4kV6XC+DlWrzxEbXgny36zd1Fffr8iMzrKFNU39p6+i3PpCy0to4Y0ASGJFCqijoAOBU7rHbghfmb1NXbaeG7tIZ7eQPDKgdGU8FSMg1GbZWbJFeFKDT8zqU777FJCznpgU8uIxzVi4KRRk8DFYcsklzJhOF7msZPlLiuYnnumdtkfJ9fSmIm0Y6nufWnRRBFwPxPrUoWs22zZJIYFpwFP20mKAHigikFOpiGigilNFAELrUDpVthxULipaKTM+ROorW8IXOyWe0Y8H94n8j/SqEq1FaTfZNTt584UPhvoeDTpS5JqQqkeeDR3lFFFe0eWFFFFABRRRQAUUUUAFUb23MjljyP5VeoNKUeZWGnZ3MCazHUCoTAV7V0Dwg9PyqrJBz0rjqUOqOmFYyduKWrskFV3iIrncGjZSTIqKUgikqLDEpMU6imMbSGnUhFADDTTUhFJikMjpjCpiKaRUsaIgOaGQMMEVJtoIpDM64slIJQUWN/cWEgBJaMdQa0KhlhSTqOfWhXTuhWvozdtLyC+jBjYBu4qX5o29q5VLaSB99u+G9K0YNWlQBbmM/Wt41U/i3MZUmvhN1ZcjmhgjVmi8jYblYYoGoRg8kVp7TuZ8jLslujdcGqslhE38IoGoQ+opft8P94VLcWNcyK8uk28y7ZE3L6Hms258DaFeZM+mWbk92gUn+VbB1GId6b/AGnH61dOq6TvBtejsEouW6Oak+FXhaX/AFml2w/3QV/kaqyfB7we/wDzDyPpNIP/AGauqk1eNe9QPradjXZHN8VT+GtNf9vS/wAzF4OEt4L7kcq/wZ8IDn7HL9PtEn+NNX4P+EEbJsHYehuJP/iq6R9dXPXNRf24ppvPsd/0ET/8Cf8AmNZfS/59r7kZUXww8JQHMej25x/z0Z3/AJtWnZ+FNEsGBtNG0yMj+JbdM/nipE1lCeanS9jnb5Wwa555piquk60n6yf+ZawlOG0EvkXooJUXbDGip0wOAKljs5iMEgCo4opmAMcgI+tW4FmU/vD8tZKcnvcbilscp8RHGjeENVvTI2+O3bYc9GIwv6kV4P4V83wRcaB4k+eawvYmjvAoyY8ucfpsI9wRXq/7Q9/5PgVoFPNxcRxn6Alv/Zal8OaJbnwvp1vdwrNbsi28kbjIKlMc/iBX0+X4yOX4GLlHmjWm1Jd4qNt+6cro86vSdeq7Ozgk16t/5I7TTb+11G3W7sJ47i2nQMkkZyD/AJ9Kq3wCy2TE4AdlJ+oP9cV5+vwz1PRJ2uvA3iKaw8wkm1uBvjP1POfxUn3qLU/D/wARtSs3i1TXtOt7VfmdrVP3je4wo/mKxqZZhal3SxMeT+8mpL5JO/yY44mpH4qbv5WsL8T/ABWZFPhbw6ftOr3v7qUx8iFD1BPqR19Bk+lTy+GoIfAq+HvJAjEJVpiOTIfm3/8AfWD9K6vwH8PtJ8LwM8G66vpR+9u5fvN3wPQe355rqLuwikhZSorixmLhRhDD4BtRg+bme8pLrbol0X36nTRg5ylUrrVq1uy7f5nmXwM8Ru/hqTSb8kXOmSmAg9QnJA/A7h+Feof2hFs4YV4Ze27+E/i2Y4R/omsw7gvQbxn9cr/4/XpNpbz3USyK67D1BPI9qjPJWxKxFNWjVSmvn8S+UkysFBOnySesXb7tvwsaN3dm9uPKjPy96sJGEUADAqOztFtwTnc56mrNeHq9Wd2i0Q0ClxS0UwCkxS0UAJS0UUCA0lLSUAIajcU+mt3pMpFaUVRu1yhrRkFVLhMocVDLTOy02bz9Pt5e7ICfrirNZXhl92jwqeqFl/WtWvapvmgmeVNWk0FFFFWSFFFFABRRRQAUUUUAFBAI5oooAheH0qB4Qe1XaCAeoqJQTKU2jKkg9BVZ4iO1bbRqfaoJIPbNc86HY2jV7mOVIpKvvB7VA0Nc7ptGymmVqKlaM0wqRUWLuMxSYp+KQ1LGMIpMU+jFIY0CkIzT6KQERWmlanxSYosO5DtoKgipdtBWiwXKzQoRyv5VA1kh6Fh+NXttG2gLlD7CP+ejUn2H/poa0QtLtosBm/YT/wA9DTTYn++a1NtIVoAyX03d/G1N/soHq5rY20YpWC5jf2Sg71GdJHZhW6RSFaLId2Ya6V6vQbCeD5ozuxWzs9KUKaLBczdM1UwNsmJGK1rjWofK/dtk1WktIpDl0BPrRFY26HiIH681SlJKxDhFu55F8c7t7zTtLiJOHux/6CR/WvYorQQ6BgDGwow/Bga8o/aBiMWm6TcqMIl0o47fKx/pXtMMiTWSrgFHX8wa+ir6ZZhJPo6n5xPOX+81Uv7v5MrQMdoA7NUxgMgZSPlIxVm2hHCqKvLCoHNeenKWxbSW5Tt4xFGqKMKoAFPf3qWZfLGe1Vi+TWM1y6M0jrqeRftC2htrDQ9dt1xPYXgXI9G+Yfqg/Ou70VklsUmi/wBXLh1PqCBWL8b4VufhvqoIyUEcg9iJF/pmp/h1MZ/Auhu3JNogP4DH9K9PF/vsqo1HvCco/JpS/O5jQ9zEzj/Mk/uujoqKKK8A9AKKKKACiiigAooooADTTT8UBCe1FgI6CM1OsJNSrBVqm2JzSKBjJ7Un2csMYrUW39qsxW2B0rSNBsiVZIbocXkWrJ/tk1o0yKPYD70+vQhHlikccnzO4UUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAhUHqKjaBTUtFJxT3Gm0VJLb05qs8PqK1KRlDdRWUqKexaqNGO0NRtCa2GgU+1RtbehrF4c1VYyDGaaUNarWx9KjaD1FZugy1VRm7TSYq+0HtUZgrN0mWqiKeKKsmA+lNMJqXBj5kQUVIYzSbDU8rKuMop2w0bTSsFxtFO20m00AJRS7TRigBKKXFGKBiUYoxRigAoxRiigAooooEcJ8bNPN98Pr1lGXtXS4H4HB/RjXT+AL/+0/B2j3R5Z7ZN3+8Bg/qDVzUbOLUNPubO4G6G4jaJx7MMH+debfB3XE0V77wfrUywX9lcOLcSHaJUJzhSevOSB3De1fQYdPFZVKlBXlSlzf8AbslZ/c0r+p59W1PEqT2krfNbfgeuz2dvqdld6fepvtbuB4JU/vIwww/Imvm7SvCPim/0nX7LxLpl99n8GeHtR0zSXeFgL6WVZUWSIEfMPKVVG3P8P0r6LMjbsqcGrSajKFAZVY+vSvMpV4xVpG86TeqPLPhhY3ll4t1GW7tLiCNvDujxK8kTKC6xtuXJHUdx2r0vzKS4mknbLn6AdBWB4j8T6P4ctmm1W+iiI6RA7pG9go5/pU8tTFVVCjFtvZLVlJRpQvN2Mb423sdr8OtSDsA8+yFB6kuCf0B/KtLwDavZ+CtDglBDi0jJB7EjOP1rz60t9S+K2vW97f20ll4Tsn3RRPw1y39c9yOAOBzk17IseAABgAYAFetmUfqeDp5fJ3qcznK3RtJKN+9t+xzYZ+1rSrr4bWXn1uR0YqYRGlER9K8DkZ38yIcUYqwIacIfamqbFzoq4pQtXFtyexqVLRj/AA1aotkuokUBGTUiwk1pJZgfeNSrboPetY4Z9TN1kZqQVPHbZ6Cr4jQdFFOFbxoJGTqtlRbY+wqVYFHWpqK0UEiHNsaFA6CnYooqrEhRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBCoPYU0xIe1PopWQ7kRgQ+tNNsp71PRS5I9h8zKrWnoRUbWjegq9RUulFjVSRn/ZG/u002rf3a0qKn2ER+1Zlm2P8AdppgPoa1qKXsEP2zMfyPak8mtnA9BSFFPVR+VT9XRXtmY3k0hhrYMSH+EU0wJ6Uvq4/bGT5NJ5JrXMCe9J9nT3qfq4/bGR5R9KTyjWv9mT1NJ9lX1NL6sw9sjI8s0vlGtX7Iv940otUHc0fVmP2yMoQmua8Y+A9H8WRqdRgZLpBiO5hO2RR6Z7j2Nd6LdB2NL5CeldGH9rhqiq0ZOMl1RlUlCpHlmro8RTwB450b5PD3i/zYF+7HeA8D05Dj+VOGk/Fs/L/a+kAdN2xP/jde2eSnpS+UnpXr/wBrVpa1adOT7uEb/gkcv1eC0jKSXlJniX/Cv/Heq8a54zMMTfeSzDcj042Ct3w18I/DmjTLcTwy6ndg58y8IYA+u3p+ea9RCKP4RTsAdAKipmuMnB04yUIvpFKP5JBHD0k+Zq783f8AMzUtsKAq4AGAAKkFs392r1FeWqKOn2jKgtT7Cni2Hc1YoqlTiTzsiWBB1GaeEUdFFOoqlFIV2FFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1173=[""].join("\n");
var outline_f1_9_1173=null;
var title_f1_9_1174="Blood supply and lymph nodes of the rectum and upper anal canal";
var content_f1_9_1174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Blood supply and lymph nodes of the rectum and upper anal canal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 539px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the lymph nodes and blood supply to the rectum and upper anal canal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1174=[""].join("\n");
var outline_f1_9_1174=null;
var title_f1_9_1175="Interdigital scabies";
var content_f1_9_1175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51161%7EPC%2F50111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51161%7EPC%2F50111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interdigital lesions of scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The essential lesion is a small, erythematous, nondescript papule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scabies. Lesions are present on the flexor wrists.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1175=[""].join("\n");
var outline_f1_9_1175=null;
var title_f1_9_1176="Insulin glulisine: Drug information";
var content_f1_9_1176=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin glulisine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/24/389?source=see_link\">",
"    see \"Insulin glulisine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/2/22566?source=see_link\">",
"    see \"Insulin glulisine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2114407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Apidra&reg;;",
"     </li>",
"     <li>",
"      Apidra&reg; SoloStar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apidra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2127492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Insulin, Rapid-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2127510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Insulin glulisine is a rapid-acting insulin analog which is normally administered SubQ as a premeal component of the insulin regimen or as a continuous SubQ infusion and should be used with an intermediate- or long-acting insulin. When compared to insulin regular, insulin glulisine has a more rapid onset and shorter duration of activity. In carefully controlled clinical settings with close medical supervision and monitoring of blood glucose and potassium, insulin glulisine may be administered I.V. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses or continuous subcutaneous infusions guided by blood glucose monitoring are the standard of diabetes care. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Initial total insulin dose:",
"     </b>",
"     0.2-0.6 units/kg/day in divided doses. Conservative initial doses of 0.2-0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia. A rapid-acting insulin may be the only insulin formulation used initially.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     0.5-1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate- or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting insulin (eg, insulin glulisine) or short-acting form of insulin. Some patients may benefit from the use of CSII which delivers rapid-acting insulin (insulin aspart) as a continuous infusion throughout the day and as boluses at mealtimes via an external pump device.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (\"intensive therapy\"):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of short- or rapid-acting insulin (eg, insulin glulisine) formulations 3 or more times daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. Treatment and monitoring regimens must be individualized. Also see Additional Information or Pharmacotherapy Pearls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Continuous SubQ insulin infusion (insulin pump):",
"     </b>",
"     A combination of a \"basal\" continuous insulin infusion rate with preprogrammed, premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of the longer-acting insulin (eg, NPH); divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same premeal regular insulin dosage may be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Diabetes mellitus, type 2:",
"     </b>",
"     SubQ: Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate): Initial dosage of 0.2 units/kg/day or 10 units/day of an intermediate-acting (eg, NPH) or long-acting insulin administered at bedtime has been recommended. As an alternative, regular insulin or rapid-acting insulin (eg, insulin glulisine) formulations administered before meals have also been used. Dosage must be carefully adjusted.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2127509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/2/22566?source=see_link\">",
"      see \"Insulin glulisine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     Children &ge;4 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2308005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2127511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8103886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Apidra&reg;: 100 units/mL (3 mL) [cartridge]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Apidra&reg;: 100 units/mL (10 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Apidra&reg; SoloStar&reg;: 100 units/mL (3 mL) [prefilled pen]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2127491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2114466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. Insulin glulisine should be administered within 15 minutes before or within 20 minutes after starting a meal. Cold injections should be avoided. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites. When mixing insulin glulisine with other preparations of insulin (eg, insulin NPH), insulin glulisine should be drawn into syringe first. Do not mix other insulin formulations with insulin glulisine contained in a cartridge or prefilled pen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CSII administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. Patients should be trained in the proper use of their external insulin pump and in intensive insulin therapy. Infusion sets, reservoirs, and infusion set insertion sites should be changed every 48 hours; rotate infusion sites. Do not dilute or mix other insulin formulations with insulin glulisine that is to be used in an external insulin pump.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. May be administered I.V. with close monitoring of blood glucose and serum potassium; appropriate medical supervision is required.",
"     <b>",
"      Do not administer insulin mixtures intravenously.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. infusions: To minimize adsorption to I.V. solution bag:",
"     <b>",
"      Note:",
"     </b>",
"     Refer to institution-specific protocols where appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      If new tubing is",
"     </i>",
"     <b>",
"      <i>",
"       not",
"      </i>",
"     </b>",
"     <i>",
"      needed:",
"     </i>",
"     Wait a minimum of 30 minutes between the preparation of the solution and the initiation of the infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      If new tubing is needed:",
"     </i>",
"     After receiving the insulin drip solution, the administration set should be attached to the I.V. container and the entire line should be flushed with a priming infusion of 20-50 mL of the insulin solution (Goldberg, 2006; Hirsch, 2006). Wait 30 minutes, and then flush the line again with the insulin solution prior to initiating the infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Because of adsorption, the actual amount of insulin being administered via I.V. infusion could be substantially less than the apparent amount. Therefore, adjustment of the I.V. infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SubQ dosing regimen (Moghissi, 2009); however, the transition to SubQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SubQ insulin should be given 1-4 hours prior to the discontinuation of I.V. insulin to prevent hyperglycemia (Moghissi, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2127501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stable in NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with dextrose solution and Ringer's solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Insulin NPH.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Insulin aspart, insulin detemir, insulin glargine, insulin lispro, insulin regular.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2114412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2127488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Insulin glulisine may be confused with insulin glargine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2114419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2127497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to insulin glulisine or any component of the formulation; during episodes of hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2114414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage or even death. Insulin requirements may be altered during illness, emotional disturbances or other stressors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Insulin (especially I.V. insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium frequently with I.V. use and supplement potassium when necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of sliding scale insulin in this population due to increased risk of hypoglycemia without benefits in management of hyperglycemia regardless of care setting (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- or long-acting insulin via continuous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin [eg, insulin glulisine]) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Due to the short duration of action of insulin glulisine, a longer acting insulin or CSII via an external insulin pump is needed to maintain adequate glucose control in patients with type 1 diabetes mellitus (insulin dependent, IDDM). In both type 1 and type 2 diabetes, preprandial administration of insulin glulisine should be immediately followed by a meal within 15 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &bull; CSII administration: May be administered via CSII; do not dilute or mix with other insulin formulations. Rule out external pump failure if unexplained hyperglycemia or ketosis occurs; temporary SubQ insulin administration may be required until the problem is identified and corrected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Insulin glulisine may be administered I.V. in selected clinical situations to control hyperglycemia; close monitoring of blood glucose and serum potassium as well as medical supervision is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8103884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2343861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2127500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Use caution with ethanol; may increase risk of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Use caution with alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle; may increase risk of hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2127493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2127494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy. Due to lack of clinical studies with insulin glulisine in pregnant women, the manufacturer recommends use during pregnancy only if the potential benefit to the mother justifies any potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2127496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2114413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if insulin glulisine distributes into breast milk. Endogenous insulin can be found in breast milk. Plasma glucose concentrations in the mother affect glucose concentrations in breast milk. The gastrointestinal tract destroys insulin when administered orally; therefore, insulin is not expected to be absorbed intact by the breast-feeding infant. All types of insulin are safe for use while breast-feeding. Although use of insulin glulisine is compatible with breast-feeding, the manufacturer recommends that caution be used when insulin glulisine is used by nursing women. Due to increased calorie expenditure, women with diabetes may require less insulin while nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8103887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4370385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Apidra Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (10 mL): $128.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Apidra SoloStar Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (3 mL): $49.57",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2127512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diabetes mellitus: Plasma glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. administration: Close monitoring of blood glucose and serum potassium",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2127503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic, serum insulin (fasting): 5-20 &mu;IU/mL (SI: 35-145 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elderly: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes mellitus (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak postprandial capillary plasma glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apidra (AR, AT, AU, BB, BE, BG, BR, BS, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HN, ID, IE, IL, IN, IT, JM, KP, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TT, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2127502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin glulisine is a rapid-acting insulin analog.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2127504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Rate of absorption, onset, and duration of activity may be affected by site of injection, exercise, presence of lipodystrophy, local blood supply, and/or temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 0.2-0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak effect: 1.6-2.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: I.V.: 13 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: SubQ: ~70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 13 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     SubQ: 42 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 0.6-2 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists Committee on Practice Bulletins, &ldquo;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 30, September 2001 (Replaces Technical Bulletin Number 200, December 1994). Gestational Diabetes,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2001, 98(3):525-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/11547793/pubmed\" id=\"11547793\" target=\"_blank\">",
"        11547793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Gestational Diabetes Mellitus,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(Suppl 1):88-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/14693936/pubmed\" id=\"14693936\" target=\"_blank\">",
"        14693936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(Suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies M, Storms F, Shutler S, et al, &ldquo;Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(6):1282-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/15920040/pubmed\" id=\"15920040\" target=\"_blank\">",
"        15920040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerstein HC, Yale JF, Harrist SB, et al, &ldquo;A Randomized Trial of Adding Insulin Glargine Vs. Avoidance of Insulin in People with Type 2 Diabetes on Either No Oral Glucose-Lowering Agents or Submaximal Doses of Metformin and/or Sulphonylureas: The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study,&rdquo;",
"      <i>",
"       Diabet Med",
"      </i>",
"      , 2006, 23(7):736-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/16842477/pubmed\" id=\"16842477\" target=\"_blank\">",
"        16842477",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldberg PA, Kedves A, Walter K, et al, &ldquo;'Waste Not, Want Not': Determining Optimal Priming Volume for Intravenous Insulin Infusions,&rdquo;",
"      <i>",
"       Diabetes Technol Ther",
"      </i>",
"      , 2006, 8(5):598-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/17037974/pubmed\" id=\"17037974\" target=\"_blank\">",
"        17037974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsch IB, &ldquo;Evidence-Based Priming,&rdquo;",
"      <i>",
"       Diabetes Technol Ther",
"      </i>",
"      , 2006, 8(5):521-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/17037966/pubmed\" id=\"17037966\" target=\"_blank\">",
"        17037966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kitabchi AE, Umpierrez GE, Miles JM, et al, &ldquo;Hyperglycemic Crises in Adult Patients With Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(7):1335-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/19564476/pubmed\" id=\"19564476\" target=\"_blank\">",
"        19564476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kitabchi AE, Umpierrez GE, Murphy MB, et al, \"Hyperglycemic Crises in Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(Suppl 1): 94-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/14693938/pubmed\" id=\"14693938\" target=\"_blank\">",
"        14693938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meneghini L, Koenen C, Rojas P, et al, &ldquo;Efficacy and Safety of Insulin Detemir in a Large Cohort of Patients With Type 2 Diabetes Using a Simplified Self-Adjusted Dosing Guideline -- Results of the Predictive 303 Study,&rdquo; Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-25, 2007; Chicago, Ill.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moghissi ES, Korytkowski MT, DiNardo M, et al, &ldquo;American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(4):353-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/19454396/pubmed\" id=\"19454396\" target=\"_blank\">",
"        19454396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Buse, JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):193-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/18945920/pubmed\" id=\"18945920\" target=\"_blank\">",
"        18945920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riddle MC, Rosenstock J, Gerich J, et al, &ldquo;The Treat-to-Target Trial: Randomized Addition of Glargine or Human NPH Insulin to Oral Therapy of Type 2 Diabetic Patients,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2003, 26(11):3080-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/14578243/pubmed\" id=\"14578243\" target=\"_blank\">",
"        14578243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverstein J, Klingensmith G, Copeland K, et al, &ldquo;Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,&rdquo;",
"      <i>",
"       Diabetes Care,",
"      </i>",
"      2005, 28(1):186-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/15616254/pubmed\" id=\"15616254\" target=\"_blank\">",
"        15616254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolfsdorf J, Craig ME, Daneman D, et al, &ldquo;Diabetic Ketoacidosis,&rdquo;",
"      <i>",
"       Pediatr Diabetes",
"      </i>",
"      , 2007, 8(1):28-43. Available at file://www.ispad.org/FileCenter/10-Wolfsdorf_Ped_Diab_2007,8.28-43.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/9/1176/abstract-text/17341289/pubmed\" id=\"17341289\" target=\"_blank\">",
"        17341289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9024 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-190.81.197.98-2125B089CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1176=[""].join("\n");
var outline_f1_9_1176=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114407\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934392\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127492\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127510\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127509\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2308005\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127511\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103886\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104248\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127491\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114466\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127501\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114412\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127488\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114419\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127497\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114414\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103884\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2343861\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127500\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127493\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127494\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127496\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114413\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103887\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370385\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127512\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127503\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038884\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127502\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127504\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9024\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9024|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/24/389?source=related_link\">",
"      Insulin glulisine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/2/22566?source=related_link\">",
"      Insulin glulisine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_9_1177="Prevention of sepsis in the asplenic patient";
var content_f1_9_1177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of sepsis in the asplenic patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/9/1177/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/9/1177/contributors\">",
"     Mark S Pasternack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/9/1177/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/9/1177/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/9/1177/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/9/1177/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/9/1177/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic function is lost when the spleen has been surgically removed, is congenitally absent, has atrophied following repeated infarction (eg, sickle cell disease), or following splenic artery thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, splenic function is reduced in the neonate and may be abnormally reduced (ie, hyposplenism or functional asplenia) when the spleen is engorged with blood (eg, splenic sequestration crisis associated with sickle cell disease, malaria, splenic vein thrombosis), or infiltrated (eg, sarcoidosis, amyloidosis, tumors, or cysts). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asplenic patients and those with impaired splenic function are at risk for a fulminant sepsis syndrome usually due to Streptococcus pneumoniae. The prevention of sepsis will be reviewed here. The importance of the spleen for clearance of bacteria and humoral immune response, conditions leading to asplenia, clinical manifestations of infection in the asplenic patient, and the management of postsplenectomy sepsis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=see_link\">",
"     \"Clinical features and management of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients must be instructed that the asplenic state carries a small risk of overwhelming and life-threatening infection. It is crucial that these individuals adhere to the preventive measures outlined below, and that they inform all caregivers of their asplenic state. The combined use of pneumococcal immunization and early administration of oral empiric antibiotic therapy for fever offers a high level of protection against postsplenectomy sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adherence to these preventive measures can be improved by developing a systematic approach within a clinic or healthcare system, such as having a registry of asplenic patients, clear guidelines for vaccinations and empiric antibiotics, and a program for patient outreach and education [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Avoid splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the high mortality rate observed in postsplenectomy sepsis, measures that avoid splenectomy should be utilized whenever possible. Performing splenic repair instead of splenectomy during exploratory laparotomy for intraabdominal trauma or following unexpected splenic injury during intraabdominal procedures preserves functional splenic tissue and is believed to reduce the risk of overwhelming bacterial sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spleen is the dominant site for the production of IgM antibodies required for opsonizing encapsulated pathogens. Thus, whenever elective splenectomy is considered, patients should undergo appropriately timed preoperative immunization against S. pneumoniae, meningococcus, and H. influenzae type b.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Timing of immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccines should be administered at least 14 days prior to scheduled splenectomy. If this is not possible, these immunizations can be given after the 14",
"    <sup>",
"     th",
"    </sup>",
"    postoperative day. This recommendation is based upon a study of pneumococcal vaccination 1, 7, and 14 days after splenectomy in 59 trauma patients compared to 12 adult controls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/4\">",
"     4",
"    </a>",
"    ]. Post vaccination immunization titers were not significantly different from control patients. However, opsonophagocytic function of the antibodies was diminished in patients vaccinated before the 14-day point.",
"    <br/>",
"    <br/>",
"    In patients undergoing immunosuppressive chemotherapy or radiotherapy, immunization should be delayed for at least three months after completion of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pneumococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two pneumococcal vaccines are available for use in the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 23-valent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      (PPSV23) contains capsular polysaccharides from 23 common serotypes of S. pneumoniae. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link\">",
"       \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"       \"Pneumococcal vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A 13-valent conjugate pneumococcal vaccine (PCV13) protects against a smaller number of capsular serotypes than PPSV23, but is more effective than PPSV23 in children younger than two years and has comparable or enhanced immunogenicity compared with PPSV23 in adults. Pneumococcal conjugate vaccines designed to protect against other numbers of serotypes are used in some other countries. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link\">",
"       \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"       \"Pneumococcal vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193369\">",
"    <span class=\"h4\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend both PSV13 (primary series) and PPSV23 (&gt;24 months of age) for children in the United States who have undergone or will undergo splenectomy. In the United States, PCV13 is included in the standard vaccination protocols for infants and young children, and is approved for infants &ge;2 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/6\">",
"     6",
"    </a>",
"    ]. It replaced the 7-valent pneumococcal conjugate vaccine (PCV7) in 2010. PPSV23 is also recommended for high-risk children, including asplenic children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H335513991\">",
"    <span class=\"h5\">",
"     Routine schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children &lt;24 months of age with functional or anatomic asplenia should receive a total of four doses of PCV13 according to the schedule for healthy children (2, 4, 6, and 12 to 15 months of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, asplenic children &ge;24 months of age should receive the 23-valent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) at least eight weeks after they have completed immunization with PCV13 (",
"    <a class=\"graphic graphic_table graphicRef79553 \" href=\"UTD.htm?23/60/24523\">",
"     table 1",
"    </a>",
"    ). In principle, this offers protection against the several pneumococcal serotypes not present in the PCV 13 vaccine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H16#H16\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Vaccine schedule'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link&amp;anchor=H6#H6\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Schedule'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H335513998\">",
"    <span class=\"h5\">",
"     Catch-up schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended pneumococcal vaccine schedule for children 24 through 71 months of age with functional or anatomic asplenia depends upon the age of the child and prior exposure to pneumococcal vaccine (",
"    <a class=\"graphic graphic_table graphicRef62519 \" href=\"UTD.htm?20/63/21501\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children aged 24 through 71 months who received zero, one, or two doses of PCV (PCV7 or PCV13) before age 24 months should receive two doses of PCV13, separated by eight weeks.",
"     </li>",
"     <li>",
"      Children aged 24 through 71 months who received three doses of PCV (PCV7 or PCV13) should receive a single dose of PCV13 at least eight weeks after the last dose of PCV13.",
"     </li>",
"     <li>",
"      After completion of the pneumococcal conjugate vaccine series, children &ge;24 months should receive PPSV23. It should be given at least eight weeks after the last dose of PCV13. A second dose of PPSV23 should be given five years after the first.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H335514416\">",
"    <span class=\"h5\">",
"     Supplemental dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with functional or anatomic asplenia who have received four doses of PCV7 or another age-appropriate, complete PCV7 schedule, a single supplemental dose of PCV13 is recommended for children through 71 months of age; this includes children who previously received PPSV23 (",
"    <a class=\"graphic graphic_table graphicRef62519 \" href=\"UTD.htm?20/63/21501\">",
"     table 2",
"    </a>",
"    ). The supplemental dose of PCV13 should be given at least eight weeks after the last dose of PCV7 or PPSV23.",
"   </p>",
"   <p>",
"    For asplenic children &ge;72 months of age who have not received at least one dose of PCV13, we also suggest a single supplemental dose of PCV13; PPSV23 should be given at least eight weeks later if it had not been administered previously [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193439\">",
"    <span class=\"h4\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend both PPSV23 and PCV13 for adults in the United States who have undergone or will undergo splenectomy. PPSV23 has been recommended for asplenic individuals for many years, but in 2012, the United States Advisory Committee on Immunization Practices (ACIP) began also recommending PCV13 for adults with functional or anatomic asplenia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/8\">",
"     8",
"    </a>",
"    ]. The evidence supporting the use of pneumococcal conjugate vaccination in high-risk adults comes from a randomized trial of PCV7 in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11047?source=see_link\">",
"     \"Pneumococcal immunization in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that adults with functional or anatomic asplenia receive PCV13 in addition to PPSV23 according to the following schedule (",
"    <a class=\"graphic graphic_table graphicRef86782 \" href=\"UTD.htm?11/48/12046\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have not previously received either PCV13 or PPSV23, a single dose of PCV13 should be given, followed by a dose of PPSV23 at least eight weeks later.",
"     </li>",
"     <li>",
"      For patients who have previously received one or more doses of PPSV23, a single dose of PCV13 should be given one or more years after the last PPSV23 dose was received.",
"     </li>",
"     <li>",
"      For patients who require additional doses of PPSV23, the first such dose should be given no sooner than eight weeks after PCV13 and at least five years after the most recent dose of PPSV23. Revaccination is discussed below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193507\">",
"    <span class=\"h4\">",
"     Revaccination in children and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The durability of the antibody response in splenectomized patients has not been entirely elucidated, but antibody titers following PPSV23 appear to decline quickly [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/11\">",
"     11",
"    </a>",
"    ]. We suggest that splenectomized children (",
"    <a class=\"graphic graphic_table graphicRef79553 \" href=\"UTD.htm?23/60/24523\">",
"     table 1",
"    </a>",
"    ) and adults (",
"    <a class=\"graphic graphic_table graphicRef86782 \" href=\"UTD.htm?11/48/12046\">",
"     table 3",
"    </a>",
"    ) who have received PPSV23 be reimmunized with one dose of PPSV23 five years after the initial immunization; we also suggest that splenectomized adults &ge;65 years of age be reimmunized with one dose of PPSV23 if they were vaccinated more than five years previously at a time when they were less than 65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, some European public health agencies recommend PPSV23 reimmunization of asplenic individuals every five years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients with underlying systemic disorders may benefit from more frequent immunizations, serial monitoring of antibody titers to guide reimmunization with PPSV23, or consideration of PCV13. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link&amp;anchor=H6#H6\">",
"     \"Immunizations in patients with cancer\", section on 'Pneumococcal vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222319\">",
"    <span class=\"h4\">",
"     Vaccination after invasive pneumococcal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have experienced invasive pneumococcal disease should complete the full series of immunizations with PCV13",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PPSV23 according to their age and underlying condition. Invasive pneumococcal disease (IPD) elicits serotype-specific antibody, but does not provide protection against the range of serotypes included in PCV13 or PPSV23. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H25#H25\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Invasive disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that asplenic adults who received PPSV23 but develop invasive pneumococcal disease should be given PCV13 following recovery if they have not received it previously. Although PPSV23 is usually effective, recurrent invasive pneumococcal disease was reported in two patients despite multiple doses of PPSV23 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/16\">",
"     16",
"    </a>",
"    ]. Analysis of serum samples in these individuals demonstrated absence of IgG to any pneumococcal serotypes. However, administration of the conjugate vaccine (PCV13), which elicits a T cell-dependent memory response, led to high levels of IgG to all of the polysaccharides in this vaccine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Haemophilus influenzae vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Haemophilus influenzae type B (Hib) conjugate vaccine is part of the routine series in children in the United States and involves a primary series of two or three doses (depending on the vaccine formulation) during infancy, followed by a booster dose at 12 to 15 months of age (",
"    <a class=\"graphic graphic_table graphicRef77170 \" href=\"UTD.htm?5/59/6077\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals over age five are almost always immune to Hib, even if they have not been immunized. Thus, the majority of asplenic individuals are not at great risk for Hib disease because most already have specific antibody to this organism. Nevertheless, an additional dose of the Hib vaccine can be given to fully vaccinated children undergoing elective splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/17\">",
"     17",
"    </a>",
"    ]. Similarly, a single dose of the Hib vaccine can be given to splenectomized adults who have not been vaccinated previously [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hib vaccination is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=see_link&amp;anchor=H2#H2\">",
"     \"Prevention of Haemophilus influenzae infection\", section on 'Immunization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H386006\">",
"    <span class=\"h4\">",
"     Catch-up schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asplenic children who did not complete the routine series of Hib vaccination during infancy should be vaccinated according to the following age-based recommendations (",
"    <a class=\"graphic graphic_table graphicRef77170 \" href=\"UTD.htm?5/59/6077\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For asplenic children 12 to 59 months of age who have not been immunized against Hib or who have received only one dose of a Hib vaccine before 12 months of age, we suggest two additional doses of Hib conjugate vaccine separated by two months.",
"     </li>",
"     <li>",
"      For asplenic children 12 to 59 months of age who received two doses of a Hib vaccine before 12 months of age, we suggest one additional dose of Hib conjugate vaccine.",
"     </li>",
"     <li>",
"      Asplenic children aged 5 years or older who have not previously been immunized against Hib should receive one dose of the Hib conjugate vaccine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H385888\">",
"    <span class=\"h4\">",
"     Vaccination after invasive Hib disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children younger than 24 months of age who develop Hib invasive infection should be immunized according to the age-appropriate schedule for unimmunized children (and as if they had not received any doses of Hib vaccine previously) since children in this age group remain at risk for developing a second episode of invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/17\">",
"     17",
"    </a>",
"    ]. The immunization series should be initiated one month after the onset of disease or as soon as possible thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H386033\">",
"    <span class=\"h4\">",
"     Hib titers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hib conjugate vaccine is immunogenic in splenectomized children and adults, although antibody titers may be lower than in normal hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/18\">",
"     18",
"    </a>",
"    ]. Assessment of anti-polyribosyl phosphate (PRP) antibody titers in immunocompromised splenectomized individuals and consideration of booster immunization are reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Meningococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomized individuals should be vaccinated with a meningococcal vaccine according to nation-specific recommendations. Recommendations for the United States are summarized in the following Table (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/13,14,19-21\">",
"     13,14,19-21",
"    </a>",
"    ]. The appropriate formulation depends upon the age of the patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combination conjugate vaccine against meningococcus serogroups C and Y and Haemophilus influenzae type B (HibMenCY, MenHibrix), was approved by the US Food and Drug Administration in June 2012 for infants and toddlers aged 6 weeks to 18 months [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. In January 2013, the ACIP began recommending HibMenCY for infants and toddlers with functional or anatomic asplenia [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/13,21\">",
"       13,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When administered together, the meningococcal quadrivalent conjugate vaccine, Menactra, may interfere with the protection conferred by the pneumococcal conjugate vaccine, although in one study, protective levels of pneumococcal antibodies were still achieved [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/24\">",
"       24",
"      </a>",
"      ]. Until the clinical significance of this finding is clarified and because pneumococcal disease is a more significant threat than meningococcal disease to children with sickle cell disease or anatomic asplenia, Menactra is",
"      <strong>",
"       not",
"      </strong>",
"      recommended for children between 9 and 23 months of age who have either of these conditions.",
"     </li>",
"     <li>",
"      A meningococcal quadrivalent conjugate vaccine (Menactra or Menveo) is recommended for asplenic individuals between 2 and 55 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Splenectomized patients greater than 55 years of age should receive the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"       meningococcal polysaccharide vaccine",
"      </a>",
"      (MPSV4, Menomune) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Revaccination against the meningococcus is recommended for splenectomized patients (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Meningococcal vaccination is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"     \"Meningococcal vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Influenza vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza vaccination is recommended for all individuals &gt;6 months of age, but is particularly important for individuals with risk factors for influenza complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/25\">",
"     25",
"    </a>",
"    ]. Although there are no data regarding the risk for severe or complicated influenza among asplenic individuals, influenza is a risk factor for secondary bacterial infections, such as pneumococcal pneumonia, that can cause severe disease among such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of seasonal influenza in adults\", section on 'Secondary bacterial pneumonia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\", section on 'Bacterial superinfection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that live attenuated vaccines cannot be given to patients with an absent or dysfunctional spleen. Thus, live attenuated vaccines should be given to asplenic individuals according to routine immunization schedules. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link\">",
"     \"Approach to immunizations in healthy adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of oral antibiotics to splenectomized individuals is the mainstay of infection prophylaxis (and initial therapy). Two complementary strategies are commonly used:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Daily antibiotic prophylaxis",
"     </li>",
"     <li>",
"      Empiric antibiotic therapy for fever",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Daily prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of daily antibiotic prophylaxis in splenectomized individuals was demonstrated in a study that evaluated pediatric patients undergoing splenectomy for all causes between 1971 and 1995 who received antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/26\">",
"     26",
"    </a>",
"    ]. Compared to a similar group at the same institution from 1958 to 1970 who did not routinely receive prophylaxis, the incidence of infection declined by 47 percent and mortality by 88 percent without a concomitant decrease in the number of splenectomies performed. Daily penicillin prophylaxis administered to children with sickle cell anemia and functional hyposplenism has also been shown to reduce the incidence of pneumococcal bacteremia by approximately 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/27\">",
"     27",
"    </a>",
"    ]. Although these landmark studies showed a high level of efficacy, it should be noted that they were performed in an era of exquisite pneumococcal susceptibility to penicillin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388180\">",
"    <span class=\"h4\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal duration of prophylaxis for children is not clear. Children with sickle cell anemia over age five have a low rate of pneumococcal bacteremia, and in one study it was difficult to demonstrate that continued daily penicillin prophylaxis beyond age five reduced the already low risk of invasive pneumococcal disease significantly in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/28\">",
"     28",
"    </a>",
"    ]. Furthermore, this study was published in 1995 when almost all isolates of S. pneumoniae were penicillin-susceptible, and the utility of prolonged daily penicillin prophylaxis at present is likely to be lower.",
"   </p>",
"   <p>",
"    Nevertheless, the risk of PSS persists indefinitely [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Recommendations for daily prophylaxis differ among different authorities. Guidelines in the United States suggest relatively limited courses of postsplenectomy prophylaxis (eg, up to five years of age and for at least one year after splenectomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/7\">",
"     7",
"    </a>",
"    ], whereas British guidelines recommend lifelong penicillin prophylaxis in high-risk individuals (defined as those less than 16 or more than 50 years of age, and those with an inadequate response to pneumococcal vaccination) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend that asplenic children should receive daily prophylaxis with oral penicillin VK or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    until at least age five and for at least one year following splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients in whom prophylaxis is being discontinued should have well-established, regular medical care, and understand the warning symptoms and signs, as well as the management, of possible post-splenectomy sepsis. We consider highly immunocompromised individuals (eg, patients with hypogammaglobulinemia, HIV infection, solid organ transplant recipients, and patients with advanced liver disease), and survivors of pneumococcal PSS to be reasonable candidates for prophylaxis until age 18 or even for life.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     Amoxicillin",
"    </a>",
"    suspension offers enhanced palatability and coverage of some H. influenzae type b strains. The dose of amoxicillin is 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally twice daily.",
"   </p>",
"   <p>",
"    The dose of penicillin depends on the patient's age:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      2 months to 5 years of age: 125 mg twice daily",
"     </li>",
"     <li>",
"      &ge;5 years of age: 250 mg twice daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Daily prophylaxis in children with penicillin allergy is problematic. First-generation cephalosporins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    250 mg twice daily) may be used in patients with non-urticarial rash reactions to penicillin, but should not be used in patients with a history of immediate hypersensitivity (anaphylaxis) to beta-lactam agents. The activity of macrolides and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    against S. pneumoniae has declined to the 70 percent range in recent years.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    , although still highly active against S. pneumoniae, is not attractive as long-term prophylaxis due to frequent gastrointestinal distress and concerns regarding C. difficile infection.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    is not routinely administered to children until they are eight years old due to the risk of dental staining with long-term use, and long-term oral fluoroquinolone agent use is avoided in children due to possible arthropathy. Thus, macrolide or trimethoprim-sulfamethoxazole prophylaxis may be considered, but the limitations of these therapies (as with oral penicillin itself) are apparent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388195\">",
"    <span class=\"h4\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the incidence of pneumococcal bacteremia in the adult population is low, the efficacy of indefinite penicillin prophylaxis for adult patients is debated. The increased incidence of penicillin-resistant pneumococci, particularly of highly resistant isolates, also threatens the efficacy of current penicillin prophylaxis regimens. We do not recommend routine prophylaxis in asplenic adults. However, lifelong daily prophylaxis may be considered in survivors of an episode of pneumococcal postsplenectomy sepsis and in highly immunocompromised individuals (eg, patients with hypogammaglobulinemia, patients with HIV infection, solid organ transplant recipients, and patients with advanced liver disease). When antibiotic prophylaxis is used in adults, the same antibiotics should be used as those recommended for children above.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     Amoxicillin",
"    </a>",
"    and penicillin are given at a dose of 250 to 500 mg twice daily. (See",
"    <a class=\"local\" href=\"#H388180\">",
"     'Children'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Antibiotics for fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asplenic individuals, especially those who no longer take penicillin on a daily basis, must recognize that any febrile illness may be the harbinger of fulminant bacteremia, and should self-medicate with high-dose oral antibiotics. These patients should have prescribed (and replaced when out-of-date) antibiotics on hand and take them immediately [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Controlled trials of self-directed empiric antibiotic regimens in this patient population have not been performed. Thus, treatment recommendations are based on expert opinion and assessment of the epidemiology and antimicrobial sensitivity patterns of the pathogens most likely to cause infection in this group. Recommended oral antibiotics for coverage of S. pneumoniae and H. influenzae include the following choices:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       Amoxicillin-clavulanate",
"      </a>",
"      &mdash; In children: 90",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided into two daily doses, up to 875 mg per dose; In adults: 875 mg twice daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       Cefuroxime",
"      </a>",
"      axetil &mdash; In children: 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided into two daily doses, up to 500 mg per dose; In adults: 500 mg twice daily",
"     </li>",
"     <li>",
"      Extended-spectrum fluoroquinolones &mdash; In adults or adolescents only:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      750 mg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      400 mg, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"       gemifloxacin",
"      </a>",
"      320 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the use of beta-lactam antibiotics is the standard and most widely accepted regimen in this clinical scenario, we favor the use of fluoroquinolones in communities with a high prevalence of beta-lactam-resistant pneumococcal isolates.",
"   </p>",
"   <p>",
"    Patients allergic to beta-lactam antibiotics can be given an extended-spectrum fluoroquinolone (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After taking the first dose, the patient should proceed without delay to the nearest urgent care facility for evaluation and further therapy.",
"   </p>",
"   <p>",
"    Acutely ill patients should undergo appropriate diagnostic evaluation, receive empiric broad-spectrum parenteral therapy such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and a second agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or an extended-spectrum fluoroquinolone), and be hospitalized pending the results of blood cultures. If a patient is suspected of having bacteremia and is being seen in a clinician's office, empiric antibiotics such as ceftriaxone (in children: 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV; in adults: 2 g IV) should be administered immediately, prior to transfer to a local hospital.",
"   </p>",
"   <p>",
"    In patients who fail to improve following the initiation of an empiric regimen, a resistant organism should be considered (eg, highly penicillin-resistant S. pneumoniae, fluoroquinolone-resistant S. pneumoniae) and the regimen should be adjusted if resistance is thought to be likely. Poor clinical response despite appropriate therapy is often seen in patients presenting with advanced sepsis&nbsp;complicated by refractory hypotension and disseminated intravascular coagulation.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=see_link\">",
"     \"Clinical features and management of sepsis in the asplenic patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Well-appearing patients without findings that are suggestive of bacterial infection (eg, significant headache, sinus congestion, purulent rhinorrhea, signs of pneumonia)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sepsis should undergo a diagnostic evaluation and continue broad-spectrum oral antibiotics for at least 72 hours while appropriate hematologic, microbiologic, and radiographic studies are pending. Patients who have improved uneventfully and whose laboratory and radiographic studies have not revealed a bacterial infection may be candidates for the discontinuation of empiric antibiotic coverage after 72 hours. Some experts continue empiric antibacterial coverage for 7 to 10 days since it is difficult to exclude early bacterial superinfection in the setting of a viral upper respiratory tract infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis for dental procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;While some clinicians and dentists prescribe antibiotics for asplenic patients undergoing dental procedures, this practice is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1177/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/24/18818?source=see_link\">",
"       \"Patient information: Preventing severe infection after splenectomy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomized patients or those with other causes of asplenia or impaired splenic function are at risk for severe sepsis, primarily from encapsulated organisms such as Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=see_link\">",
"     \"Clinical features and management of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prevention of postsplenectomy sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient who has undergone splenectomy or who is functionally asplenic needs to be educated about the need for prompt medical attention after the onset of fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Immunizations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a patient has anatomic or functional asplenia, we recommend immunization with pneumococcal (",
"      <a class=\"graphic graphic_table graphicRef86782 \" href=\"UTD.htm?11/48/12046\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef62519 \" href=\"UTD.htm?20/63/21501\">",
"       table 2",
"      </a>",
"      ), meningococcal (",
"      <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"       table 5",
"      </a>",
"      ), and conjugate H. influenzae type b vaccines (",
"      <a class=\"graphic graphic_table graphicRef77170 \" href=\"UTD.htm?5/59/6077\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Immunizations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a patient will be undergoing elective splenectomy, we recommend that the pneumococcal, meningococcal, and Haemophilus influenzae vaccines be administered at least 14 days prior to surgery. If it is not possible to administer these vaccines prior to splenectomy, they can be given after the 14",
"      <sup>",
"       th",
"      </sup>",
"      postoperative day. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Timing of immunizations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend annual influenza vaccination. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Influenza vaccine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Antibiotic prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that asplenic children receive daily prophylaxis with oral penicillin VK or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      until at least age five and for at least one year following splenectomy. We do not recommend routine prophylaxis in asplenic adults, since postsplenectomy sepsis is less common than in children and there are concerns regarding antibiotic resistance and side effects. Highly immunocompromised individuals and survivors of pneumococcal postsplenectomy sepsis may be considered for prophylaxis until age 18 or even for life. Amoxicillin suspension offers enhanced palatability and coverage of some H. influenzae type b strains. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Antibiotics for fever",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prescriptions should be given to asplenic individuals and those with impaired splenic function to fill and have on hand in their home, at work, and ideally on their person for immediate initiation at the onset of fever or rigors.",
"     </li>",
"     <li>",
"      Recommended antibiotics for coverage of Streptococcus pneumoniae and H. influenzae include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      axetil, or, for adolescents and adults only, an extended-spectrum fluoroquinolone (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"       gemifloxacin",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with immediate hypersensitivity reactions (anaphylaxis) to beta-lactam antibiotics can be given an extended-spectrum fluoroquinolone (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"       gemifloxacin",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      After taking the first dose, the patient should proceed without delay to the nearest urgent care facility for evaluation and further therapy.",
"     </li>",
"     <li>",
"      If a patient is suspected of having bacteremia and is being seen in a clinician's office, empiric antibiotics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      should be administered immediately, prior to transfer to a local hospital. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Antibiotics for fever'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/1\">",
"      Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet 2011; 378:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/2\">",
"      Konradsen HB, Henrichsen J. Pneumococcal infections in splenectomized children are preventable. Acta Paediatr Scand 1991; 80:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/3\">",
"      Kim HS, Kriegel G, Aronson MD. Improving the preventive care of asplenic patients. Am J Med 2012; 125:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/4\">",
"      Shatz DV, Schinsky MF, Pais LB, et al. Immune responses of splenectomized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy. J Trauma 1998; 44:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/5\">",
"      Davies JM, Barnes R, Milligan D, British Committee for Standards in Haematology. Working Party of the Haematology/Oncology Task Force. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med 2002; 2:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/6\">",
"      Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     Immunocompromised Children. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th edition, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.74.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/9\">",
"      French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812.",
"     </a>",
"    </li>",
"    <li>",
"     Advisory Committee on Immunization Practices. Summary Report, February 22-23, 2012. file://www.cdc.gov/vaccines/recs/acip/downloads/min-feb12.pdf (Accessed on June 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/11\">",
"      Giebink GS, Le CT, Cosio FG, et al. Serum antibody responses of high-risk children and adults to vaccination with capsular polysaccharides of Streptococcus pneumoniae. Rev Infect Dis 1981; 3 Suppl:S168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/12\">",
"      Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/13\">",
"      ACIP Childhood/Adolescent Immunization Work Group, Akinsanya-Beysolow I, Jenkins R, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/14\">",
"      ACIP Adult Immunization Work Group, Bridges CB, Woods L, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/15\">",
"      Mourtzoukou EG, Pappas G, Peppas G, Falagas ME. Vaccination of asplenic or hyposplenic adults. Br J Surg 2008; 95:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/16\">",
"      Musher DM, Ceasar H, Kojic EM, et al. Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. J Infect Dis 2005; 191:1063.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Haemophilus influenzae infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th edition, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.345.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/18\">",
"      Cimaz R, Mensi C, D'Angelo E, et al. Safety and immunogenicity of a conjugate vaccine against Haemophilus influenzae type b in splenectomized and nonsplenectomized patients with Cooley anemia. J Infect Dis 2001; 183:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/19\">",
"      Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/20\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011; 60:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013; 62:52.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. News &amp; Events. FDA approves new combination vaccine that protects children against two bacterial diseases. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm308350.htm?utm_campaign=Google2&amp;utm_source=fdaSearch&amp;utm_medium=website&amp;utm_term=Menhibrix&amp;utm_content=1 (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     GSK receives FDA approval for MenHibrix. file://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1134059.htm (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2011; 60:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/26\">",
"      Jugenburg M, Haddock G, Freedman MH, et al. The morbidity and mortality of pediatric splenectomy: does prophylaxis make a difference? J Pediatr Surg 1999; 34:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/27\">",
"      Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/28\">",
"      Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr 1995; 127:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/29\">",
"      Cullingford GL, Watkins DN, Watts AD, Mallon DF. Severe late postsplenectomy infection. Br J Surg 1991; 78:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/30\">",
"      Eber SW, Langend&ouml;rfer CM, Ditzig M, et al. Frequency of very late fatal sepsis after splenectomy for hereditary spherocytosis: impact of insufficient antibody response to pneumococcal infection. Ann Hematol 1999; 78:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/31\">",
"      Davies JM, Lewis MP, Wimperis J, et al. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. Br J Haematol 2011; 155:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/32\">",
"      Keenan RD, Boswell T, Milligan DW. Do post-splenectomy patients take prophylactic penicillin? Br J Haematol 1999; 105:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/33\">",
"      De Rossi SS, Glick M. Dental considerations in asplenic patients. J Am Dent Assoc 1996; 127:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1177/abstract/34\">",
"      Tong DC, Rothwell BR. Antibiotic prophylaxis in dentistry: a review and practice recommendations. J Am Dent Assoc 2000; 131:366.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1412 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1177=[""].join("\n");
var outline_f1_9_1177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Avoid splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Timing of immunizations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pneumococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1193369\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H335513991\">",
"      - Routine schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H335513998\">",
"      - Catch-up schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H335514416\">",
"      - Supplemental dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1193439\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1193507\">",
"      Revaccination in children and adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H222319\">",
"      Vaccination after invasive pneumococcal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Haemophilus influenzae vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H386006\">",
"      Catch-up schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H385888\">",
"      Vaccination after invasive Hib disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H386033\">",
"      Hib titers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Meningococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Daily prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H388180\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H388195\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Antibiotics for fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antibiotic prophylaxis for dental procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prevention of postsplenectomy sepsis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Immunizations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Antibiotics for fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1412\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1412|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/60/24523\" title=\"table 1\">",
"      PPSV23 schedule for high-risk children older than two years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/63/21501\" title=\"table 2\">",
"      PCV and PPSV23 in high risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/48/12046\" title=\"table 3\">",
"      Pneumococcal vaccination indications for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/59/6077\" title=\"table 4\">",
"      Hib schedule US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9999\" title=\"table 5\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=related_link\">",
"      Clinical features and management of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/24/18818?source=related_link\">",
"      Patient information: Preventing severe infection after splenectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11047?source=related_link\">",
"      Pneumococcal immunization in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_9_1178="Clinical manifestations, diagnosis, and management of ectopic pregnancy";
var content_f1_9_1178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/9/1178/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/9/1178/contributors\">",
"     Togas Tulandi, MD, MHCM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/9/1178/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/9/1178/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/9/1178/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/9/1178/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/9/1178/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ectopic pregnancy is based on a combination of quantitative assay for human chorionic gonadotropin (hCG) and findings on high resolution transvaginal ultrasonography (TVUS). These tests enable early diagnosis of the ectopic pregnancy, before tubal rupture.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of ectopic pregnancy will be reviewed here. The epidemiology, risk factors, pathology, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21752?source=see_link\">",
"     \"Incidence, risk factors, and pathology of ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=see_link\">",
"     \"Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations typically appear six to eight weeks after the last normal menstrual period, but can occur later, especially if the pregnancy is not in the fallopian tube. Normal pregnancy discomforts (eg, breast tenderness, frequent urination, nausea) are often present in addition to the symptoms described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic symptoms of ectopic pregnancy are [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal pain",
"     </li>",
"     <li>",
"      Amenorrhea",
"     </li>",
"     <li>",
"      Vaginal bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These symptoms can occur in both ruptured and unruptured cases. In one representative series of 147 patients with ectopic pregnancy (78 percent were ruptured), abdominal pain was a presenting symptom in 99 percent, amenorrhea in 74 percent, and vaginal bleeding in 56 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ectopic pregnancy should be suspected in any women of reproductive age with these symptoms, especially those who have risk factors for an extrauterine pregnancy (",
"    <a class=\"graphic graphic_table graphicRef82282 \" href=\"UTD.htm?10/38/10860\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/3\">",
"     3",
"    </a>",
"    ]. However, these symptoms are not diagnostic of ectopic pregnancy; they are the same as those associated with threatened abortion, which is far more common (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Differential diagnosis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In addition, blood leaking out of the fallopian tube may irritate the diaphragm and cause shoulder pain, whereas blood pooling in the posterior cul-de-sac (pouch of Douglas) may cause an urge to defecate. Lightheadedness or shock suggests tubal rupture has occurred, resulting in severe intraabdominal hemorrhage.",
"   </p>",
"   <p>",
"    Failure to diagnose ectopic pregnancy before tubal rupture limits the treatment options and increases maternal morbidity and mortality. A population-based French study identified four factors that increased the risk of rupture when an ectopic pregnancy was suspected: (1) never having used contraception, (2) history of tubal damage and infertility, (3) induction of ovulation, and (4) high level of human chorionic gonadotropin (at least 10,000",
"    <span class=\"nowrap\">",
"     IU/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/4\">",
"     4",
"    </a>",
"    ]. The overall rate of tubal rupture in this series was 18 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vital signs may reveal orthostatic changes and, occasionally, low grade fever. Findings on physical examination may include adnexal, cervical motion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abdominal tenderness, an adnexal mass, and mild uterine enlargement. However, the physical examination is often unremarkable in a woman with a small, unruptured ectopic pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No constellation of historical and physical findings can confirm or exclude the diagnosis of ectopic pregnancy with a high degree of reliability [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The diagnosis is usually made clinically, based upon results of the imaging studies (ultrasound) and laboratory tests (hCG) described below (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnostic evaluation'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The diagnosis can also be made by observation of the ectopic gestation at surgery or histopathologic examination, but surgery is not required in most cases. However, in the absence of definitive surgical, histopathologic, or sonographic findings, it is sometimes impossible to differentiate between an ectopic pregnancy and an early failed intrauterine gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of lower abdominal pain in women includes urinary tract infection, kidney stones, diverticulitis, appendicitis, ovarian neoplasms, endometriosis, endometritis, leiomyomas, pelvic inflammatory disease, and pregnancy-related conditions. Vaginal bleeding also has several pregnancy-related and nonpregnancy-related etiologies. Thus, a pregnancy test is important in premenopausal women who present with abdominal pain or vaginal bleeding in order to guide the direction of further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"     \"Overview of causes of genital tract bleeding in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Amenorrhea and abdominal pain, with or without vaginal bleeding, are common symptoms of complications of early pregnancy other than an ectopic pregnancy, such as threatened abortion, ruptured or torsed corpus luteum cyst, and degenerating uterine leiomyoma. Other common etiologies of pelvic pain or pressure in early pregnancy include constipation or ongoing uterine enlargement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link\">",
"     \"Clinical manifestations and diagnosis of early pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=see_link\">",
"     \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Recommended diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;TVUS is the most useful test for determining the location of a pregnancy. If the imaging study is nondiagnostic, it may be because the gestation is too early to be visualized on ultrasound. If so, serial measurements of the serum human chorionic gonadotropin (hCG) concentration should be taken until the hCG discriminatory zone is reached (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Discriminatory zone'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    This combination of TVUS and hCG will permit a definitive diagnosis in almost all cases at a very early stage of pregnancy, thereby permitting treatment options less invasive than surgical excision [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other diagnostic tests (eg, serum progesterone level, curettage, laparoscopy, culdocentesis) do not provide additional clinically useful information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Transvaginal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound is used to detect the presence (or absence) of a pregnancy within or outside of the uterus. Ultrasound evaluation for ectopic pregnancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=see_link\">",
"     \"Ultrasonography of pregnancy of unknown location\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Human chorionic gonadotropin",
"    </span>",
"    &nbsp;&mdash;&nbsp;hCG can be detected in serum and urine as early as eight days after the LH surge, if pregnancy has occurred. The hCG concentration in a normal intrauterine pregnancy rises in a curvilinear fashion until about 41 days of gestation, after which it rises more slowly until approximately 10 weeks, and then declines until reaching a plateau in the second and third trimesters [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. There is a wide range in the normal hCG level across individuals at each week of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link\">",
"     \"Clinical manifestations and diagnosis of early pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies in viable intrauterine pregnancies have reported the following changes in serum hCG [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/12,14-16\">",
"     12,14-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean doubling time for the hormone ranges from 1.4 to 2.1 days in early pregnancy.",
"     </li>",
"     <li>",
"      In 85 percent of viable intrauterine pregnancies, the hCG concentration rises by at least 66 percent every 48 hours during the first 40 days of pregnancy; only 15 percent of viable pregnancies have a rate of rise less than this threshold.",
"     </li>",
"     <li>",
"      The slowest recorded rise over 48 hours associated with a viable intrauterine pregnancy was 53 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The hCG concentration rises at a much slower rate in most, but not all, ectopic and nonviable intrauterine pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In one series, as an example, only 21 percent of ectopic pregnancies were associated with hCG levels that followed the minimum doubling time of a viable intrauterine pregnancy (defined in this series as &ge;53 percent increase over two days) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a 10 to 15 percent interassay variability in hCG measurements as well as variability among laboratories. Thus, interpretation of serial hCG concentrations is more reliable when the assays are performed in the same laboratory. In addition, the possibility of falsely positive hCG test results should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23015?source=see_link&amp;anchor=H14#H14\">",
"     \"Gestational trophoblastic disease: Management of hydatidiform mole\", section on 'Human chorionic gonadotropin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A falling hCG concentration is most consistent with a failed pregnancy (eg, arrested pregnancy, anembryonic pregnancy, tubal abortion, spontaneously resolving ectopic pregnancy, complete or incomplete abortion).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Discriminatory zone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discriminatory zone is based upon the correlation between visibility of the gestational sac and the hCG concentration, and is of major diagnostic importance (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnostic evaluation'",
"    </a>",
"    below). It is defined as the serum hCG level above which a gestational sac should be visualized by ultrasound examination if an intrauterine pregnancy is present [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/17\">",
"     17",
"    </a>",
"    ]. In most institutions, this serum hCG level is 1500 or 2000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    with TVS (the level is higher [6500",
"    <span class=\"nowrap\">",
"     IU/L]",
"    </span>",
"    with transabdominal ultrasound).",
"   </p>",
"   <p>",
"    The level of the discriminatory zone was based upon observations that an intrauterine gestational sac could be detected by TVS in patients with serum hCG concentrations as low as 800",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    and was usually identified by expert ultrasonographers at concentrations above 1500 to 2000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/21\">",
"     21",
"    </a>",
"    ]. In one representative study, 185 of 188 (98 percent) intrauterine pregnancies in women with hCG above 1500",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    were visualized [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/22\">",
"     22",
"    </a>",
"    ]. Setting a threshold of 2000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    instead of 1500",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    for the discriminatory zone minimizes the risk of interfering with a viable intrauterine pregnancy, if present, but increases the risk of delaying diagnosis of an ectopic pregnancy.",
"   </p>",
"   <p>",
"    The absence of an intrauterine gestational sac at hCG concentrations above the discriminatory zone strongly suggests an ectopic or nonviable intrauterine pregnancy, but is nondiagnostic with hCG values below the discriminatory zone. A negative ultrasound examination at hCG levels below the discriminatory zone is consistent with an early viable intrauterine pregnancy or an ectopic pregnancy or nonviable intrauterine pregnancy. Such cases are termed \"pregnancy of unknown location\" and 8 to 40 percent are ultimately diagnosed as ectopic pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discriminatory zone is dependent upon the skill of the ultrasonographer, the quality of the ultrasound equipment, the presence of physical factors (eg, fibroids, multiple gestation), and the laboratory characteristics of the hCG assay used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a pregnant woman with suspected ectopic gestation begins with TVS and quantitative hCG level (",
"    <a class=\"graphic graphic_algorithm graphicRef80606 \" href=\"UTD.htm?32/7/32882\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80277 \" href=\"UTD.htm?19/50/20269\">",
"     table 2",
"    </a>",
"    ). TVS alone is diagnostic if a yolk sac, embryo, or embryonic cardiac activity is demonstrable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     HCG above the discriminatory zone",
"    </span>",
"    &nbsp;&mdash;&nbsp;An hCG concentration above the discriminatory zone is sensitive for detecting an intrauterine pregnancy. Visualization of an intrauterine pregnancy almost always excludes the presence of an ectopic pregnancy; exceptions include heterotopic pregnancies (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Heterotopic pregnancy'",
"    </a>",
"    below) and misdiagnoses (eg, pregnancy in a rudimentary uterine horn or cornua).",
"   </p>",
"   <p>",
"    If TVS does not reveal an intrauterine pregnancy and shows a complex adnexal mass, an extrauterine pregnancy is almost certain. Embryonic cardiac activity or a gestational sac with a definite yolk sac or embryo at an extrauterine location is certain evidence of an ectopic gestation. Treatment of ectopic pregnancy should be instituted.",
"   </p>",
"   <p>",
"    The diagnosis of ectopic pregnancy is less certain if no complex adnexal mass can be visualized, since there is variability in the level of expertise among ultrasonographers. Furthermore, a serum hCG greater than 1500",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    without visualization of intrauterine or extrauterine pathology may represent a multiple gestation, since there is no proven discriminatory level for multiple gestations. For these reasons, our next step in this setting is to repeat the TVS examination and hCG concentration two days later. If an intrauterine pregnancy is still not observed on TVS, then the pregnancy is abnormal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An ectopic pregnancy can be diagnosed if the serum hCG concentration is increasing or plateaued. Treatment can be instituted.",
"     </li>",
"     <li>",
"      A falling hCG concentration is most consistent with a failed pregnancy (eg, arrested pregnancy, blighted ovum, tubal abortion, spontaneously resolving ectopic pregnancy). The rate of fall is slower with an ectopic pregnancy than with a complete abortion. Weekly hCG concentrations should be monitored until the result is negative for pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     HCG below the discriminatory zone",
"    </span>",
"    &nbsp;&mdash;&nbsp;TVS is not sensitive for determining the location of the pregnancy when the hCG level is below the discriminatory zone. A serum hCG concentration less than 1500",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    should be followed by repetition of hCG in three days to follow the rate of rise. HCG concentrations usually double every 1.4 to two days until six to seven weeks of gestation in viable intrauterine pregnancies (and in some ectopic gestations) (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Human chorionic gonadotropin'",
"    </a>",
"    above). We find that measurement every 72 hours is more practical than every 48 hours, and allowing 72 hours for doubling helps to avoid misclassifying those viable pregnancies with slower than average doubling times.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A normally rising hCG concentration should be evaluated with TVS when the hCG reaches the discriminatory zone. At that time, an intrauterine pregnancy or an ectopic pregnancy can be diagnosed.",
"     </li>",
"     <li>",
"      If the hCG concentration does not double over 72 hours (as discussed above, the minimum rise [99th percentile] over 48 hours for a potentially viable intrauterine pregnancy is 53 percent), then the pregnancy is abnormal (an ectopic gestation or intrauterine pregnancy that is destined to abort). The clinician can be reasonably certain that a normal intrauterine pregnancy is not present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If an adnexal mass is visualized on TVS, then medical or surgical treatment is administered for a presumed ectopic pregnancy. If an adnexal mass is not visualized, some clinicians administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and others perform curettage to determine the type of nonviable pregnancy and thereby avoid medical therapy of nonviable intrauterine pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Curettage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment of ectopic pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=see_link\">",
"     \"Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A falling hCG concentration is most consistent with a failed pregnancy (eg, arrested pregnancy, blighted ovum, tubal abortion, spontaneously resolving ectopic pregnancy). The rate of fall is slower with an ectopic pregnancy than with a completed abortion. Weekly hCG concentrations should be monitored until the result is negative for pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ancillary diagnostic tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Progesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum progesterone concentrations are higher in viable intrauterine pregnancies than in ectopic pregnancies and intrauterine pregnancies that are destined to abort [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/25\">",
"     25",
"    </a>",
"    ]. A meta-analysis of 26 cohort studies including 9436 women in the first trimester of pregnancy evaluated use of a single measurement of serum progesterone for the diagnosis of a nonviable pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/26\">",
"     26",
"    </a>",
"    ]. For women with bleeding or pain and an inconclusive pelvic ultrasound, a progesterone &lt;3.2 to 6",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (10.2 to 19.1",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    had a sensitivity of 75 percent and a specificity of 98 percent. For women with bleeding or pain alone, a progesterone &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (31.8",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    had a sensitivity of 67 percent and a specificity of 96 percent. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The predictive value of a low serum progesterone for identifying nonviable pregnancies varies with the patient population. The sensitivity and specificity of a low serum progesterone concentration for predicting a nonviable pregnancy in spontaneously pregnant patients are different from those in infertile patients who have undergone controlled ovarian hyperstimulation for in vitro fertilization or intrauterine insemination [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our experience, progesterone measurements merely confirm diagnostic impressions already obtained by hCG measurements and transvaginal sonography. We do not routinely measure serum progesterone. However, serum progesterone may be useful in a patient with abdominal pain and bleeding and who has a serum hCG level below that expected for her gestational age. It should be noted, however, that the definition of a low progesterone is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Curettage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intrauterine location of a pregnancy is diagnosed with certainty if trophoblastic tissue is obtained by uterine curettage. Obviously, the use of curettage as a diagnostic tool is limited by the potential for disruption of a viable pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/7\">",
"     7",
"    </a>",
"    ]. Moreover, false negatives can occur: chorionic villi are not detected by histopathology in 20 percent of curettage specimens from elective termination of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/28\">",
"     28",
"    </a>",
"    ]. Pipelle endometrial biopsy is even less sensitive than curettage for detection of villi; sensitivities reported in two small series were 30 and 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. If curettage is performed, serum hCG levels can be followed post curettage if histopathology does not confirm the clinical impression. When an intrauterine pregnancy has been evacuated, hCG levels should drop by at least 15 percent the day after evacuation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors have recommended performing curettage only on women with both a hCG concentration below the discriminatory zone and a low doubling rate (see",
"    <a class=\"local\" href=\"#H13\">",
"     'HCG below the discriminatory zone'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Approximately 30 percent of these patients have a nonviable intrauterine gestation and the remainder have an ectopic pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Knowing the results of curettage avoids unnecessary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    treatment of the 30 percent of patients without ectopic pregnancy.",
"   </p>",
"   <p>",
"    A decision analysis comparing the",
"    <span class=\"nowrap\">",
"     cost/complication",
"    </span>",
"    rates in patients who undergo diagnostic curettage before administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    to those who do not have a curettage concluded there was no significant benefit of one approach over the other [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/33\">",
"     33",
"    </a>",
"    ]. However, the authors' preference was to perform curettage in these patients to be more certain of the diagnosis, and felt this information was useful prognostically (eg, risk of recurrence) and for future decision making. In contrast, we and others believe it is more practical and less invasive to continue observation or administer one dose of methotrexate than to perform curettage [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The side effects of one dose of methotrexate are negligible. In addition, curettage carries a risk of intrauterine adhesion formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=see_link\">",
"     \"Intrauterine adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood flow in the arteries of the fallopian tube containing an ectopic pregnancy is 20 to 45 percent higher than in the opposite tube and the Doppler waveform shows low impedance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/11,36\">",
"     11,36",
"    </a>",
"    ]. Color Doppler may demonstrate a ring of blood flow. These findings on Doppler support the diagnosis of ectopic pregnancy, especially if a complex adnexal mass is also visualized. Doppler examination can be performed when an adnexal mass is seen. In one study, the resistive index of ectopic pregnancies was higher than that of corpus luteum cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/37\">",
"     37",
"    </a>",
"    ]. A resistive index of less than 0.39 had a specificity of 100 percent and a positive predictive value of 100 percent for diagnosing ectopic pregnancy, but was present in only 15 percent of ectopic pregnancies. A resistive index of greater than 0.7 had a specificity of 100 percent and a positive predictive value of 100 percent for diagnosing ectopic pregnancy and was present in 31 percent of ectopic pregnancies. However, the use of TVS and hCG measurements is usually sufficient in establishing the diagnosis in routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopy is rarely required for diagnostic purposes only; transvaginal ultrasound examination and hCG measurements are usually sufficient for diagnosis. However, an ectopic pregnancy detected at laparoscopy should be treated immediately by surgery. In this situation, a medical approach confers additional risk and has no proven benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Culdocentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culdocentesis is employed to detect blood in the posterior cul-de-sac; however, this finding can be easily demonstrated by transvaginal ultrasound (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Transvaginal ultrasound'",
"    </a>",
"    above). Blood in the posterior cul-de-sac may be from bleeding from an unruptured or ruptured tubal pregnancy, but it may also be the result of a ruptured ovarian cyst. Therefore, a culdocentesis positive for blood is nondiagnostic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/54/24420?source=see_link\">",
"     \"Culdocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging can be used to diagnose ectopic pregnancy, but is not a cost effective approach [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SCREENING ASYMPTOMATIC WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, over 50 percent of women are asymptomatic before tubal rupture and do not have an identifiable risk factor for ectopic pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/39\">",
"     39",
"    </a>",
"    ]. Identifying these women at a very early stage of pregnancy could reduce their risk of adverse outcome and permit treatment options less invasive than surgical excision.",
"   </p>",
"   <p>",
"    A decision analysis model showed that screening asymptomatic pregnant women for ectopic pregnancy reduced the frequency of rupture, but approximately three false positive diagnoses would occur per tubal rupture prevented if the prevalence of ectopic pregnancy was 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/40\">",
"     40",
"    </a>",
"    ]. Screening only appeared to be cost-effective in populations with a high prevalence (at least 8 percent) of ectopic pregnancy.",
"   </p>",
"   <p>",
"    We monitor women at high risk of ectopic pregnancy, such as those with a previous ectopic pregnancy, with laboratory and imaging studies as soon as their first missed menses. The diagnosis can then be established early, possibly before the occurrence of any symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21752?source=see_link&amp;anchor=H15#H15\">",
"     \"Incidence, risk factors, and pathology of ectopic pregnancy\", section on 'In vitro fertilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     UNCOMMON TYPES OF ECTOPIC PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility that an ectopic pregnancy may occur in a nontubal location, in conjunction with an intrauterine pregnancy, or even bilaterally [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/41\">",
"     41",
"    </a>",
"    ], should be considered. These types of pregnancies are uncommon, and include heterotopic, hysterotomy scar, cervical, ovarian, rudimentary uterine horn, and abdominal pregnancy. Regardless of the location, the endometrium often responds to ovarian and placental production of pregnancy related hormones, so vaginal bleeding is a common symptom.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical pregnancy is estimated to occur in",
"      <span class=\"nowrap\">",
"       1/2500",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       1/18,000",
"      </span>",
"      pregnancies and accounts for 1 percent of ectopic pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/42-44\">",
"       42-44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ovarian pregnancy occurs in",
"      <span class=\"nowrap\">",
"       1/2100",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       1/60,000",
"      </span>",
"      pregnancies and accounts for 1 to 3 percent of ectopic pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interstitial pregnancy accounts for up to 1 to 3 percent of ectopic pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abdominal pregnancy accounts for up to 1.4 percent of ectopic pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/48-50\">",
"       48-50",
"      </a>",
"      ]. These pregnancies can go undetected until an advanced age and often result in severe hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/51\">",
"       51",
"      </a>",
"      ]. Rates of maternal mortality have been reported as high as 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intramural pregnancy refers to pregnancy implanted within the myometrium of the uterus. This type of pregnancy is extremely rare with less than 50 reported cases in the literature [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Heterotopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The investigation for ectopic pregnancy can be terminated, under most circumstances, if a transvaginal sonogram reveals an intrauterine pregnancy. Combined intrauterine and extrauterine pregnancy (heterotopic pregnancy) is rare, except among women conceiving through IVF. The extrauterine pregnancy is usually in the fallopian tube, but can be at another location, such as the cervix. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early diagnosis of heterotopic pregnancy is difficult because of lack of symptoms. Thus, a high index of suspicion for this diagnosis is important, especially in patients who have undergone IVF and who experience pelvic pain.",
"   </p>",
"   <p>",
"    Serial hCG concentrations are not interpretable in the presence of both a viable intrauterine and ectopic pregnancy. On ultrasound examination, the diagnosis is suggested by visualization of both an ectopic and intrauterine pregnancy or the presence of echogenic fluid in the posterior cul de sac in the presence of an intrauterine pregnancy. Heterotopic tubal pregnancies have been reported as late as 16 weeks of gestation, while abdominal or rudimentary horn pregnancies can continue to develop late in gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/52,55\">",
"     52,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ultrasonographer should carefully examine not only the uterus, but also the adnexae of women who conceive following IVF. We suggest that women with a confirmed intrauterine pregnancy who are experiencing abdominal or pelvic pain undergo serial TVS examinations every week until the possibility of a concomitant tubal ectopic pregnancy can be eliminated.",
"   </p>",
"   <p>",
"    Surgery (salpingectomy) is the standard treatment of heterotopic pregnancy with a tubal component, since the intrauterine pregnancy is a contraindication to medical therapy. If the ectopic pregnancy has not ruptured, then local injection of 5 mEq",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    into the sac is another option [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. Injection of potassium chloride can be guided sonographically, thus avoiding a surgical procedure.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is absolutely contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cervical pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptom of cervical pregnancy is vaginal bleeding, which is often profuse and painless. Lower abdominal pain or cramps occur in fewer than one-third of patients; pain without bleeding is rare. Diagnosis and management of cervical pregnancy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11062?source=see_link\">",
"     \"Cervical pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hysterotomy scar pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms are similar to tubal ectopic pregnancy, and include vaginal bleeding and abdominal pain. The diagnosis is made by sonographically visualizing an enlarged hysterotomy scar with an embedded mass [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/61\">",
"     61",
"    </a>",
"    ]. Features which should be present include presence of trophoblast between the bladder and the anterior uterine wall, no fetal parts in the uterine cavity, absence of myometrium between the gestational sac and the bladder, and Doppler evidence of perfusion of the peritrophoblastic vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the pregnancy has not ruptured, then local injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    into the sac under sonographic guidance is an effective treatment. Rupture can result in significant bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Ovarian pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonographic diagnosis of an ovarian pregnancy is difficult. Ultrasound evaluation for ovarian pregnancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=see_link\">",
"     \"Ultrasonography of pregnancy of unknown location\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of ovarian pregnancy is typically made at the time of surgery, but differentiation from a hemorrhagic ovarian cyst or pregnancy in the distal fallopian tube can be difficult. Ultrasound may suggest the diagnosis preoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/45\">",
"     45",
"    </a>",
"    ]. Strict histopathological criteria are used to distinguish ovarian pregnancies from those originating in the fallopian tube. The exact diagnosis is not clinically important as these pregnancies are usually treated by surgical excision of the involved organs.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    treatment has been successful in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21752?source=see_link&amp;anchor=H22#H22\">",
"     \"Incidence, risk factors, and pathology of ectopic pregnancy\", section on 'Ovarian pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Abdominal pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the variable location in the abdomen, abdominal pregnancy is associated with a wide range of signs and symptoms. These include abdominal pain, vaginal bleeding, vomiting, painful fetal movement, oligohydramnios, persistent unusual fetal lie, failure to deliver an intrauterine fetal demise, and labor abnormalities. In one report, hemothorax developed from implantation on the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/68\">",
"     68",
"    </a>",
"    ]. Abdominal pregnancies rarely result in the birth of a viable infant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Interstitial pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interstitial portion of the fallopian tube is the proximal segment that is embedded within the muscular wall of the uterus. A pregnancy implanted at this site is called an interstitial pregnancy (",
"    <a class=\"graphic graphic_figure graphicRef55921 \" href=\"UTD.htm?10/35/10804\">",
"     figure 1",
"    </a>",
"    ); the term cornual pregnancy is also widely used to describe a pregnancy at this location. Originally, the term cornual pregnancy referred only to pregnancies implanted in either the horn of a bicornuate uterus, a rudimentary horn of a unicornuate uterus, or in the lateral half of a septated or partially septated uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/47,69\">",
"     47,69",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    An interstitial pregnancy can be difficult to distinguish on ultrasound from an intrauterine pregnancy that is eccentrically positioned. Ultrasound evaluation for interstitial pregnancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=see_link\">",
"     \"Ultrasonography of pregnancy of unknown location\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Grossly, an interstitial pregnancy appears as a gestational swelling lateral to the insertion of the round ligament (",
"    <a class=\"graphic graphic_figure graphicRef55921 \" href=\"UTD.htm?10/35/10804\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/47\">",
"     47",
"    </a>",
"    ]. The unique anatomic location of an interstitial pregnancy often leads to a delay in diagnosis, although an average delay of only four days in comparison with tubal pregnancies was reported in a large series [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interstitial pregnancy presents with rupture in approximately 20 to 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. A series of cases of interstitial pregnancy reported to a surgical registry included 14 patients with tubal rupture, all of which were before 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/71\">",
"     71",
"    </a>",
"    ]. This is in contrast to previous reports that rupture of interstitial pregnancy occurred late in pregnancy. Other clinical manifestations are the same as for all ectopic gestations (pelvic or abdominal pain, vaginal bleeding) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the maternal mortality rate associated with tubal pregnancy is decreasing, the rate for interstitial pregnancies remains at 2 to 2.5 percent because of misdiagnosis of these gestations as intrauterine pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;If left untreated, an ectopic pregnancy in the fallopian tube can progress to a tubal abortion or tubal rupture, or it may regress spontaneously.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rupture &mdash; Tubal rupture is usually associated with profound hemorrhage, which can be fatal if surgery is not performed expeditiously to remove the ectopic gestation. Salpingectomy is the most common surgical approach when the tube has ruptured. Ruptured ectopic pregnancy is the major cause of pregnancy-related maternal mortality in the first trimester [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/74\">",
"       74",
"      </a>",
"      ]. Most of these deaths occur prior to hospitalization or proximate to the woman's arrival in the emergency department.",
"     </li>",
"     <li>",
"      Abortion &mdash; Tubal abortion refers to expulsion of the products of conception through the fimbria. This can be followed by resorption of the tissue or by reimplantation of the trophoblasts in the abdominal cavity (ie, abdominal pregnancy) or on the ovary (ie, ovarian pregnancy). Tubal abortion may be accompanied by severe intraabdominal bleeding, necessitating surgical intervention, or by minimal bleeding, not requiring further treatment.",
"     </li>",
"     <li>",
"      Spontaneous resolution &mdash; The incidence of spontaneous resolution of an ectopic pregnancy is unknown. In one older (1955) series of 119 hospitalized patients with typical ectopic pregnancy symptoms, 57 were safely managed expectantly, without surgical or medical intervention (except opiates) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/75\">",
"       75",
"      </a>",
"      ]. It is difficult to predict which patients will experience uncomplicated spontaneous resolution. Potential candidates are hemodynamically stable women with an initial hCG concentration less than 2000",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      that is declining [",
"      <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/76-78\">",
"       76-78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gestational products left in the fallopian tube may resorb completely or, less commonly, may cause tubal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/9/1178/abstract/79\">",
"     79",
"    </a>",
"    ]. Alternatively, a tubal abortion may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all women diagnosed with an ectopic gestation undergo medical or surgical treatment because the frequency and potential",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    of rupture are high.",
"   </p>",
"   <p>",
"    Specific indications for surgical therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Impending or ongoing ectopic mass rupture",
"     </li>",
"     <li>",
"      Not able or willing to comply with medical therapy posttreatment follow-up",
"     </li>",
"     <li>",
"      Lack of timely access to a medical institution for management of tubal rupture",
"     </li>",
"     <li>",
"      Failed medical therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of these criteria, medical therapy is an option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=see_link\">",
"     \"Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link&amp;anchor=H20#H20\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\", section on 'Medical versus surgical treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Expectant management is considered rarely in women with low and declining hCG levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21444?source=see_link\">",
"     \"Expectant management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/20/35138?source=see_link\">",
"       \"Patient information: Ectopic pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/43/38578?source=see_link\">",
"       \"Patient information: Ectopic (tubal) pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal pain, amenorrhea, and vaginal bleeding are the classic symptoms of ectopic pregnancy. Ectopic pregnancy should be suspected in any women of reproductive age with these symptoms, especially those who have risk factors for an extrauterine pregnancy (",
"      <a class=\"graphic graphic_table graphicRef82282 \" href=\"UTD.htm?10/38/10860\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, over 50 percent of women are asymptomatic before tubal rupture and do not have an identifiable risk factor for ectopic pregnancy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis is usually made clinically based upon results from ultrasound examination and human chorionic gonadotropin hormone (hCG) testing. Confirmation of the diagnosis by visualization at surgery or histopathological examination of tissue is not necessary. However, in the absence of definitive surgical, sonographic, or histopathological findings, it may not be possible to differentiate between a failed intrauterine pregnancy and an ectopic pregnancy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of a woman with suspected ectopic gestation begins with a transvaginal ultrasound examination and quantitative human chorionic gonadotropin (hCG) level. Transvaginal ultrasound is diagnostic if a true gestational sac, yolk sac, embryo, or embryonic cardiac activity is demonstrable inside or outside of the uterus. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An extrauterine pregnancy is almost certain when the hCG concentration is greater than 1500",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      (discriminatory zone threshold) and transvaginal ultrasound examination reveals a complex adnexal mass and no intrauterine pregnancy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'HCG above the discriminatory zone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A serum hCG concentration less than 1500",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      with a negative transvaginal ultrasound examination should be followed by repetition of both of these tests in three days to follow the rate of rise of the hCG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A normally rising hCG concentration should be evaluated with ultrasound examination when the hCG reaches the discriminatory zone. At that time, an intrauterine pregnancy or an ectopic pregnancy can be diagnosed.",
"     </li>",
"     <li>",
"      If the hCG concentration rises but does not double over 72 hours, then the pregnancy is abnormal (an ectopic gestation or intrauterine pregnancy that is destined to abort).",
"     </li>",
"     <li>",
"      A falling hCG concentration is most consistent with a failed pregnancy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'HCG below the discriminatory zone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uncommon types of ectopic pregnancy include heterotopic, cervical, hysterotomy scar, ovarian, interstitial, and abdominal pregnancy. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Uncommon types of ectopic pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/1\">",
"      Ankum WM, Mol BW, Van der Veen F, Bossuyt PM. Risk factors for ectopic pregnancy: a meta-analysis. Fertil Steril 1996; 65:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/2\">",
"      Alsuleiman SA, Grimes EM. Ectopic pregnancy: a review of 147 cases. J Reprod Med 1982; 27:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/3\">",
"      Weckstein LN. Current perspective on ectopic pregnancy. Obstet Gynecol Surv 1985; 40:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/4\">",
"      Job-Spira N, Fernandez H, Bouyer J, et al. Ruptured tubal ectopic pregnancy: risk factors and reproductive outcome: results of a population-based study in France. Am J Obstet Gynecol 1999; 180:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/5\">",
"      Dart RG, Kaplan B, Varaklis K. Predictive value of history and physical examination in patients with suspected ectopic pregnancy. Ann Emerg Med 1999; 33:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/6\">",
"      Buckley RG, King KJ, Disney JD, et al. History and physical examination to estimate the risk of ectopic pregnancy: validation of a clinical prediction model. Ann Emerg Med 1999; 34:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/7\">",
"      Tulandi, T. Current protocol for ectopic pregnancy. Contemp Obstet Gynecol 1999; 44:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/8\">",
"      Yao M, Tulandi T. Current status of surgical and nonsurgical management of ectopic pregnancy. Fertil Steril 1997; 67:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/9\">",
"      Ankum WM, Van der Veen F, Hamerlynck JV, Lammes FB. Laparoscopy: a dispensable tool in the diagnosis of ectopic pregnancy? Hum Reprod 1993; 8:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/10\">",
"      Gabrielli S, Romero R, Pilu G, et al. Accuracy of transvaginal ultrasound and serum hCG in the diagnosis of ectopic pregnancy. Ultrasound Obstet Gynecol 1992; 2:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/11\">",
"      Kirchler HC, Seebacher S, Alge AA, et al. Early diagnosis of tubal pregnancy: changes in tubal blood flow evaluated by endovaginal color Doppler sonography. Obstet Gynecol 1993; 82:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/12\">",
"      Daya S. Human chorionic gonadotropin increase in normal early pregnancy. Am J Obstet Gynecol 1987; 156:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/13\">",
"      Cole LA. Individual deviations in human chorionic gonadotropin concentrations during pregnancy. Am J Obstet Gynecol 2011; 204:349.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/14\">",
"      Kadar N, DeCherney AH, Romero R. Receiver operating characteristic (ROC) curve analysis of the relative efficacy of single and serial chorionic gonadotropin determinations in the early diagnosis of ectopic pregnancy. Fertil Steril 1982; 37:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/15\">",
"      Barnhart KT, Sammel MD, Rinaudo PF, et al. Symptomatic patients with an early viable intrauterine pregnancy: HCG curves redefined. Obstet Gynecol 2004; 104:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/16\">",
"      Silva C, Sammel MD, Zhou L, et al. Human chorionic gonadotropin profile for women with ectopic pregnancy. Obstet Gynecol 2006; 107:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/17\">",
"      Kadar N, DeVore G, Romero R. Discriminatory hCG zone: its use in the sonographic evaluation for ectopic pregnancy. Obstet Gynecol 1981; 58:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/18\">",
"      Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. Lancet 2000; 355:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/19\">",
"      Cole LA. Phantom hCG and phantom choriocarcinoma. Gynecol Oncol 1998; 71:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/20\">",
"      Olsen TG, Hubert PR, Nycum LR. Falsely elevated human chorionic gonadotropin leading to unnecessary therapy. Obstet Gynecol 2001; 98:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/21\">",
"      Paul M, Schaff E, Nichols M. The roles of clinical assessment, human chorionic gonadotropin assays, and ultrasonography in medical abortion practice. Am J Obstet Gynecol 2000; 183:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/22\">",
"      Barnhart KT, Simhan H, Kamelle SA. Diagnostic accuracy of ultrasound above and below the beta-hCG discriminatory zone. Obstet Gynecol 1999; 94:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/23\">",
"      Condous G, Kirk E, Lu C, et al. Diagnostic accuracy of varying discriminatory zones for the prediction of ectopic pregnancy in women with a pregnancy of unknown location. Ultrasound Obstet Gynecol 2005; 26:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/24\">",
"      Seeber BE, Barnhart KT. Suspected ectopic pregnancy. Obstet Gynecol 2006; 107:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/25\">",
"      Rausch ME, Barnhart KT. Serum biomarkers for detecting ectopic pregnancy. Clin Obstet Gynecol 2012; 55:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/26\">",
"      Verhaegen J, Gallos ID, van Mello NM, et al. Accuracy of single progesterone test to predict early pregnancy outcome in women with pain or bleeding: meta-analysis of cohort studies. BMJ 2012; 345:e6077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/27\">",
"      Perkins SL, Al-Ramahi M, Claman P. Comparison of serum progesterone as an indicator of pregnancy nonviability in spontaneously pregnant emergency room and infertility clinic patient populations. Fertil Steril 2000; 73:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/28\">",
"      Lindahl B, Ahlgren M. Identification of chorion villi in abortion specimens. Obstet Gynecol 1986; 67:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/29\">",
"      Ries A, Singson P, Bidus M, Barnes JG. Use of the endometrial pipelle in the diagnosis of early abnormal gestations. Fertil Steril 2000; 74:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/30\">",
"      Barnhart KT, Gracia CR, Reindl B, Wheeler JE. Usefulness of pipelle endometrial biopsy in the diagnosis of women at risk for ectopic pregnancy. Am J Obstet Gynecol 2003; 188:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/31\">",
"      Lipscomb GH, Stovall TG, Ling FW. Nonsurgical treatment of ectopic pregnancy. N Engl J Med 2000; 343:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/32\">",
"      Barnhart KT, Katz I, Hummel A, Gracia CR. Presumed diagnosis of ectopic pregnancy. Obstet Gynecol 2002; 100:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/33\">",
"      Ailawadi M, Lorch SA, Barnhart KT. Cost-effectiveness of presumptively medically treating women at risk for ectopic pregnancy compared with first performing a dilatation and curettage. Fertil Steril 2005; 83:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/34\">",
"      Condous G, Kirk E, Lu C, et al. There is no role for uterine curettage in the contemporary diagnostic workup of women with a pregnancy of unknown location. Hum Reprod 2006; 21:2706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/35\">",
"      Condous G, Timmerman D, Goldstein S, et al. Pregnancies of unknown location: consensus statement. Ultrasound Obstet Gynecol 2006; 28:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/36\">",
"      Pellerito JS, Taylor KJ, Quedens-Case C, et al. Ectopic pregnancy: evaluation with endovaginal color flow imaging. Radiology 1992; 183:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/37\">",
"      Atri M. Ectopic pregnancy versus corpus luteum cyst revisited: best Doppler predictors. J Ultrasound Med 2003; 22:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/38\">",
"      Kataoka ML, Togashi K, Kobayashi H, et al. Evaluation of ectopic pregnancy by magnetic resonance imaging. Hum Reprod 1999; 14:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/39\">",
"      Stovall TG, Kellerman AL, Ling FW, Buster JE. Emergency department diagnosis of ectopic pregnancy. Ann Emerg Med 1990; 19:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/40\">",
"      Mol BW, van der Veen F, Bossuyt PM. Symptom-free women at increased risk of ectopic pregnancy: should we screen? Acta Obstet Gynecol Scand 2002; 81:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/41\">",
"      De Los R&iacute;os JF, Casta&ntilde;eda JD, Miryam A. Bilateral ectopic pregnancy. J Minim Invasive Gynecol 2007; 14:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/42\">",
"      Cepni I, Ocal P, Erkan S, Erzik B. Conservative treatment of cervical ectopic pregnancy with transvaginal ultrasound-guided aspiration and single-dose methotrexate. Fertil Steril 2004; 81:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/43\">",
"      Benson CB, Doubilet PM. Strategies for conservative treatment of cervical ectopic pregnancy. Ultrasound Obstet Gynecol 1996; 8:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/44\">",
"      Ushakov FB, Elchalal U, Aceman PJ, Schenker JG. Cervical pregnancy: past and future. Obstet Gynecol Surv 1997; 52:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/45\">",
"      Comstock C, Huston K, Lee W. The ultrasonographic appearance of ovarian ectopic pregnancies. Obstet Gynecol 2005; 105:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/46\">",
"      Dilbaz S, Katas B, Demir B, Dilbaz B. Treating cornual pregnancy with a single methotrexate injection: a report of 3 cases. J Reprod Med 2005; 50:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/47\">",
"      Lau S, Tulandi T. Conservative medical and surgical management of interstitial ectopic pregnancy. Fertil Steril 1999; 72:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/48\">",
"      Fisch JD, Ortiz BH, Tazuke SI, et al. Medical management of interstitial ectopic pregnancy: a case report and literature review. Hum Reprod 1998; 13:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/49\">",
"      Atrash HK, Friede A, Hogue CJ. Abdominal pregnancy in the United States: frequency and maternal mortality. Obstet Gynecol 1987; 69:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/50\">",
"      Dover RW, Powell MC. Management of a primary abdominal pregnancy. Am J Obstet Gynecol 1995; 172:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/51\">",
"      Fisch B, Peled Y, Kaplan B, et al. Abdominal pregnancy following in vitro fertilization in a patient with previous bilateral salpingectomy. Obstet Gynecol 1996; 88:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/52\">",
"      Onan MA, Turp AB, Saltik A, et al. Primary omental pregnancy: case report. Hum Reprod 2005; 20:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/53\">",
"      Varma R, Mascarenhas L, James D. Successful outcome of advanced abdominal pregnancy with exclusive omental insertion. Ultrasound Obstet Gynecol 2003; 21:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/54\">",
"      Bernstein HB, Thrall MM, Clark WB. Expectant management of intramural ectopic pregnancy. Obstet Gynecol 2001; 97:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/55\">",
"      Shinohara A, Yamada A, Imai A. Rupture of noncommunicating rudimentary uterine horn at 27 weeks' gestation with neonatal and maternal survival. Int J Gynaecol Obstet 2005; 88:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/56\">",
"      Fernandez H, Lelaidier C, Doumerc S, et al. Nonsurgical treatment of heterotopic pregnancy: a report of six cases. Fertil Steril 1993; 60:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/57\">",
"      Goldstein JS, Ratts VS, Philpott T, Dahan MH. Risk of surgery after use of potassium chloride for treatment of tubal heterotopic pregnancy. Obstet Gynecol 2006; 107:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/58\">",
"      Doubilet PM, Benson CB, Frates MC, Ginsburg E. Sonographically guided minimally invasive treatment of unusual ectopic pregnancies. J Ultrasound Med 2004; 23:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/59\">",
"      Gyamfi C, Cohen S, Stone JL. Maternal complication of cervical heterotopic pregnancy after successful potassium chloride fetal reduction. Fertil Steril 2004; 82:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/60\">",
"      Salomon LJ, Fernandez H, Chauveaud A, et al. Successful management of a heterotopic Caesarean scar pregnancy: potassium chloride injection with preservation of the intrauterine gestation: case report. Hum Reprod 2003; 18:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/61\">",
"      Rotas MA, Haberman S, Levgur M. Cesarean scar ectopic pregnancies: etiology, diagnosis, and management. Obstet Gynecol 2006; 107:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/62\">",
"      Vial Y, Petignat P, Hohlfeld P. Pregnancy in a cesarean scar. Ultrasound Obstet Gynecol 2000; 16:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/63\">",
"      Ash A, Smith A, Maxwell D. Caesarean scar pregnancy. BJOG 2007; 114:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/64\">",
"      Valley MT, Pierce JG, Daniel TB, Kaunitz AM. Cesarean scar pregnancy: imaging and treatment with conservative surgery. Obstet Gynecol 1998; 91:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/65\">",
"      Habbu J, Read MD. Ovarian pregnancy successfully treated with methotrexate. J Obstet Gynaecol 2006; 26:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/66\">",
"      Raziel A, Golan A. Primary ovarian pregnancy successfully treated with methotrexate. Am J Obstet Gynecol 1993; 169:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/67\">",
"      Shamma FN, Schwartz LB. Primary ovarian pregnancy successfully treated with methotrexate. Am J Obstet Gynecol 1992; 167:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/68\">",
"      Fishman DA, Padilla LA, Joob A, Lurain JR. Ectopic pregnancy causing hemothorax managed by thoracoscopy and actinomycin D. Obstet Gynecol 1998; 91:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/69\">",
"      Jansen RP, Elliott PM. Angular intrauterine pregnancy. Obstet Gynecol 1981; 58:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/70\">",
"      Larra&iacute;n D, Marengo F, Bourdel N, et al. Proximal ectopic pregnancy: a descriptive general population-based study and results of different management options in 86 cases. Fertil Steril 2011; 95:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/71\">",
"      Tulandi T, Al-Jaroudi D. Interstitial pregnancy: results generated from the Society of Reproductive Surgeons Registry. Obstet Gynecol 2004; 103:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/72\">",
"      Soriano D, Vicus D, Mashiach R, et al. Laparoscopic treatment of cornual pregnancy: a series of 20 consecutive cases. Fertil Steril 2008; 90:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/73\">",
"      Chan LY, Fok WY, Yuen PM. Pitfalls in diagnosis of interstitial pregnancy. Acta Obstet Gynecol Scand 2003; 82:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/74\">",
"      Anderson FW, Hogan JG, Ansbacher R. Sudden death: ectopic pregnancy mortality. Obstet Gynecol 2004; 103:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/75\">",
"      LUND J. Early ectopic pregnancy; comments on conservative treatment. J Obstet Gynaecol Br Emp 1955; 62:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/76\">",
"      Shalev E, Peleg D, Tsabari A, et al. Spontaneous resolution of ectopic tubal pregnancy: natural history. Fertil Steril 1995; 63:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/77\">",
"      Korhonen J, Stenman UH, Yl&ouml;stalo P. Serum human chorionic gonadotropin dynamics during spontaneous resolution of ectopic pregnancy. Fertil Steril 1994; 61:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/78\">",
"      Trio D, Strobelt N, Picciolo C, et al. Prognostic factors for successful expectant management of ectopic pregnancy. Fertil Steril 1995; 63:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/9/1178/abstract/79\">",
"      Tulandi T, Ferenczy A, Berger E. Tubal occlusion as a result of retained ectopic pregnancy: a case report. Am J Obstet Gynecol 1988; 158:1116.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5487 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1178=[""].join("\n");
var outline_f1_9_1178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Recommended diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Transvaginal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Human chorionic gonadotropin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Discriminatory zone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - HCG above the discriminatory zone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - HCG below the discriminatory zone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ancillary diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Progesterone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Curettage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Doppler",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Culdocentesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SCREENING ASYMPTOMATIC WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      UNCOMMON TYPES OF ECTOPIC PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cervical pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hysterotomy scar pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Ovarian pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Abdominal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Interstitial pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5487\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5487|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?32/7/32882\" title=\"algorithm 1\">",
"      Algorithm ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5487|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/35/10804\" title=\"figure 1\">",
"      Normal female anat detail",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5487|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/38/10860\" title=\"table 1\">",
"      Risk factors ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/50/20269\" title=\"table 2\">",
"      features of ectopic pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=related_link\">",
"      Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11062?source=related_link\">",
"      Cervical pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=related_link\">",
"      Clinical manifestations and diagnosis of early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/54/24420?source=related_link\">",
"      Culdocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21444?source=related_link\">",
"      Expectant management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23015?source=related_link\">",
"      Gestational trophoblastic disease: Management of hydatidiform mole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21752?source=related_link\">",
"      Incidence, risk factors, and pathology of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=related_link\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=related_link\">",
"      Methotrexate treatment of tubal and interstitial ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=related_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=related_link\">",
"      Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/43/38578?source=related_link\">",
"      Patient information: Ectopic (tubal) pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/20/35138?source=related_link\">",
"      Patient information: Ectopic pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=related_link\">",
"      Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=related_link\">",
"      Ultrasonography of pregnancy of unknown location",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_9_1179="Presentation liver disease CF";
var content_f1_9_1179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modes of presentation of liver disease in cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Cholestatic jaundice in infancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemorrhagic disease in infancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient hepatomegaly with malnutrition in infancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymptomatic hepatosplenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymptomatic elevation of liver enzymes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Davis, PB, Drumm, M, Konstan, MW. Cystic Fibrosis. Am J Respir Crit Care Med 1996; 154:1229.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1179=[""].join("\n");
var outline_f1_9_1179=null;
var title_f1_9_1180="Femoral shaft fracture treatment in children and adolescents";
var content_f1_9_1180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment options for femoral shaft fractures in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Age",
"      </td>",
"      <td class=\"subtitle1\">",
"       Treatment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Birth to 24 mo",
"      </td>",
"      <td>",
"       Pavlik harness (newborn to 6 mo)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Immediate spica cast",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Traction &rarr; spica cast",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       24 mo to 5 yr",
"      </td>",
"      <td>",
"       Immediate spica cast",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Traction &rarr; spica cast",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       External fixation (rare)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Flexible intramedullary rod (rare)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       6-11 yr",
"      </td>",
"      <td>",
"       Traction &rarr; spica cast",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Flexible intramedullary rod",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Compression plate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       External fixation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       12 yr to maturity",
"      </td>",
"      <td>",
"       Flexible intramedullary rod",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Compression plate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Locked intramedullary rod",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       External fixation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Treatment choices are influenced by the presence of multiple trauma (vs. an isolated femoral shaft fracture) or an open fracture with soft tissue trauma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kasser JR, Beaty JH. Femoral Shaft Fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1180=[""].join("\n");
var outline_f1_9_1180=null;
var title_f1_9_1181="CF oral formulas";
var content_f1_9_1181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commercially available oral supplements used for individuals with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Supplement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Company",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fat",
"        <br/>",
"        (grams per 8 oz formula)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type of fat",
"       </td>",
"       <td class=\"subtitle1\">",
"        Kcal/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ensure",
"       </td>",
"       <td>",
"        Abbott",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Soy, canola, corn oil",
"       </td>",
"       <td>",
"        1.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boost",
"       </td>",
"       <td>",
"        Nestle",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Canola, high oleic sunflower, corn oil",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pediasure",
"       </td>",
"       <td>",
"        Abbott",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        High oleic safflower, soy, MCT oil",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pediasure 1.5&nbsp;",
"       </td>",
"       <td>",
"        Abbott&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        16&nbsp;",
"       </td>",
"       <td>",
"        High oleic safflower, soy, MCT oil&nbsp;",
"       </td>",
"       <td>",
"        1.5&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carnation Breakfast Essentials (powder mixed with 8 oz. whole milk)",
"       </td>",
"       <td>",
"        Nestle",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        Butter fat",
"       </td>",
"       <td>",
"        1.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ensure Plus",
"       </td>",
"       <td>",
"        Abbott",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        Canola, corn oil",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boost Plus",
"       </td>",
"       <td>",
"        Nestle",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        Canola, high oleic sunflower, corn oil",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resource 2.0",
"       </td>",
"       <td>",
"        Nestle",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        Canola oil",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boost Kids Essentials 1.5",
"       </td>",
"       <td>",
"        Nestle",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        Soybean oil, high oleic sunflower oil, MCT oil",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boost Kids Essentials 1.0",
"       </td>",
"       <td>",
"        Nestle",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        High oleic sunflower oil, soybean oil, MCT oil",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scandishake",
"       </td>",
"       <td>",
"        Axcan",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        Partially hydrogenated vegetable oil, butter fat",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resource Breeze",
"       </td>",
"       <td>",
"        Nestle",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pediasure&nbsp;Sidekicks Clear&nbsp;",
"       </td>",
"       <td>",
"        Abbott&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        None&nbsp;",
"       </td>",
"       <td>",
"        0.6&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MCT: medium-chain triglycerides; kcal: kilocalories.",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Data in this table from the manufacturers' websites.",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1181=[""].join("\n");
var outline_f1_9_1181=null;
var title_f1_9_1182="Lifetime rate incarceration";
var content_f1_9_1182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Prevalence of imprisonment in the US by race and gender",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 396px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rate of imprisonment in the US by race and gender per 100,000 US residents.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Guerino P, Harrison PM, Sabol WJ. Prisoners in 2010 (Revised). US Department of Justice 2011. Available at",
"     <a href=\"file://www.bjs.gov/index.cfm?ty=pbdetail&amp;iid=2230\" style=\"font-style: italic;\" target=\"_blank\">",
"      file://www.bjs.gov/index.cfm?ty=pbdetail&amp;iid=2230",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1182=[""].join("\n");
var outline_f1_9_1182=null;
var title_f1_9_1183="IPSS risk class outcome in MDS";
var content_f1_9_1183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    International Prognostic Scoring System (IPSS) predicts clinical outcome in myelodysplastic syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 492px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier curves of patient survival (top panel) and freedom from acute myeloid leukemia (AML) evolution (bottom panel) in patients with myelodysplastic syndrome (MDS) according to their classification by the International Prognostic Scoring System (IPSS) for MDS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Greenberg, P, Cox, Le Beau, MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997: 89:2079.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_9_1183=[""].join("\n");
var outline_f1_9_1183=null;
